

A Polymer-Based, Paclitaxel-Eluting Stent in Patients w

New England Journal of Medicine

350, 221-231

DOI: [10.1056/nejmoa032441](https://doi.org/10.1056/nejmoa032441)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. <i>Thrombosis and Haemostasis</i> , 2004, 92, 668-669.	1.8	9
3	Inflammation and restenosis after percutaneous coronary interventions. <i>European Heart Journal</i> , 2004, 25, 1679-1687.	1.0	162
4	Long-term clopidogrel therapy in the drug eluting stent era: beyond CREDO and CURE-PCI: Reply. <i>European Heart Journal</i> , 2004, 25, 1364-1365.	1.0	0
5	The interventionalist's dilemma: innocent intimal hyperplasia or in-stent restenosis?. <i>European Heart Journal</i> , 2004, 25, 1970-1971.	1.0	0
6	Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2209-2220.	0.9	10
7	Vascular restenosis "striving for therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2221-2232.	0.9	19
8	Paclitaxel-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2004, 350, 2099-2100.	13.9	8
9	Prevention of Cardiovascular Events after Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2004, 350, 2708-2710.	13.9	6
10	"Me-Too" Products " Friend or Foe?. <i>New England Journal of Medicine</i> , 2004, 350, 211-212.	13.9	68
11	High-Bone-Mass Disease and LRP5. <i>New England Journal of Medicine</i> , 2004, 350, 2096-2099.	13.9	63
12	The Drug-Eluting Stent Information Gap. <i>The American Heart Hospital Journal</i> , 2004, 2, 21-25.	0.2	5
13	Long-term assessment of a novel biodegradable paclitaxel-eluting coronary poly(lactide) stent. <i>European Heart Journal</i> , 2004, 25, 1330-1340.	1.0	153
14	Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents: Clinical Results and Restenosis Analysis. <i>Journal of Endovascular Therapy</i> , 2004, 11, 719-726.	0.8	61
15	Diabetes Is Still a Risk Factor for Restenosis After Drug-Eluting Stent in Coronary Arteries. <i>Diabetes Care</i> , 2004, 27, 1840-1841.	4.3	41
16	Inhibition of Vascular Smooth Muscle Cell Proliferation and Neointimal Formation in Injured Arteries by a Novel, Oral Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Inhibitor. <i>Circulation</i> , 2004, 110, 3367-3371.	1.6	73
17	One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent in Patients With Diabetes Mellitus. <i>Circulation</i> , 2004, 110, e318-9; author reply e318-9.	1.6	2
18	Rationale and study design of the CardioGene Study: genomics of in-stent restenosis. <i>Pharmacogenomics</i> , 2004, 5, 949-1004.	0.6	37
19	Drug-eluting stents: an early systematic review to inform policy*1, *2. <i>European Heart Journal</i> , 2004, 25, 902-919.	1.0	114

#	ARTICLE	IF	CITATIONS
20	Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation. <i>European Heart Journal</i> , 2004, 25, 895-897.	1.0	33
21	Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE. <i>European Heart Journal</i> , 2004, 25, 1364.	1.0	4
22	Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel. <i>Circulation</i> , 2004, 110, 3627-3635.	1.6	288
23	Clinical and Economic Outcomes of Percutaneous Coronary Interventions in the Elderly. <i>Circulation</i> , 2004, 110, 259-264.	1.6	38
24	Correlations Between Fractional Flow Reserve and Intravascular Ultrasound in Patients With an Ambiguous Left Main Coronary Artery Stenosis. <i>Circulation</i> , 2004, 110, 2831-2836.	1.6	357
25	Late incomplete lesion coverage following Cypher stent deployment for diffuse right coronary artery stenosis. <i>Heart</i> , 2004, 90, e45-e45.	1.2	64
26	One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent. <i>Circulation</i> , 2004, 109, 1942-1947.	1.6	732
27	Nonâ€“Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions. <i>Circulation</i> , 2004, 109, 1948-1954.	1.6	203
28	Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 745-752.	0.6	0
29	An Evidence-Based Approach to the Use of Drug-Eluting Stents in Clinical Practice. <i>The American Heart Hospital Journal</i> , 2004, 2, 132-141.	0.2	2
30	Drug-Eluting Stents: Are They Really Safe?. <i>The American Heart Hospital Journal</i> , 2004, 2, 85-88.	0.2	66
31	Extracellular Matrix Changes in Stented Human Coronary Arteries. <i>Circulation</i> , 2004, 110, 940-947.	1.6	196
32	A Chicken in Every Pot and a Drug-Eluting Stent in Every Lesion. <i>Circulation</i> , 2004, 109, 1906-1910.	1.6	25
33	Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes. <i>Journal of Pharmacy Practice</i> , 2004, 17, 347-369.	0.5	1
34	A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. <i>Journal of Internal Medicine</i> , 2004, 256, 388-397.	2.7	54
35	Polymer-Based Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: A Review of the TAXUS Trials. <i>Journal of Interventional Cardiology</i> , 2004, 17, 271-282.	0.5	49
36	Which Parameter Should Be Chosen as Primary Endpoint for Randomized Drug-Eluting Stent Studies?. <i>Journal of Interventional Cardiology</i> , 2004, 17, 375-385.	0.5	6
40	Drug-Eluting Stents: A Mechanical and Pharmacologic Approach to Coronary Artery Disease. <i>Pharmacotherapy</i> , 2004, 24, 1554-1577.	1.2	28

#	ARTICLE	IF	CITATIONS
41	Effects of stent length and lesion length on coronary restenosis. American Journal of Cardiology, 2004, 93, 1340-1346.	0.7	80
42	Comparison of early and late results of a Carbofilm-coated stent versus a pure high-grade stainless steel stent (the Carbostent-Trial). American Journal of Cardiology, 2004, 93, 1351-1356. Comparison of neointimal formation in polymer-free paclitaxel stents versus stainless stents (from) Tj ETQq0 0.0 rgBT /Overlock 10 Tf 50	0.7	32
43	clinical trials sponsored by the Cook Group, Inc., Bloomington, Indiana. Drs. Fearnot and Voorhees are employees of the MED Institute, a Cook company. Drs. KaÅ,uÅ¼a and Raizner served as core angiographic analysts for the 2 trials. Other investigators served in either of the trials.. American	0.7	18
44	Comparison of acute and long-term results and underlying mechanisms from sirolimus-eluting stent implantation for the treatment of in-stent restenosis and recurrent in-stent restenosis in patients in whom intracoronary radiation failed as assessed by intravascular ultrasound. American Journal of Cardiology, 2004, 94, 917-921.	0.7	10
45	Angiographic and three-dimensional intravascular ultrasound analysis of combined intracoronary beta radiation and self-expanding stent implantation in human coronary arteries. American Journal of Cardiology, 2004, 94, 1237-1242.	0.7	3
46	Stent implantation in very small coronary arteries: The Tsunami SV international registry. American Journal of Cardiology, 2004, 94, 1429-1432.	0.7	4
48	Effect of ionizing radiation on the stability and performance of the TAXUS Express2 paclitaxel-eluting stent. Cardiovascular Radiation Medicine, 2004, 5, 136-141.	0.7	6
49	Percutaneous Coronary Intervention in Diabetics. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 277-285.	2.6	6
53	Intracoronary brachytherapy for in-stent restenosis: will it remain a viable therapy?. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1219-23.	3.3	1
54	Biomimetic actuators: where technology and cell biology merge. Cellular and Molecular Life Sciences, 2004, 61, 2497-2509.	2.4	51
55	Polymer-Based Paclitaxel-Eluting Coronary Stents. Herz, 2004, 29, 147-151.	0.4	18
58	Drug-Eluting Stents for In-Stent Restenosis and Acute Myocardial Infarction. Herz, 2004, 29, 195-200.	0.4	5
59	Classification and Current Treatment Options of In-Stent Restenosis. Herz, 2004, 29, 187-194.	0.4	18
60	Direct Stenting with TAXUS Stents Seems to be as Safe and Effective as with Predilatation. Herz, 2004, 29, 171-180.	0.4	27
61	Management of Acute Coronary Syndrome in Diabetes Mellitus. Herz, 2004, 29, 532-41.	0.4	6
62	Diabetes and Percutaneous Coronary Revascularization in the Drug-Eluting Stent Era. Herz, 2004, 29, 542-50.	0.4	1
63	Physical characterization of controlled release of paclitaxel from the TAXUS? Express2? drug-eluting stent. Journal of Biomedical Materials Research Part B, 2004, 71A, 625-634.	3.0	169
64	Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheterization and Cardiovascular Interventions, 2004, 61, 518-527.	0.7	37

#	ARTICLE	IF	CITATIONS
65	Vascular brachytherapy vs. drug-eluting stents for the treatment of in-stent restenosis: The jury's still out. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 62, 290-291.	0.7	4
66	Drug-eluting stents for secondary prevention of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 63, 265-266.	0.7	1
67	Sirolimus- versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1431-1434.	0.9	5
68	Coronary aneurysm after implantation of a paclitaxel-eluting stent. <i>Scandinavian Cardiovascular Journal</i> , 2004, 38, 349-352.	0.4	29
69	The Paclitaxel (TAXUS???) -Eluting Stent. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 257-268.	1.0	38
70	Paclitaxel-Eluting Stents. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 355-360.	1.0	15
71	Intravascular Brachytherapy. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 385-394.	1.0	7
72	¿Está justificado el uso sistemático de stents con fármacos? Argumentos en contra. <i>Revista Espanola De Cardiologia</i> , 2004, 57, 109-115.	0.6	10
74	Prostate cancer and coronary heart disease: correlation or coincidence?. <i>Urologic Clinics of North America</i> , 2004, 31, 207-212.	0.8	8
76	Is Systematic Use of Drug-Eluting Stents Justified? Arguments Against. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004, 57, 109-115.	0.4	1
77	Antiproliferative Drug-Eluting Stents: Systematic Review of the Benefits and Estimate of Economic Impact. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004, 57, 617-628.	0.4	4
78	Ethical dilemmas encountered during clinical drug trials. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 24-31.	1.1	2
79	Coronary stenting versus balloon angioplasty in small vessels. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1964-1972.	1.2	93
80	Preclinical restenosis models and drug-eluting stents. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1373-1385.	1.2	121
81	High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1368-1372.	1.2	25
82	Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2301-2306.	1.2	168
83	Combination of Paclitaxel and Nitric Oxide as a Novel Treatment for the Reduction of Restenosis. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2276-2282.	2.9	31
84	PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. <i>Cytokine and Growth Factor Reviews</i> , 2004, 15, 229-235.	3.2	92

#	ARTICLE	IF	CITATIONS
85	Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. <i>Health Policy</i> , 2004, 70, 207-216.	1.4	30
86	Commentary. <i>Evidence-based Cardiovascular Medicine</i> , 2004, 8, 239-240.	0.0	0
87	Commentary. <i>Evidence-based Cardiovascular Medicine</i> , 2004, 8, 344-345.	0.0	0
88	The influence of physical stent parameters upon restenosis. <i>Pathologie Et Biologie</i> , 2004, 52, 196-205.	2.2	100
89	Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: Part II. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 472-477.	0.8	27
90	Clinical implications of growth factors in flexor tendon wound healing. <i>Journal of Hand Surgery</i> , 2004, 29, 551-563.	0.7	142
91	Oral rapamycin to prevent human coronary stent restenosis: A pilot study. <i>American Heart Journal</i> , 2004, 148, 341-343.	1.2	21
92	Advances in Stent-Assisted Management of Intracranial Occlusive Disease and Cerebral Aneurysms. <i>Techniques in Vascular and Interventional Radiology</i> , 2004, 7, 202-209.	0.4	5
93	A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. <i>Lancet, The</i> , 2004, 364, 583-591.	6.3	597
94	Drug-eluting stents: some bare facts. <i>Lancet, The</i> , 2004, 364, 1466-1467.	6.3	61
95	Prevention of restenosis after coronary angioplasty. <i>Current Opinion in Cardiology</i> , 2004, 19, 500-509.	0.8	27
96	Brachytherapy for restenosis after stenting for coronary artery disease: its role in the drug-eluting stent era. <i>Current Opinion in Cardiology</i> , 2004, 19, 601-607.	0.8	14
97	New devices for percutaneous coronary intervention are rapidly making bypass surgery obsolete. <i>Current Opinion in Cardiology</i> , 2004, 19, 593-597.	0.8	12
98	Drug-eluting stents have made brachytherapy obsolete. <i>Current Opinion in Cardiology</i> , 2004, 19, 598-600.	0.8	4
99	Emergency Department Evaluation and Treatment of Patients With ST-Segment Elevation Myocardial Infarction. <i>Critical Pathways in Cardiology</i> , 2004, 3, 110-113.	0.2	1
100	Ten Years of Advancements in Interventional Cardiology. <i>Journal of Endovascular Therapy</i> , 2004, 11, II-10-II-18.	0.8	5
101	An Update on Endovascular Therapy of the Lower Extremities. <i>Journal of Endovascular Therapy</i> , 2004, 11, II-107-II-127.	0.8	25
102	Intravascular Stents in the Last and the Next 10 Years. <i>Journal of Endovascular Therapy</i> , 2004, 11, II-200-II-206.	0.8	35

#	ARTICLE	IF	CITATIONS
103	High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularizationOne-year results from the SCORE randomized trial. Journal of the American College of Cardiology, 2004, 44, 1368-1372.	1.2	59
104	Utility of the fractional flow reserve in the evaluation of angiographically moderate in-stent restenosis. European Heart Journal, 2004, 25, 2040-2047.	1.0	55
105	Antithrombotic Therapy During Percutaneous Coronary Intervention. Chest, 2004, 126, 576S-599S.	0.4	220
106	Drug-coated Stents. Journal of Cardiovascular Nursing, 2004, 19, 404-408.	0.6	4
107	Approaches to restenosis: mechanical and pharmacological strategies. Coronary Artery Disease, 2004, 15, 303-305.	0.3	1
108	Sirolimus-Eluting vs Uncoated Stents for Prevention of Restenosis in Small Coronary Arteries. JAMA - Journal of the American Medical Association, 2004, 292, 2727.	3.8	291
109	The role of platelet inhibition in the drug-eluting stent era. Coronary Artery Disease, 2004, 15, 327-329.	0.3	6
110	Cutting balloon angioplasty is superior to balloon angioplasty or stent implantation for small coronary artery disease. Coronary Artery Disease, 2004, 15, 435-440.	0.3	6
111	Tissue Doppler and cardiac resynchronisation therapy: a new challenge for the optimal choice of candidates. European Heart Journal, 2004, 25, 1363.	1.0	0
112	Preclinical restenosis models and drug-eluting stentsStill important, still much to learn. Journal of the American College of Cardiology, 2004, 44, 1373-1385.	1.2	210
113	Treatment of unprotected left main coronary artery disease with drug-eluting stents: is it time for a randomized trial?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 396-400.	3.3	16
114	Cardiac revascularization--a need for independent decision-makers. Journal of the Royal Society of Medicine, 2005, 98, 1-2.	1.1	2
115	Percutaneous Coronary Interventions: what the general practitioner should know. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2005, 47, 26-30.	0.2	0
116	Hula-Hoops, Pet Rocks And Intravascular Brachy Therapy. Methodist DeBakey Cardiovascular Journal, 2005, 1, 7-10.	0.5	0
119	Complete myocardial revascularization: between myth and reality. European Heart Journal, 2005, 26, 1824-1830.	1.0	50
120	Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part I. Current Opinion in Urology, 2005, 15, 1-6.	0.9	12
121	Use of drug-eluting stents for the treatment of in-stent restenosis in routine clinical practice. Coronary Artery Disease, 2005, 16, 327-330.	0.3	3
122	NMR characterization of paclitaxel/poly (styrene-isobutylene-styrene) formulations. International Journal of Pharmaceutics, 2005, 305, 129-144.	2.6	18

#	ARTICLE	IF	CITATIONS
123	Styrenic block copolymers for biomaterial and drug delivery applications. <i>Acta Biomaterialia</i> , 2005, 1, 137-144.	4.1	105
124	Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: Results of a Taxus CTO registry. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 173-177.	0.7	15
125	Immediate and Mid-term Outcomes of Sirolimus-Eluting Stent Implantation for Chronic Total Occlusions. <i>ACC Current Journal Review</i> , 2005, 14, 44.	0.1	0
126	Drug-Eluting Stents Compared With Thin-Strut Bare Stents for the Reduction of Restenosis: A Prospective, Randomized Trial. <i>ACC Current Journal Review</i> , 2005, 14, 33-34.	0.1	0
128	Five-Year Clinical Effect of Coronary Stenting and Coronary Artery Bypass Grafting in Renal Insufficient Patients With Multivessel Coronary Artery Disease: Insights From ARTS Trial. <i>ACC Current Journal Review</i> , 2005, 14, 47.	0.1	0
129	Treatment of saphenous vein graft lesions with drug-eluting stents. <i>Journal of the American College of Cardiology</i> , 2005, 45, 989-994.	1.2	142
130	Looking for the culprit of coronary in-stent restenosis: debatable role for the fibrinolytic system?. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 230-232.	1.9	4
131	Recurrence of in-stent restenosis in cardiac allograft vasculopathy following implantation of a sirolimus-eluting stent. <i>Transplant International</i> , 2005, 18, 1113-1115.	0.8	3
132	Cypher Versus Taxus: Are There Differences?. <i>Journal of Interventional Cardiology</i> , 2005, 18, 441-446.	0.5	17
133	Treatment of Unprotected Left Main Coronary Artery Stenosis in the Drug-Eluting Stent Era. <i>Journal of Interventional Cardiology</i> , 2005, 18, 455-465.	0.5	9
134	Should Degenerated Saphenous Vein Grafts Routinely Be Sealed with Drug-Eluting Stents?. <i>Journal of Interventional Cardiology</i> , 2005, 18, 467-473.	0.5	18
135	Review of Subacute Stent Thrombosis Following Percutaneous Coronary Intervention at a Low-Volume Catheterization Laboratory. <i>Journal of Interventional Cardiology</i> , 2005, 18, 11-15.	0.5	3
136	32P Brachytherapy in the Treatment of Complex Cypher In-Stent Restenosis. <i>Journal of Interventional Cardiology</i> , 2005, 18, 205-211.	0.5	9
137	Sirolimus-Eluting Stent Implantation for Chronic Total Occlusion of the Left Main Coronary Artery. <i>Journal of Interventional Cardiology</i> , 2005, 18, 65-69.	0.5	7
138	EDITOR'S RESPONSE. <i>Journal of Interventional Cardiology</i> , 2005, 18, 69-69.	0.5	1
139	Double blockade of cell cycle progression by coptisine in vascular smooth muscle cells. <i>Biochemical Pharmacology</i> , 2005, 70, 1176-1184.	2.0	36
140	Comparison of quantitative angiographic parameters with the magnitude of neointimal hyperplasia measured by volumetric intravascular ultrasound in patients treated with bare metal and nonpolymeric paclitaxel-coated stents. <i>American Journal of Cardiology</i> , 2005, 95, 105-107.	0.7	7
141	Meta-analysis comparing drug-eluting stents with bare metal stents. <i>American Journal of Cardiology</i> , 2005, 95, 640-643.	0.7	83

#	ARTICLE	IF	CITATIONS
142	Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). American Journal of Cardiology, 2005, 95, 709-715.	0.7	59
143	In-hospital and nine-month outcome of treatment of coronary bifurcational lesions with sirolimus-eluting stent. American Journal of Cardiology, 2005, 95, 757-760.	0.7	59
144	Influence of Stent Length to Lesion Length Ratio on Angiographic and Clinical Outcomes After Implantation of Bare Metal and Drug-Eluting Stents (the TAXUS-IV Study). American Journal of Cardiology, 2005, 95, 1043-1048.	0.7	15
145	Comparison of Thrombosis and Restenosis Risk from Stent Length of Sirolimus-Eluting Stents Versus Bare Metal Stents. American Journal of Cardiology, 2005, 95, 1140-1145.	0.7	68
146	Drug-Eluting Stents Versus Bare Metal Stents in Percutaneous Coronary Interventions (A Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 582 Td (0.7	80
147	Incidence and Predictors of Target Vessel Revascularization and Clinical Event Rates of the Sirolimus-Eluting Coronary Stent (Results from the Prospective Multicenter German Cypher Stent) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	14
148	Two-Year-Plus Follow-Up of a Paclitaxel-Eluting Stent in De Novo Coronary Narrowings (TAXUS I). American Journal of Cardiology, 2005, 96, 79-82.	0.7	45
149	Effect of Lumen Narrowing Within Coronary Stents on Proximal and Distal Vessel Segments Following Bare Metal Stent Implantation. American Journal of Cardiology, 2005, 96, 376-378.	0.7	5
150	Immediate and One-Year Outcome of Percutaneous Intervention of Saphenous Vein Graft Disease With Paclitaxel-Eluting Stents. American Journal of Cardiology, 2005, 96, 395-398.	0.7	24
151	Impact of Platelet Glycoprotein IIb/IIIa Inhibition on the Paclitaxel-Eluting Stent in Patients With Stable or Unstable Angina Pectoris or Provocable Myocardial Ischemia (A TAXUS IV Substudy). American Journal of Cardiology, 2005, 96, 500-505.	0.7	11
152	17-Beta-Estradiol Eluting Stent Versus Phosphorylcholine-Coated Stent for the Treatment of Native Coronary Artery Disease. American Journal of Cardiology, 2005, 96, 664-667.	0.7	25
153	Frequency, Predictors, and Outcomes of Drug-Eluting Stent Utilization in Patients With High-Risk Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2005, 96, 750-755.	0.7	63
154	Usefulness of Multislice Computed Tomographic Coronary Angiography to Assess In-Stent Restenosis. American Journal of Cardiology, 2005, 96, 799-802.	0.7	71
155	Thirty-Month Outcome After Fractional Flow Reserveâ€“Guided Versus Conventional Multivessel Percutaneous Coronary Intervention. American Journal of Cardiology, 2005, 96, 877-884.	0.7	74
156	Prediction of Complications Following Nonemergency Percutaneous Coronary Interventions. American Journal of Cardiology, 2005, 96, 907-912.	0.7	27
157	Impact of Coronary Culprit Lesion Calcium in Patients Undergoing Paclitaxel-Eluting Stent Implantation (a TAXUS-IV Sub Study). American Journal of Cardiology, 2005, 96, 1242-1247.	0.7	128
158	Impact of Diabetes Mellitus on Angiographic and Clinical Outcomes in the Drug-Eluting Stents Era. American Journal of Cardiology, 2005, 96, 1389-1392.	0.7	39
159	Impact of Asymmetric Stent Expansion on Neointimal Hyperplasia Following Sirolimus-Eluting Stent Implantation. American Journal of Cardiology, 2005, 96, 1404-1407.	0.7	13

#	ARTICLE	IF	CITATIONS
160	Clinical Outcome Following Aleatory Implantation of Paclitaxel-Eluting or Sirolimus-Eluting Stents in Complex Coronary Lesions. <i>American Journal of Cardiology</i> , 2005, 96, 1663-1668.	0.7	42
162	Actualizaci3n en cardiolog4a intervencionista 2004. <i>Revista Espanola De Cardiologia Suplementos</i> , 2005, 5, 104A-117A.	0.2	0
163	In vitro study of drug loading on polymer-free oxide films of metallic implants. <i>Journal of Biomedical Materials Research - Part A</i> , 2005, 75A, 519-529.	2.1	5
164	Percutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior descending coronary artery stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 64, 75-81.	0.7	80
165	Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 227-232.	0.7	27
166	Two-year follow-up intravascular ultrasound analysis after bare metal stent implantation in 120 lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 247-253.	0.7	7
167	Effect of bare metal stenting on angiographic and clinical outcomes in diabetic and nondiabetic patients undergoing percutaneous coronary intervention of nonacute occluded coronary arteries: A report from the total occlusion study of Canada (TOSCA). <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 178-184.	0.7	2
168	Percutaneous recanalization of chronically occluded coronary arteries: Procedural techniques, devices, and results. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 217-236.	0.7	119
169	Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 507-511.	0.7	83
170	Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: A serial intravascular ultrasound study. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 535-540.	0.7	15
171	First human experience with angiopeptin-eluting stent: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 541-546.	0.7	16
174	Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. <i>Clinical Research in Cardiology</i> , 2005, 94, 445-452.	1.2	22
175	Comparative endoluminal visualization of TAXUS crush-stenting at 9 months follow-up by intravascular ultrasound and optical coherence tomography. <i>Clinical Research in Cardiology</i> , 2005, 94, 690-694.	1.2	4
178	Contemporary use of drug-eluting stents. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 35-46.	0.4	7
179	Advances in nuclear imaging for preoperative risk assessment. <i>Current Cardiology Reports</i> , 2005, 7, 143-147.	1.3	0
180	Systemic Inflammation After Drug-Eluting Stent Placement. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 87-92.	1.0	34
181	Solutions for Hemodialysis Vascular access Dysfunction: Thinking out of the Box!!. <i>Journal of Vascular Access</i> , 2005, 6, 3-8.	0.5	7
182	Angina. , 2005, , 127-174.		0

#	ARTICLE	IF	CITATIONS
183	Cost-effectiveness of drug-eluting stents: if only all things were equal. Medical Journal of Australia, 2005, 182, 376-377.	0.8	11
184	Cardiac Revascularization—a need for Independent Decision-Makers. Journal of the Royal Society of Medicine, 2005, 98, 1-2.	1.1	2
185	Stents nus, Stents habillÃ©s. Bulletin De L'Academie Nationale De Medecine, 2005, 189, 237-247.	0.0	0
186	Homocysteine and Its Effects on In-Stent Restenosis. Circulation, 2005, 112, e307-11.	1.6	18
187	Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thrombosis and Haemostasis, 2005, 93, 820-823.	1.8	65
188	Obstructive Sleep Apnea and Stroke. Annals of Internal Medicine, 2005, 143, 390.	2.0	0
189	Pegylated Interferon-Î±2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis B. Annals of Internal Medicine, 2005, 143, 391.	2.0	1
190	Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovascular Research, 2005, 68, 483-492.	1.8	52
191	Diabetic keto-acidosis and hyperkalaemia induced pseudo-myocardial infarction. Heart, 2005, 91, 1180-1180.	1.2	4
192	Pharmacistsâ€™ role in preventing stent thrombosis. American Journal of Health-System Pharmacy, 2005, 62, 2239-2239.	0.5	0
193	Oesophageal stenting. Scandinavian Journal of Gastroenterology, 2005, 40, 1-14.	0.6	19
194	Targeting drug-eluting stents to lesions at high risk of restenosis: a flawed approach?. Heart, 2005, 93, 251-252.	1.2	0
195	Molecular Basis of Restenosis and Drug-Eluting Stents. Circulation, 2005, 111, 2257-2273.	1.6	439
196	One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents. Heart, 2005, 91, 1176-1180.	1.2	37
197	Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients. Circulation, 2005, 112, 2175-2183.	1.6	345
198	Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). Heart, 2005, 91, 1433-1437.	1.2	29
199	Is there any place for oral anti-restenotic treatment in the era of drug eluting stents?. Heart, 2005, 91, 1377-1379.	1.2	3
200	Late Follow-Up From RAVEL. Circulation, 2005, 111, 958-960.	1.6	1

#	ARTICLE	IF	CITATIONS
201	Robustness of Late Lumen Loss in Discriminating Drug-Eluting Stents Across Variable Observational and Randomized Trials. <i>Circulation</i> , 2005, 112, 2833-2839.	1.6	117
202	Do Drug-Eluting Stents Mark the End of Coronary Artery Bypass Surgery?. <i>Asian Cardiovascular and Thoracic Annals</i> , 2005, 13, 1-3.	0.2	2
203	Paclitaxel-Eluting Stents in Complex Lesions. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1268.	3.8	9
204	Coronary Stent Restenosis in Patients Treated With Cilostazol. <i>Circulation</i> , 2005, 112, 2826-2832.	1.6	535
205	Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents. <i>Circulation</i> , 2005, 111, 321-327.	1.6	99
206	Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 165-71.	3.8	534
207	Surgery Is Preferred for the Diabetic With Multivessel Disease. <i>Circulation</i> , 2005, 112, 1500-1515.	1.6	31
208	Genomics of In-Stent Restenosis. <i>Circulation</i> , 2005, 112, 2378-2379.	1.6	7
209	Clinical and Procedural Predictors of Nurse Workload During and After Invasive Coronary Procedures: The Potential Benefit of a Systematic Radial Access. <i>European Journal of Cardiovascular Nursing</i> , 2005, 4, 234-241.	0.4	37
210	Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women. <i>Circulation</i> , 2005, 111, 940-953.	1.6	214
211	Percutaneous coronary intervention: recommendations for good practice and training. <i>Heart</i> , 2005, 91, vi1-vi27.	1.2	38
213	Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1215.	3.8	692
214	Clopidogrel: cardiologistsâ€™ panacea or neurologistsâ€™ headache?. <i>Future Cardiology</i> , 2005, 1, 579-590.	0.5	1
215	Diabetes and Coronary Revascularization. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1501.	3.8	229
216	Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 633-641.	0.2	2
217	Drug-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2005, 353, 2404-2408.	13.9	1
218	Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients. <i>New England Journal of Medicine</i> , 2005, 353, 663-670.	13.9	462
219	Percutaneous coronary intervention and drug-eluting stents. <i>Cmaj</i> , 2005, 172, 323-325.	0.9	5

#	ARTICLE	IF	CITATIONS
220	New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opinion on Investigational Drugs, 2005, 14, 1-17.	1.9	33
221	Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents. Expert Review of Cardiovascular Therapy, 2005, 3, 635-646.	0.6	1
222	Dollars and Stents: The Economics of Drug-Eluting Stents. The American Heart Hospital Journal, 2005, 3, 94-104.	0.2	4
223	Direct Stenting With Sirolimus-Eluting Stents. The American Heart Hospital Journal, 2005, 3, 182-192.	0.2	4
224	Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. Expert Opinion on Pharmacotherapy, 2005, 6, 35-43.	0.9	13
225	A cath lab hero is something to be? Comments on left main stem percutaneous coronary intervention for ST-elevation myocardial infarction. Scandinavian Cardiovascular Journal, 2005, 39, 6-9.	0.4	0
226	Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial. Circulation, 2005, 112, 3306-3313.	1.6	296
227	Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart, 2005, 91, 641-645.	1.2	60
228	Early and Mid-Term Results of Drug-Eluting Stent Implantation in Unprotected Left Main. Circulation, 2005, 111, 791-795.	1.6	358
229	An intrapericardial pheochromocytoma presented with paroxysmal attacks of hypertension and palpitation: typical presentation with unusual location of the tumour. Heart, 2005, 91, 1379-1379.	1.2	1
230	Prevention of Restenosis by Systemic Drug Therapy. Circulation, 2005, 112, 2759-2761.	1.6	25
231	Endoluminal Phototherapy for Prevention of Restenosis: Preliminary Results at 6-Month Follow-Up. Photomedicine and Laser Surgery, 2005, 23, 536-542.	2.1	5
232	Drug-eluting versus third-generation bare metal stents: The US strategy. International Journal of Cardiovascular Interventions, 2005, 7, 171-175.	0.5	7
233	Drugs to suppress cough. Expert Opinion on Investigational Drugs, 2005, 14, 19-27.	1.9	40
234	Late Loss in Lumen Diameter and Binary Restenosis for Drug-Eluting Stent Comparison. Circulation, 2005, 111, 3435-3442.	1.6	164
235	Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome. Diabetes and Vascular Disease Research, 2005, 2, 128-135.	0.9	6
236	Paclitaxel-eluting stents in coronary artery disease. American Journal of Health-System Pharmacy, 2005, 62, 2241-2251.	0.5	10
237	Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents. Circulation, 2005, 111, 1040-1044.	1.6	203

#	ARTICLE	IF	CITATIONS
238	Drug-Eluting Stents and In-Stent Restenosis—Reply. JAMA - Journal of the American Medical Association, 2005, 293, 1855.	3.8	3
239	Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents. JAMA - Journal of the American Medical Association, 2005, 293, 2126.	3.8	2,769
240	Drug-Eluting Stents in Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 2154.	3.8	8
241	Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease. Circulation, 2005, 111, 1383-1389.	1.6	305
242	Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention. Circulation, 2005, 111, 2099-2106.	1.6	635
243	Perils of polypectomy. Heart, 2005, 91, 1437-1437.	1.2	0
244	Late angiographic stent thrombosis of polymer based paclitaxel eluting stent. Heart, 2005, 92, 551-553.	1.2	26
245	Drug Eluting Coronary Stent: In Vitro Evaluation of Magnet Resonance Safety at 3 Tesla. Journal of Cardiovascular Magnetic Resonance, 2005, 7, 415-419.	1.6	49
246	Treatment of bifurcation lesions with two stents: one year angiographic and clinical follow up of crush versus T stenting. Heart, 2005, 92, 371-376.	1.2	99
247	Guidelines for Percutaneous Coronary Interventions. European Heart Journal, 2005, 26, 804-847.	1.0	1,408
248	Drug-Eluting Stents and In-Stent Restenosis. JAMA - Journal of the American Medical Association, 2005, 293, 1855.	3.8	0
249	Drug Eluting Stent Technology. Journal of Pharmacy Practice, 2005, 18, 461-478.	0.5	1
250	Sirolimus-Eluting Stents vs Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2005, 294, 819.	3.8	272
251	Recent advances in endoluminal revascularization for intracranial atherosclerotic disease. Neurological Research, 2005, 27, 89-94.	0.6	4
252	Endovascular reconstruction by means of stent placement in symptomatic intracranial atherosclerotic stenosis. Neurological Research, 2005, 27, 84-88.	0.6	37
253	Novel Therapies for Hemodialysis Vascular Access Dysfunction: Fact or Fiction!. Blood Purification, 2005, 23, 29-35.	0.9	19
254	Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. European Heart Journal, 2005, 26, 1488-1493.	1.0	63
255	Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 748-753.	1.1	125

#	ARTICLE	IF	CITATIONS
256	Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. <i>European Heart Journal</i> , 2005, 26, 1262-1268.	1.0	113
257	Comparison of synchrotron radiation angiography with conventional angiography for the diagnosis of in-stent restenosis after percutaneous transluminal coronary angioplasty. <i>European Heart Journal</i> , 2005, 26, 1284-1291.	1.0	40
258	Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. <i>European Heart Journal</i> , 2005, 26, 1056-1062.	1.0	133
259	Drug-eluting stents for chronic total occlusions make sense, but it is too early to close the discussion The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2005, 26, 1049-1051.	1.0	3
260	Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. <i>European Heart Journal</i> , 2005, 26, 1475-1481.	1.0	106
261	New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios. <i>Country Review Ukraine</i> , 2005, 7, K31-K35.	0.8	1
262	Frequency and management of recurrent stenosis after carotid artery stent implantation. <i>Journal of Neurosurgery</i> , 2005, 102, 29-37.	0.9	70
263	Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). <i>Lancet</i> , The, 2005, 366, 921-929.	6.3	322
265	Management of Coronary Heart Disease: Stable Angina, Acute Coronary Syndrome, Myocardial Infarction. <i>Primary Care - Clinics in Office Practice</i> , 2005, 32, 1057-1081.	0.7	5
266	Modulation of vascular remodeling induced by a brief intraluminal exposure to the recombinant R7020 strain of Herpes simplex-1. <i>Journal of Vascular Surgery</i> , 2005, 41, 115-121.	0.6	2
267	La valutazione dei benefici e dei costi dei dispositivi medici. Il caso degli stent medicati. <i>Pharmacoeconomics Italian Research Articles</i> , 2005, 7, 195-206.	0.2	5
268	Randomized Comparison of a Titanium-Nitride-Oxide-Coated Stent With a Stainless Steel Stent for Coronary Revascularization. <i>Circulation</i> , 2005, 111, 2617-2622.	1.6	139
269	The drug-based pipeline against restenosis. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 67-86.	1.0	2
270	Oral antiplatelet therapy and percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 3-12.	0.9	3
271	Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization. <i>New England Journal of Medicine</i> , 2005, 353, 653-662.	13.9	547
272	Plaque sealing—a concept waiting for support. <i>International Journal of Cardiovascular Interventions</i> , 2005, 7, 72-74.	0.5	4
273	Cost-effectiveness of primary percutaneous coronary intervention versus thrombolytic therapy for acute myocardial infarction. <i>Scandinavian Cardiovascular Journal</i> , 2005, 39, 276-285.	0.4	31
274	Percutaneous Recanalization of Chronically Occluded Coronary Arteries. <i>Circulation</i> , 2005, 112, 2364-2372.	1.6	490

#	ARTICLE	IF	CITATIONS
275	Percutaneous therapy of bifurcation lesions with drug-eluting stent implantation: the Culotte technique revisited. <i>International Journal of Cardiovascular Interventions</i> , 2005, 7, 36-40.	0.5	32
276	Interventional Cardiovascular Pharmacotherapy. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 93-102.	1.0	2
277	Syntheses and Characterization of Poly(cyclohexyl vinyl ether-stat-vinyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 672 Td (alcohol)-b-polyiso Their Application as Coatings To Deliver Paclitaxel from Coronary Stents. <i>Macromolecules</i> , 2005, 38, 8183-8191.	2.2	28
278	Controlled Delivery of Paclitaxel from Stent Coatings Using Poly(hydroxystyrene-b-isobutylene-b-hydroxystyrene) and Its Acetylated Derivative. <i>Biomacromolecules</i> , 2005, 6, 2570-2582.	2.6	65
279	Intracoronary I^{125} -irradiation prevents excessive in-stent neointimal proliferation in de novo lesions of patients with high plasma ACE levels. The BetAce randomized trial. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 7-13.	0.3	3
280	Drug-eluting stents for the treatment of in-stent restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 38-43.	0.3	14
281	Clinical and angiographic follow-up in patients with Cypher or Taxus stents in populations with high percentage of trial-excluded lesions. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 92-98.	0.3	9
282	Comparison of a centered ^{32}P source wire system with a noncentered $^{90}\text{Sr}/\text{Y}$ brachytherapy system for intracoronary I^{125} -radiation following PCI of diffuse in-stent restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 140-146.	0.3	4
283	Commentary. <i>Evidence-based Cardiovascular Medicine</i> , 2005, 9, 50-51.	0.0	0
284	Coronary Artery Surgery. <i>Annals of Thoracic Surgery</i> , 2005, 79, S2221-S2227.	0.7	9
285	Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: Results from the TAXUS-IV Trial. <i>American Heart Journal</i> , 2005, 150, 1163-1170.	1.2	86
286	Full metal jacket (stented length 64 mm) using drug-eluting stents for de novo coronary artery lesions. <i>American Heart Journal</i> , 2005, 150, 994-999.	1.2	74
287	Design of a registry to characterize real-world outcomes of percutaneous coronary revascularization in the drug-eluting stent era. <i>American Heart Journal</i> , 2005, 150, 887-892.	1.2	30
288	The preoperative cardiovascular evaluation of the intermediate-risk patient: New data, changing strategies. <i>American Journal of Medicine</i> , 2005, 118, 1413.e1-1413.e9.	0.6	39
296	Technology Insight: an overview of research in drug-eluting stents. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 647-658.	3.3	51
297	Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents. <i>Drugs</i> , 2005, 65, 725-732.	4.9	38
298	Angiotensin Antagonism in Coronary Artery Disease. <i>Drugs</i> , 2005, 65, 1073-1096.	4.9	14
299	Advances in Adjunctive Pharmacological Therapy for Percutaneous Coronary Interventions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2005, 58, 729-743.	0.4	0

#	ARTICLE	IF	CITATIONS
300	Emergent Strategies in Interventional Cardiology. Revista Espanola De Cardiologia (English Ed), 2005, 58, 962-973.	0.4	3
301	Treatment of Lesions With a High Risk of Stenosis. Comparative Study in 300 Patients of Rapamycin-and Paclitaxel-Eluting Polymer-Based Stents, and Bare Metal Stents. Revista Espanola De Cardiologia (English Ed), 2005, 58, 262-269.	0.4	5
302	Drug-Eluting Stents and Other Anti-Restenosis Devices. Revista Espanola De Cardiologia (English Ed), 2005, 58, 842-862.	0.4	6
303	Influence of Clinical and Anatomical Factors on the Outcome of Percutaneous Coronary Interventions. Revista Espanola De Cardiologia (English Ed), 2005, 58, 430-441.	0.4	0
304	Percutaneous Coronary Intervention in Myocardial Infarction. Current Concepts. Revista Espanola De Cardiologia (English Ed), 2005, 58, 567-584.	0.4	1
305	Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. Journal of the American College of Cardiology, 2005, 45, 947-953.	1.2	413
306	Coronary stenting versus balloon angioplasty in small vessels. Journal of the American College of Cardiology, 2005, 45, 323-324.	1.2	10
307	Drug-eluting stents for diabetes mellitus. Journal of the American College of Cardiology, 2005, 45, 479-483.	1.2	45
308	Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes. Journal of the American College of Cardiology, 2005, 45, 1165-1171.	1.2	56
309	Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. Journal of the American College of Cardiology, 2005, 45, 1172-1179.	1.2	230
310	Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. Journal of the American College of Cardiology, 2005, 45, 1180-1185.	1.2	118
311	Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. Journal of the American College of Cardiology, 2005, 45, 1186-1192.	1.2	43
312	Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation. Journal of the American College of Cardiology, 2005, 45, 1201-1205.	1.2	88
313	Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation. Journal of the American College of Cardiology, 2005, 45, 1193-1200.	1.2	149
314	What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?. Journal of the American College of Cardiology, 2005, 45, 941-946.	1.2	151
315	Drug-eluting stent thrombosis. Journal of the American College of Cardiology, 2005, 45, 954-959.	1.2	505
316	Angiographic patterns of restenosis after paclitaxel-eluting stent implantation. Journal of the American College of Cardiology, 2005, 45, 805-806.	1.2	36
317	Five-Year Outcomes After Coronary Stenting Versus Bypass Surgery for the Treatment of Multivessel Disease. Journal of the American College of Cardiology, 2005, 46, 575-581.	1.2	559

#	ARTICLE	IF	CITATIONS
320	The year in interventional cardiology. Journal of the American College of Cardiology, 2005, 45, 1117-1134.	1.2	47
321	The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population. Journal of the American College of Cardiology, 2005, 45, 1135-1141.	1.2	204
322	Endothelial Progenitor Cell Capture by Stents Coated With Antibody Against CD34. Journal of the American College of Cardiology, 2005, 45, 1574-1579.	1.2	510
323	The Effect of Variable Dose and Release Kinetics on Neointimal Hyperplasia Using a Novel Paclitaxel-Eluting Stent Platform. Journal of the American College of Cardiology, 2005, 46, 253-260.	1.2	154
324	Physiologic Assessment of Jailed Side Branch Lesions Using Fractional Flow Reserve. Journal of the American College of Cardiology, 2005, 46, 633-637.	1.2	297
325	Clinical and Angiographic Outcome After Implantation of Drug-Eluting Stents in Bifurcation Lesions With the Crush Stent Technique. Journal of the American College of Cardiology, 2005, 46, 613-620.	1.2	320
326	Late Incomplete Stent Apposition After Sirolimus-Eluting Stent Implantation. Journal of the American College of Cardiology, 2005, 46, 1002-1005.	1.2	219
327	Cost-Benefit of Drug Eluting Stents—Time for a Reality Check. Heart Lung and Circulation, 2005, 14, 74-77.	0.2	12
328	Vascular Access in Hemodialysis: Issues, Management, and Emerging Concepts. Cardiology Clinics, 2005, 23, 249-273.	0.9	86
329	Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model. Journal of Vascular Surgery, 2005, 42, 980-988.	0.6	52
330	Drug-Eluting Stents in the Management of Coronary Artery Disease. Disease Management and Health Outcomes, 2005, 13, 1-7.	0.3	1
331	Obstructive Sleep Apnea and Stroke. Annals of Internal Medicine, 2005, 143, 390.	2.0	16
332	Update on drug-eluting coronary stents. Expert Review of Cardiovascular Therapy, 2005, 3, 953-968.	0.6	32
333	Evaluation of Acrylate-Based Block Copolymers Prepared by Atom Transfer Radical Polymerization as Matrices for Paclitaxel Delivery from Coronary Stents. Biomacromolecules, 2005, 6, 3410-3418.	2.6	75
334	DRUG-ELUTING BIORESORBABLE STENTS FOR VARIOUS APPLICATIONS. Annual Review of Biomedical Engineering, 2006, 8, 153-180.	5.7	94
335	CÃ3mo mantienen el flujo coronario los stent con capacidad de liberaciÃ3n de fÃ3rmas. Nursing (Ed) Tj ETQq1 1 0,784314 rgBT /Ov	0,0	0
336	Coronary-Artery Stents. New England Journal of Medicine, 2006, 354, 483-495.	13.9	646
337	Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system. Scandinavian Cardiovascular Journal, 2006, 40, 17-24.	0.4	23

#	ARTICLE	IF	CITATIONS
339	Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions. <i>Circulation</i> , 2006, 114, 798-806.	1.6	439
340	The cell cycle: A critical therapeutic target to prevent vascular proliferative disease. <i>Canadian Journal of Cardiology</i> , 2006, 22, 41B-55B.	0.8	29
341	The vascular effects of cilostazol. <i>Canadian Journal of Cardiology</i> , 2006, 22, 56B-60B.	0.8	50
342	The early invasive strategy revisited: FRISC II at 5 years. <i>Lancet, The</i> , 2006, 368, 966-969.	6.3	4
343	Ursolic acid inhibits neointima formation in the rat carotid artery injury model. <i>Atherosclerosis</i> , 2006, 184, 53-62.	0.4	26
344	Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization. <i>Atherosclerosis</i> , 2006, 189, 342-349.	0.4	38
345	Immediate and 1-Year Outcome of Percutaneous Intervention of Saphenous Vein Graft Disease with Paclitaxel-Eluting Stents. <i>Journal of Vascular Surgery</i> , 2006, 43, 427.	0.6	0
346	Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. <i>Mayo Clinic Proceedings</i> , 2006, 81, 641-652.	1.4	49
347	The Role of Radiation Therapy in Benign Diseases. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 523-557.	0.9	17
348	Drug-Eluting Stents. <i>Cardiology Clinics</i> , 2006, 24, 217-231.	0.9	8
349	Conduite à tenir devant un patient porteur d'une endoprothèse coronaire devant être anesthésié et opéré. <i>Praticien En Anesthésie Réanimation</i> , 2006, 10, 202-212.	0.0	0
355	Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. <i>European Heart Journal</i> , 2006, 27, 260-266.	1.0	198
356	Synthesis, Characterization, Properties, and Drug Release of Poly(alkyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262 Td (methacrylate-b-iso	2.6	55
358	Is there an alternative to systemic anticoagulation, as related to interventional biomedical devices?. <i>Expert Review of Medical Devices</i> , 2006, 3, 245-261.	1.4	25
360	Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 47, 708-714.	1.2	172
361	Noncalcified and Calcified Coronary Plaque Detection by Contrast-Enhanced Multi-Detector Computed Tomography: A Study of Interobserver Agreement. <i>Journal of the American College of Cardiology</i> , 2006, 47, 207-209.	1.2	54
362	Coronary Stent Thrombosis in the Current Drug-Eluting Stent Era: Insights From the ERACI III Trial. <i>Journal of the American College of Cardiology</i> , 2006, 47, 205-207.	1.2	87
363	The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) Trial. <i>Journal of the American College of Cardiology</i> , 2006, 47, 449-455.	1.2	107

#	ARTICLE	IF	CITATIONS
364	Initial Experience With a Magnetic Navigation System for Percutaneous Coronary Intervention in Complex Coronary Artery Lesions. <i>Journal of the American College of Cardiology</i> , 2006, 47, 515-521.	1.2	61
365	Two-Year Outcomes After Sirolimus-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1350-1355.	1.2	146
366	Long-Term Outcomes After Stenting of Bifurcation Lesions With the "Crush" Technique. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1949-1958.	1.2	228
367	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2006, 47, e1-e121.	1.2	435
368	Drug-Eluting Stenting for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2006, 47, 878-881.	1.2	65
369	Fourth Annual American College of Cardiology International Lecture. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1754-1768.	1.2	19
370	Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1522-1529.	1.2	95
371	Rapid Decline of Collateral Circulation Increases Susceptibility to Myocardial Ischemia. <i>Journal of the American College of Cardiology</i> , 2006, 48, 59-65.	1.2	62
372	Drug-Eluting Stents in the Treatment of Intermediate Lesions. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2164-2171.	1.2	63
373	Mechanisms and Predictors of Carotid Artery Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2390-2396.	1.2	91
374	Cost Analysis From Two Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in High-Risk Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, 262-267.	1.2	11
375	The Year in Interventional Cardiology. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1689-1706.	1.2	28
376	Drug-Eluting Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2399-2404.	1.2	92
377	Periprocedural and Late Consequences of Overlapping Cypher Sirolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 48, 21-31.	1.2	81
378	Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 48, 32-36.	1.2	134
379	Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2006, 48, 253-261.	1.2	64
380	Pathology of Drug-Eluting Stents in Humans. <i>Journal of the American College of Cardiology</i> , 2006, 48, 193-202.	1.2	2,537
381	Clinical Outcomes for Sirolimus-Eluting Stents and Polymer-Coated Paclitaxel-Eluting Stents in Daily Practice. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1312-1318.	1.2	41

#	ARTICLE	IF	CITATIONS
382	Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1139-1145.	1.2	51
383	Vessel Size and Outcome After Coronary Drug-Eluting Stent Placement. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1304-1309.	1.2	87
384	An Initial Strategy of Intensive Medical Therapy Is Comparable to That of Coronary Revascularization for Suppression of Scintigraphic Ischemia in High-Risk But Stable Survivors of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2458-2467.	1.2	120
385	Two-Year Follow-Up of the Quantitative Angiographic and Volumetric Intravascular Ultrasound Analysis After Nonpolymeric Paclitaxel-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2432-2439.	1.2	101
386	Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2440-2447.	1.2	342
387	Late Ischemic Events After Clopidogrel Cessation Following Drug-Eluting Stenting. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2592-2595.	1.2	24
388	Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2584-2591.	1.2	1,242
389	Release of Plasmid DNA from Intravascular Stents Coated with Ultrathin Multilayered Polyelectrolyte Films. <i>Biomacromolecules</i> , 2006, 7, 2483-2491.	2.6	153
390	Coronary Interventional Devices: Balloon, Atherectomy, Thrombectomy and Distal Protection Devices. <i>Cardiology Clinics</i> , 2006, 24, 201-215.	0.9	4
391	Hemodialysis Vascular Access Dysfunction: A Cellular and Molecular Viewpoint. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1112-1127.	3.0	500
392	Surface and Depth Profiling Investigation of a Drug-Loaded Copolymer Utilized To Coat Taxus Express2Stents. <i>Analytical Chemistry</i> , 2006, 78, 8347-8353.	3.2	37
393	In Situ Visualization of Paclitaxel Distribution and Release by Coherent Anti-Stokes Raman Scattering Microscopy. <i>Analytical Chemistry</i> , 2006, 78, 8036-8043.	3.2	67
394	Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. <i>European Heart Journal</i> , 2006, 27, 2784-2814.	1.0	433
395	Comparison between stenting and balloon angioplasty in patients undergoing primary angioplasty of small coronary vessels. <i>American Heart Journal</i> , 2006, 152, 915-920.	1.2	8
396	Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: Subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). <i>American Heart Journal</i> , 2006, 152, 1140-1145.	1.2	76
397	Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry. <i>American Heart Journal</i> , 2006, 152, 1146-1152.	1.2	25
398	Angioscopic evaluation of neointima coverage: Sirolimus drug-eluting stent versus bare metal stent. <i>American Heart Journal</i> , 2006, 152, 1168-1174.	1.2	90
399	Late Thrombosis of Drug-Eluting Stents: A Meta-Analysis of Randomized Clinical Trials. <i>American Journal of Medicine</i> , 2006, 119, 1056-1061.	0.6	452

#	ARTICLE	IF	CITATIONS
400	Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction. <i>Annals of Thoracic Surgery</i> , 2006, 81, 1162-1171.	0.7	18
401	Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Patients with Diabetes Mellitus. <i>Annals of Thoracic Surgery</i> , 2006, 82, 1692-1697.	0.7	23
402	Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: Results from the Cilostazol for RESTenosis (CREST) trial. <i>American Heart Journal</i> , 2006, 152, 770-776.	1.2	27
403	Sirolimus versus bare metal stent implantation in patients with total coronary occlusions. <i>American Heart Journal</i> , 2006, 152, 882-886.	1.2	29
404	The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: Randomized controlled prospective study. <i>American Heart Journal</i> , 2006, 152, 887.e1-887.e7.	1.2	18
405	Is sirolimus better than paclitaxel? A review of the comparative data on drug-eluting stents. <i>Cardiovascular Revascularization Medicine</i> , 2006, 7, 159-164.	0.3	4
406	Double jeopardy: balance between bleeding and stent thrombosis with prolonged dual antiplatelet therapy after drug-eluting stent implantation. <i>Cardiovascular Revascularization Medicine</i> , 2006, 7, 155-158.	0.3	18
407	Expression of lectin-like oxidized LDL receptor-1 in smooth muscle cells after vascular injury. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 591-598.	1.0	53
408	A Fully Integrated Multisite Pressure Sensor for Wireless Arterial Flow Characterization. <i>Journal of Microelectromechanical Systems</i> , 2006, 15, 678-685.	1.7	48
409	Acute coronary syndrome and myocardial infarction after orthopedic surgery in a patient with a recently placed drug-eluting stent. <i>Journal of Clinical Anesthesia</i> , 2006, 18, 537-540.	0.7	8
410	Percutaneous Coronary Interventions With Stents in Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 298-301.	0.3	67
411	New diagnostic technique in multi-slice computed tomography for in-stent restenosis: Pixel count method. <i>International Journal of Cardiology</i> , 2006, 108, 251-258.	0.8	32
412	Directional atherectomy before stenting versus stenting alone in percutaneous coronary interventions: A meta-analysis. <i>International Journal of Cardiology</i> , 2006, 112, 178-183.	0.8	10
413	Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2006, 110, 237-241.	0.8	21
414	Risk factors for impaired health status differ in women and men treated with percutaneous coronary intervention in the drug-eluting stent era. <i>Journal of Psychosomatic Research</i> , 2006, 61, 11-17.	1.2	6
415	Anxiety enhances the detrimental effect of depressive symptoms on health status following percutaneous coronary intervention. <i>Journal of Psychosomatic Research</i> , 2006, 61, 783-789.	1.2	41
416	Coronary Restenosis after Drug-Eluting Stent Implantation in Diabetic Patients. <i>Korean Circulation Journal</i> , 2006, 36, 1.	0.7	2
417	Treatment of Diffuse Long Coronary Artery Disease with Overlapping Drug-Eluting Stents is Effective?. <i>Korean Circulation Journal</i> , 2006, 36, 8.	0.7	1

#	ARTICLE	IF	CITATIONS
418	Clinical Outcomes of Using Sirolimus-Eluting Stents for Treating In-Stent Restenosis: A Quantitative Coronary Angiography Study. Korean Circulation Journal, 2006, 36, 121.	0.7	0
419	The Efficacy of Drug Eluting Stents on Restenosis Reduction in Small Coronary Arteries. Korean Circulation Journal, 2006, 36, 450.	0.7	4
420	Late Stent Thrombosis Associated with Late Stent Malapposition after Drug-Eluting Stenting: A Case Report. Korean Circulation Journal, 2006, 36, 472.	0.7	6
421	Comparisons of the Short-Term Angiographic Outcomes of Cypher and Taxus Stents Implanted in the Same Patient. Korean Circulation Journal, 2006, 36, 600.	0.7	3
422	Consenso de especialistas (SBC/SBHCI) sobre o uso de stents farmacolÃ3gicos: recomendaÃšÃµes da sociedade brasileira de cardiologia/sociedade brasileira de hemodinÃ¢mica e cardiologia intervencionista ao sistema Ãºnico de saÃºde. Arquivos Brasileiros De Cardiologia, 2006, 87, e162-e167.	0.3	7
423	Utilization Pattern of Drug-Eluting Stents and Prognosis of Patients Who Underwent Drug-Eluting Stenting Compared with Bare Metal Stenting in the Real World. Korean Circulation Journal, 2006, 36, 178.	0.7	2
424	Potential role of Chinese medicinal herbs in the prevention of coronary artery restenosis. Chinese Medical Journal, 2006, 119, 3-5.	0.9	3
425	A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chinese Medical Journal, 2006, 119, 360-366.	0.9	27
426	Comparison of drug-eluting stent and bare-metal stent in the complex small vessel intervention. Chinese Medical Journal, 2006, 119, 596-600.	0.9	2
427	One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. Chinese Medical Journal, 2006, 119, 165-168.	0.9	27
428	Comparison of drug eluting stents with bare metal stents in daily practice for bifurcation lesions in Chinese patients. Chinese Medical Journal, 2006, 119, 1157-1164.	0.9	7
429	Use of drug-eluting stents in Victorian public hospitals. Medical Journal of Australia, 2006, 185, 363-367.	0.8	28
430	La chirurgie cardiaque du sujet Ã¢gÃ©. Bulletin De L'Academie Nationale De Medecine, 2006, 190, 855-872.	0.0	1
431	Stents. , 2006, , 565-568.		0
433	Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization. Yearbook of Medicine, 2006, 2006, 331-333.	0.1	0
434	Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents. Yearbook of Cardiology, 2006, 2006, 260-261.	0.0	3
435	Drug-eluting stents and stent thrombosis: a cause for concern?. Coronary Artery Disease, 2006, 17, 661-665.	0.3	25
436	Histopathology of Carotid Atherosclerotic Disease. Neurosurgery, 2006, 59, S3-219-S3-227.	0.6	157

#	ARTICLE	IF	CITATIONS
437	Initial impact of drug-eluting stent use on the spectrum of patients undergoing percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2006, 17, 379-384.	0.3	3
438	Clinical Outcomes in Metabolic Syndrome. <i>Journal of Cardiovascular Nursing</i> , 2006, 21, 298-305.	0.6	9
439	Clinical Benefits of Drug-Eluting Stents. <i>Journal of Cardiovascular Nursing</i> , 2006, 21, 442-450.	0.6	3
440	Drug-eluting stent era: will we improve 5-year outcomes?. <i>Coronary Artery Disease</i> , 2006, 17, 289-292.	0.3	2
441	Open new pathways with drug-eluting stents. <i>Nurs Crit Care (Ambler)</i> , 2006, 1, 34-39.	0.3	0
442	From randomized trials to routine clinical practice: an evidence-based approach for the use of drug-eluting stents. <i>Coronary Artery Disease</i> , 2006, 17, 673-679.	0.3	3
443	The Paclitaxel-Eluting Stent in Percutaneous Coronary Intervention. <i>Cardiology in Review</i> , 2006, 14, 88-98.	0.6	13
444	Current Concepts in the Management of Intracranial Atherosclerotic Disease. <i>Neurosurgery</i> , 2006, 59, S210-S218.	0.6	21
445	Drug-eluting stents for stent thrombosis elevation acute myocardial infarction: do we need randomized trials?. <i>Coronary Artery Disease</i> , 2006, 17, 667-671.	0.3	3
446	Drug Eluting Stents. <i>Coronary Artery Disease</i> , 2006, 17, 657-659.	0.3	3
447	Drug-eluting stent era: will we improve 5-year outcomes?. <i>Coronary Artery Disease</i> , 2006, 17, 681-684.	0.3	2
448	Optimal revascularization strategies for multivessel coronary artery disease. <i>Current Opinion in Cardiology</i> , 2006, 21, 595-601.	0.8	7
449	Sirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1264.	3.8	218
450	Narrative Review: Drug-Eluting Stents for the Management of Restenosis: A Critical Appraisal of the Evidence. <i>Annals of Internal Medicine</i> , 2006, 144, 913.	2.0	96
451	Polymers for tissue engineering, medical devices, and regenerative medicine. Concise general review of recent studies. <i>Polymers for Advanced Technologies</i> , 2006, 17, 395-418.	1.6	338
452	Adjunctive Balloon Postdilatation after Stent Deployment: Is It Still Necessary with Drug-Eluting Stents?. <i>Journal of Interventional Cardiology</i> , 2006, 19, 43-50.	0.5	33
453	Analysis of Location and Pattern of Target Vessel Failure in Chronic Total Occlusions after Stent Implantation and Its Potential for the Efficient Use of Drug-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2006, 19, 226-231.	0.5	5
455	"Do Least Harm" Philosophy May Suffice for Percutaneous Coronary Intervention in Octogenarians. <i>Journal of Interventional Cardiology</i> , 2006, 19, 313-318.	0.5	8

#	ARTICLE	IF	CITATIONS
456	Unprotected Left Main Coronary Intervention with Drug-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2006, 19, S21-S26.	0.5	4
457	Drug-Eluting Stent Restenosis: Incidence, Predictors, Mechanisms, and Treatment. <i>Journal of Interventional Cardiology</i> , 2006, 19, S47-S53.	0.5	9
458	An Overview of the TAXUS ₂ Express ₂ , Paclitaxel-Eluting Stent Clinical Trial Program. <i>Journal of Interventional Cardiology</i> , 2006, 19, 422-431.	0.5	23
459	Overview of Pharmacology and Clinical Trials Program with the Zotarolimus-Eluting Endeavor Stent. <i>Journal of Interventional Cardiology</i> , 2006, 19, 405-413.	0.5	66
460	Off-Label Use: An Industry Perspective on Expanding Use Beyond Approved Indications. <i>Journal of Interventional Cardiology</i> , 2006, 19, 432-438.	0.5	15
461	New Developments in Coronary Stent Technology. <i>Journal of Interventional Cardiology</i> , 2006, 19, 493-499.	0.5	24
462	A New and Rapid Scoring System to Assess the Scientific Evidence from Clinical Trials. <i>Journal of Interventional Cardiology</i> , 2006, 19, 485-492.	0.5	23
463	Efficacy and Safety of Drug-Eluting Stents: Current Best Available Evidence. <i>Journal of Cardiac Surgery</i> , 2006, 21, 605-612.	0.3	5
464	BRAVO I: A pilot study of vascular brachytherapy in polytetrafluoroethylene dialysis access grafts. <i>Kidney International</i> , 2006, 70, 2006-2013.	2.6	38
465	The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. <i>Kidney International</i> , 2006, 70, 2021-2030.	2.6	227
466	Drug/device combinations for local drug therapies and infection prophylaxis. <i>Biomaterials</i> , 2006, 27, 2450-2467.	5.7	440
467	Safety and efficacy with drug-eluting stent in st-segment elevation and non-ST-segment elevation myocardial infarction. <i>Clinical Cardiology</i> , 2006, 29, 199-203.	0.7	2
468	Zotarolimus (ABT-578) eluting stents. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 437-446.	6.6	88
469	Role of stent design and coatings on restenosis and thrombosis. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 377-386.	6.6	151
470	The Taxus ₂ drug-eluting stent: A new paradigm in controlled drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 412-436.	6.6	158
471	Computational Approach to Estimating the Effects of Blood Properties on Changes in Intra-stent Flow. <i>Annals of Biomedical Engineering</i> , 2006, 34, 1259-1271.	1.3	33
472	How to revascularize patients with diabetes mellitus? <i>Clinical Research in Cardiology</i> , 2006, 95, 195-203.	1.5	16
475	Clopidogrel treatment surrounding percutaneous coronary intervention: When should it be started and stopped?. <i>Current Cardiology Reports</i> , 2006, 8, 267-271.	1.3	10

#	ARTICLE	IF	CITATIONS
476	Use of an audible ultrasonic flowmeter to locate deeply buried coronary arteries for off-pump coronary artery bypass grafting. <i>General Thoracic and Cardiovascular Surgery</i> , 2006, 54, 75-77.	0.4	0
477	The Impact of Lesion Length on Angiographic Restenosis after Vertebral Artery Origin Stenting. <i>European Journal of Vascular and Endovascular Surgery</i> , 2006, 32, 379-385.	0.8	52
478	Heterogeneity of Neointimal Distribution of In-Stent Restenosis in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2006, 97, 340-342.	0.7	8
479	Impact of Three or More Versus a Single Sirolimus-Eluting Stent on Outcomes in Patients Who Undergo Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2006, 97, 606-610.	0.7	13
480	Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary In-Stent Restenosis. <i>American Journal of Cardiology</i> , 2006, 97, 1182-1187.	0.7	24
481	C-Reactive Protein, Clinical Outcome, and Restenosis Rates After Implantation of Different Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2006, 97, 1311-1316.	0.7	40
482	Sirolimus-Eluting Stents at Two Years: A Pooled Analysis of SIRIUS, E-SIRIUS, and C-SIRIUS With Emphasis on Late Revascularizations and Stent Thromboses. <i>American Journal of Cardiology</i> , 2006, 98, 36-41.	0.7	83
483	Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in the Treatment of Coronary Artery Disease in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2006, 98, 187-192.	0.7	38
484	Procedural Results and Outcomes After Extensive Stent Coverage With Drug-Eluting Stent Implantation in Single Coronary Lesions. <i>American Journal of Cardiology</i> , 2006, 98, 357-361.	0.7	4
485	Review of Randomized Clinical Trials of Drug-Eluting Stents for the Prevention of In-Stent Restenosis—All study acronyms used in this review are defined in Table 1.. <i>American Journal of Cardiology</i> , 2006, 98, 375-382.	0.7	83
486	Angiographic Results of the First Human Experience With the Biolimus A9 Drug-Eluting Stent for De Novo Coronary Lesions. <i>American Journal of Cardiology</i> , 2006, 98, 443-446.	0.7	64
487	Twelve-Month Outcomes With a Paclitaxel-Eluting Stent Transitioning from Controlled Trials to Clinical Practice (the WISDOM Registry). <i>American Journal of Cardiology</i> , 2006, 98, 1028-1032.	0.7	27
488	Intravascular Brachytherapy Versus Drug-Eluting Stents for the Treatment of Patients With Drug-Eluting Stent Restenosis. <i>American Journal of Cardiology</i> , 2006, 98, 1340-1344.	0.7	61
489	Early- and Medium-Term Outcomes After Paclitaxel-Eluting Stent Implantation for Sirolimus-Eluting Stent Failure. <i>American Journal of Cardiology</i> , 2006, 98, 1345-1348.	0.7	30
490	Comparison With Conventional Therapies of Repeated Sirolimus-Eluting Stent Implantation for the Treatment of Drug-Eluting Coronary Stent Restenosis. <i>American Journal of Cardiology</i> , 2006, 98, 1451-1454.	0.7	48
491	Comparison of Clinical Outcomes of Overlapping Sirolimus- Versus Paclitaxel-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2006, 98, 1563-1566.	0.7	12
492	Drug-Eluting Coronary Stents. <i>Current Problems in Cardiology</i> , 2006, 31, 8-119.	1.1	45
493	Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. <i>Biochemical Pharmacology</i> , 2006, 71, 806-817.	2.0	69

#	ARTICLE	IF	CITATIONS
494	Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. <i>Journal of Controlled Release</i> , 2006, 113, 23-30.	4.8	63
495	Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: A strategy of extensive lesion coverage with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 1-9.	0.7	42
496	Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 181-187.	0.7	52
497	Sirolimus-eluting stents and calcified coronary lesions: Clinical outcomes of patients treated with and without rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 873-878.	0.7	92
498	Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 344-348.	0.7	65
499	LIMA thoracic branch coronary steal syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 332-332.	0.7	5
500	Author's response to Dr. Kern's letter. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 333-333.	0.7	0
501	Impact of overlapping drug-eluting stents in patients undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 595-599.	0.7	21
502	Very late thrombosis after drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 83-88.	0.7	112
503	Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 589-594.	0.7	19
504	Reply to the letter: Oral sirolimus after bare metal stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 336-336.	0.7	0
505	The paclitaxel-eluting Coroflexâ„¢ please stent pilot study (PECOPS I): Acute and 6-month clinical and angiographic follow-up. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 703-710.	0.7	14
506	Impact of three or more sirolimus-eluting stents versus paclitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 62-66.	0.7	3
507	Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID)â€”A single-center study comparing Cypherâ„¢ sirolimus-eluting with Taxusâ„¢ paclitaxel-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 663-668.	0.7	10
508	Bifurcation stenting with drug eluting stents: Illustration of the crush technique. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 839-845.	0.7	16
509	â€œHead-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: An intravascular ultrasound studyâ€. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 846-851.	0.7	23
510	Oral Sirolimus after bare metal stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 334-335.	0.7	0
511	Experimental efficacy of an everolimus eluting cobalt chromium stent. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 97-103.	0.7	51

#	ARTICLE	IF	CITATIONS
512	Use of Taxus polymer-coated paclitaxel-eluting stents for treatment of in-stent restenosis in real world patients: Results of clinical and angiographic follow-up at six months in a single-center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 343-348.	0.7	5
513	Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 567-573.	0.7	4
514	Improved survival with drug-eluting stent implantation in comparison with bare metal stent in patients with severe left ventricular dysfunction. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 392-398.	0.7	19
515	Trends in percutaneous versus surgical revascularization of unprotected left main coronary stenosis in the drug-eluting stent era—a report from the American College of Cardiology-National Cardiovascular data registry (ACC-NCDR). <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 867-872.	0.7	55
516	Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells. <i>Journal of Cellular Biochemistry</i> , 2006, 99, 835-844.	1.2	9
517	Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2425-2431.	0.4	65
518	Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1253.	3.8	243
519	Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. <i>European Heart Journal</i> , 2006, 27, 1305-1310.	1.0	240
520	Development of a Local Perivascular Paclitaxel Delivery System for Hemodialysis Vascular Access Dysfunction: Polymer Preparation and in vitro Activity. <i>Blood Purification</i> , 2006, 24, 289-298.	0.9	25
521	Safety, Feasibility, and Short-Term Follow-Up of Drug-Eluting Stent Placement in the Intracranial and Extracranial Circulation. <i>Stroke</i> , 2006, 37, 2562-2566.	1.0	177
522	Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. <i>European Heart Journal</i> , 2006, 27, 2330-2337.	1.0	59
523	Guidelines on the management of stable angina pectoris. <i>European Heart Journal</i> , 2006, 27, 2606-2606.	1.0	25
524	Sirolimus- or paclitaxel-eluting stents for coronary artery revascularisation. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 225-228.	0.9	0
525	Coronary artery restenosis: vascular biology and emerging therapeutic strategies. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 543-556.	0.6	17
526	Drug-Eluting Stents in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2006, 355, 1169-1170.	13.9	26
527	Paclitaxel-Eluting versus Uncoated Stents in Primary Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2006, 355, 1105-1113.	13.9	399
528	Drug eluting stents: an updated meta-analysis of randomised controlled trials. <i>Heart</i> , 2006, 92, 641-649.	1.2	171
529	Premature discontinuation of antiplatelet therapy in patients with drug-eluting coronary stents. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2308-2310.	0.5	1

#	ARTICLE	IF	CITATIONS
530	Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model. <i>Cardiovascular Research</i> , 2006, 69, 536-544.	1.8	10
531	Update on Drug-Eluting Stents for Prevention of Restenosis. <i>Asian Cardiovascular and Thoracic Annals</i> , 2006, 14, 75-82.	0.2	5
532	Role of Endogenous Fas (CD95/Apo-1) Ligand in Balloon-Induced Apoptosis, Inflammation, and Neointima Formation. <i>Circulation</i> , 2006, 113, 1879-1887.	1.6	35
533	Diabetes Does Not Influence Treatment Decisions Regarding Revascularization in Patients With Stable Coronary Artery Disease. <i>Diabetes Care</i> , 2006, 29, 2003-2011.	4.3	12
534	Comparative Effects of Paclitaxel and Rapamycin on Smooth Muscle Migration and Survival. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1473-1480.	1.1	68
535	Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. <i>Heart</i> , 2006, 92, 1119-1124.	1.2	92
536	Impact of Routine Stenting on Clinical Outcome in Diabetic Patients Undergoing Primary Angioplasty for ST-Segment Elevation Myocardial Infarction. <i>Diabetes Care</i> , 2006, 29, 920-923.	4.3	11
537	Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 895.	3.8	419
538	A Newly Designed Glaucoma Drainage Implant Made of Poly(styrene-b-isobutylene-b-styrene). <i>JAMA Ophthalmology</i> , 2006, 124, 1742.	2.6	72
539	Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. <i>European Journal of Cardio-thoracic Surgery</i> , 2006, 29, 486-491.	0.6	181
540	Are Drug-Eluting Stents Cost-Effective?. <i>Circulation</i> , 2006, 114, 1736-1744.	1.6	45
541	Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss. <i>Circulation</i> , 2006, 113, 273-279.	1.6	176
542	Status of percutaneous coronary intervention and coronary artery bypass. <i>European Journal of Cardio-thoracic Surgery</i> , 2006, 30, 419-424.	0.6	7
543	Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH 2 Kinase Activation. <i>Circulation Research</i> , 2006, 99, 149-155.	2.0	110
544	ACC/AHA/SCAI Practice Guidelines, February 21, 2006. <i>Circulation</i> , 2006, 113, e166-286.	1.6	525
545	Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. <i>Heart</i> , 2006, 92, 650-657.	1.2	70
546	Antiplatelet Therapy after Percutaneous Coronary Intervention. <i>Cerebrovascular Diseases</i> , 2006, 21, 25-34.	0.8	14
547	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. <i>Circulation</i> , 2006, 114, 2850-2870.	1.6	346

#	ARTICLE	IF	CITATIONS
548	Adjunctive pharmacotherapy for coronary interventions—time to read the writing on the wall. <i>Acute Cardiac Care</i> , 2006, 8, 186-195.	0.2	2
549	The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 815-826.	1.0	17
550	Restenosis related to percutaneous coronary intervention has been solved?. <i>Annals of Medicine</i> , 2006, 38, 173-187.	1.5	24
552	Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter. <i>New England Journal of Medicine</i> , 2006, 355, 2113-2124.	13.9	675
553	The 5-Year Projection on the Future of Interventional Cardiology. <i>The American Heart Hospital Journal</i> , 2006, 4, 195-201.	0.2	3
554	Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents. <i>Circulation</i> , 2006, 113, 2293-2300.	1.6	266
555	Coronary artery overexpansion increases neointimal hyperplasia after stent placement in a porcine model. <i>Heart</i> , 2006, 93, 1609-1615.	1.2	30
556	Drug-Eluting Stent Thrombosis vs Bare Metal Stent Restenosis: Finding the Lesser of Two Evils. <i>The American Heart Hospital Journal</i> , 2007, 5, 151-154.	0.2	1
557	Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation. <i>Circulation</i> , 2007, 115, 2842-2847.	1.6	162
558	The economic burden of complications during percutaneous coronary intervention. <i>Quality and Safety in Health Care</i> , 2007, 16, 154-159.	2.5	38
559	Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. <i>Heart</i> , 2007, 93, 1087-1092.	1.2	47
560	Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention. <i>Circulation</i> , 2007, 116, 2802-2808.	1.6	25
561	Vascular pathology as a result of drug-eluting stents. <i>Heart</i> , 2007, 93, 895-896.	1.2	2
562	Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 939-953.	0.6	1
563	Drug-Eluting Stents: Can We Move Beyond Stent Thrombosis?. <i>The American Heart Hospital Journal</i> , 2007, 5, 155-158.	0.2	2
564	Percutaneous coronary intervention for left main coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 213-220.	0.6	0
565	Drug-Eluting Stent Update 2007. <i>Circulation</i> , 2007, 116, 316-328.	1.6	106
566	Gene therapy and stem cell therapy for cardiovascular diseases today: a model for translational research. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, S1-S8.	3.3	13

#	ARTICLE	IF	CITATIONS
567	Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention With Drug-Eluting Stents for Patients With Multivessel Coronary Artery Disease. <i>Circulation</i> , 2007, 116, 1200-6.	1.6	134
568	The Case for Outpatient Coronary Intervention. <i>Circulation</i> , 2007, 115, 2248-2250.	1.6	10
569	Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. <i>European Heart Journal</i> , 2007, 28, 1583-1591.	1.0	51
570	Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. <i>European Heart Journal</i> , 2007, 28, 726-732.	1.0	270
571	Recruitable collateral blood flow index predicts coronary in-stent restenosis after percutaneous coronary intervention. <i>European Heart Journal</i> , 2007, 28, 1820-1826.	1.0	17
572	Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. <i>European Heart Journal</i> , 2007, 28, 1574-1582.	1.0	47
573	TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. <i>European Heart Journal</i> , 2007, 28, 2578-2582.	1.0	52
574	The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis. <i>Country Review Ukraine</i> , 2007, 9, D10-D19.	0.8	1
575	The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). <i>European Heart Journal</i> , 2007, 28, 433-442.	1.0	113
577	Review of the TAXUS® Liberté SR paclitaxel-eluting coronary stent. <i>Expert Review of Medical Devices</i> , 2007, 4, 117-120.	1.4	9
578	Dose calculation formalisms and consensus dosimetry parameters for intravascular brachytherapy dosimetry: Recommendations of the AAPM Therapy Physics Committee Task Group No. 149. <i>Medical Physics</i> , 2007, 34, 4126-4157.	1.6	47
579	Controversies Surrounding the Use of Drug-Eluting Stents. <i>The American Heart Hospital Journal</i> , 2007, 5, 141-145.	0.2	0
580	Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. <i>Heart</i> , 2007, 93, 922-927.	1.2	61
581	Pathological Correlates of Late Drug-Eluting Stent Thrombosis. <i>Circulation</i> , 2007, 115, 2435-2441.	1.6	1,200
582	Favorable Long-Term Outcome After Drug-Eluting Stent Implantation in Nonbifurcation Lesions That Involve Unprotected Left Main Coronary Artery. <i>Circulation</i> , 2007, 116, 158-162.	1.6	182
583	Drug-Eluting Stent Update 2007. <i>Circulation</i> , 2007, 116, 1424-1432.	1.6	56
584	Adverse clinical events in patients treated with sirolimus-eluting stents: the impact of Type D personality. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 135-140.	3.1	43
585	Endovascular Therapies for Peripheral Arterial Disease. <i>Circulation</i> , 2007, 116, 2203-2215.	1.6	122

#	ARTICLE	IF	CITATIONS
586	Coronary artery stents and non-cardiac surgery. <i>British Journal of Anaesthesia</i> , 2007, 98, 560-574.	1.5	109
587	Success, Safety, and Efficacy of Implantation of Diamond-Like Carbon-Coated Stents. <i>Angiology</i> , 2007, 58, 203-210.	0.8	22
588	A HUVEC Line with a Stable Expression of the VEGF121 Gene to Achieve Complete Endothelialization of Blood Conduits. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 2007, 35, 319-331.	0.9	4
589	Long-Term Safety and Efficacy of Drug-Eluting Stents. <i>Circulation</i> , 2007, 115, 3181-3188.	1.6	138
590	Activation of Nuclear Receptor Nur77 by 6-Mercaptopurine Protects Against Neointima Formation. <i>Circulation</i> , 2007, 115, 493-500.	1.6	68
591	Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1769.	3.8	2
592	Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 32, 906-911.	0.6	12
593	Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent. <i>Heart</i> , 2007, 93, 694-697.	1.2	16
594	Metastatic squamous cell carcinoma causing right ventricular outflow tract obstruction. <i>Heart</i> , 2007, 93, 697-697.	1.2	5
595	Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. <i>Heart</i> , 2007, 93, 331-334.	1.2	45
596	Vascular Responses to Drug Eluting Stents. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1500-1510.	1.1	826
597	Restenosis and Stent Fracture Following Sirolimus-Eluting Stent (SES) Implantation A Serial Quantitative Coronary Angiography (QCA) and Intravascular Ultrasound (IVUS) Study. <i>Circulation Journal</i> , 2007, 71, 1669-1677.	0.7	54
598	Effect of Cilostazol on In-Stent Neointimal Hyperplasia After Coronary Artery Stenting A Quantitative Coronary Angiography and Volumetric Intravascular Ultrasound Study. <i>Circulation Journal</i> , 2007, 71, 1685-1690.	0.7	36
599	Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2001.	3.8	311
600	Current issues in coronary artery stenting in the elderly. <i>Aging Health</i> , 2007, 3, 105-114.	0.3	2
601	Impact of Cutting Balloon Angioplasty (CBA) Prior to Bare Metal Stenting on Restenosis A Prospective Randomized Multicenter Trial Comparing CBA With Balloon Angioplasty (BA) Before Stenting (REDUCE) Tj ETQq1 100784314rgBT /Ove		
603	Tetramethylpyrazine-Eluting Stents Prevented In-Stent Restenosis in a Porcine Model. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 201-205.	0.8	5
604	Rational Use of Drug-Eluting Stents. <i>Critical Pathways in Cardiology</i> , 2007, 6, 85-89.	0.2	2

#	ARTICLE	IF	CITATIONS
605	Peripheral atherosclerosis is associated with the occurrence of restenosis after percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2007, 18, 627-631.	0.3	8
606	Drug-Eluting Stents. <i>Cardiology in Review</i> , 2007, 15, 1-12.	0.6	37
607	Hematologic Adverse Effects of Clopidogrel. <i>American Journal of Therapeutics</i> , 2007, 14, 106-112.	0.5	28
608	The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. <i>Current Opinion in Cardiology</i> , 2007, 22, 565-571.	0.8	31
609	Late coronary thrombosis in paclitaxel-eluting stents. Case reports. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 284-288.	0.6	1
610	Economic appraisal of the angioplasty procedures performed in 2004 in a high-volume diagnostic and interventional cardiology unit. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 792-798.	0.6	1
611	Long-term health outcome and mortality evaluation after invasive coronary treatment using drug-eluting stents: HOME DES registry. <i>Coronary Artery Disease</i> , 2007, 18, 577-581.	0.3	1
612	Implantation of sirolimus-eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels. <i>Coronary Artery Disease</i> , 2007, 18, 559-564.	0.3	25
613	Paclitaxel-eluting stents for the treatment of complex coronary lesions: immediate and 12-month results. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 582-588.	0.6	3
614	Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 625-628.	0.6	2
615	Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. <i>European Heart Journal</i> , 2007, 28, 1946-1952.	1.0	73
616	Intravascular ultrasound assessment of drug-eluting stent expansion. <i>American Heart Journal</i> , 2007, 153, 297-303.	1.2	76
617	Anatomical and physiologic assessments in patients with small coronary artery disease: Final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial. <i>American Heart Journal</i> , 2007, 153, 296.e1-296.e7.	1.2	51
618	Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent. <i>American Heart Journal</i> , 2007, 153, 354-359.	1.2	79
619	The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) Trial study design: Advancing the active-control evaluation of second-generation drug-eluting stents. <i>American Heart Journal</i> , 2007, 153, 743-748.	1.2	15
620	Neointimal progression and luminal narrowing in sirolimus-eluting stent treatment for bare metal in-stent restenosis: A quantitative intravascular ultrasound analysis. <i>American Heart Journal</i> , 2007, 154, 361-365.	1.2	13
621	Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels. <i>American Heart Journal</i> , 2007, 154, 373-378.	1.2	28
622	A comparison of mortality, myocardial infarction, and repeated revascularization for sirolimus-eluting and paclitaxel-eluting coronary stents. <i>American Heart Journal</i> , 2007, 154, 545-553.	1.2	6

#	ARTICLE	IF	CITATIONS
623	Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. <i>American Heart Journal</i> , 2007, 154, 688-693.	1.2	91
624	Comparison of angiographically guided direct stenting technique with direct stenting and optimal balloon angioplasty guided with intravascular ultrasound. The multicenter, randomized trial results. <i>American Heart Journal</i> , 2007, 154, 669-675.	1.2	41
625	A tale of two stents: perioperative management of patients with drug-eluting coronary stents. <i>Journal of Clinical Anesthesia</i> , 2007, 19, 386-396.	0.7	15
626	Impaired health status in Type D patients following PCI in the drug-eluting stent era. <i>International Journal of Cardiology</i> , 2007, 114, 358-365.	0.8	36
627	In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: A case report. <i>International Journal of Cardiology</i> , 2007, 116, 399-400.	0.8	5
628	Sirolimus-eluting stent showed better one-year outcomes than paclitaxel-eluting stent in a real life setting of coronary intervention in Koreans. <i>International Journal of Cardiology</i> , 2007, 117, 31-36.	0.8	9
629	Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients. <i>International Journal of Cardiology</i> , 2007, 117, 349-354.	0.8	37
630	CYPHER versus TAXUS stent for bifurcation lesions beyond 30 days long-term follow-up results. <i>International Journal of Cardiology</i> , 2007, 117, 422-424.	0.8	3
631	Comparison between stenting and balloon in elderly patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2007, 119, 306-309.	0.8	13
632	Dilemma of drug-eluting stent implantation in a patient with systemic lupus erythematosus. <i>International Journal of Cardiology</i> , 2007, 114, E107-E108.	0.8	3
633	Comparison of angiographic patterns of in-stent restenosis between sirolimus- and paclitaxel-eluting stent. <i>International Journal of Cardiology</i> , 2007, 120, 387-390.	0.8	27
634	Angiographic and intravascular ultrasound study of the effects of overlapping sirolimus- and paclitaxel-eluting stents: Comparison with same drug-eluting overlapping stents. <i>International Journal of Cardiology</i> , 2007, 123, 12-17.	0.8	14
635	Effect of preinterventional arterial remodeling on intimal hyperplasia after implantation of a polymer-based paclitaxel-eluting stent: Angiographic and IVUS study. <i>International Journal of Cardiology</i> , 2007, 123, 50-54.	0.8	6
636	Percutaneous Coronary Revascularization Using a Trilayer Metal Phosphorylcholine-Coated Zotarolimus-Eluting Stent. <i>American Journal of Cardiology</i> , 2007, 99, 1403-1408.	0.7	26
637	Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: An experimental study. <i>Atherosclerosis</i> , 2007, 195, 269-276.	0.4	49
638	Thrombosis: the last frontier of coronary stenting?. <i>Lancet, The</i> , 2007, 369, 619-621.	6.3	18
639	Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. <i>Lancet, The</i> , 2007, 369, 667-678.	6.3	1,879
640	Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. <i>Lancet, The</i> , 2007, 370, 567-574.	6.3	36

#	ARTICLE	IF	CITATIONS
641	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. <i>Lancet, The</i> , 2007, 370, 937-948.	6.3	1,329
642	Usefulness of Drug Eluting Stent in Percutaneous Coronary Intervention—A Single Center Experience in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2007, 106, 624-630.	0.8	1
643	Early restenosis after drug-eluting stent implantation: A putative role for platelet activation. <i>Canadian Journal of Cardiology</i> , 2007, 23, 57-59.	0.8	7
644	The Truth and Consequences of the COURAGE Trial. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1598-1603.	1.2	101
645	Inhibition of neointimal hyperplasia in a sheep model of dialysis access failure with the bioabsorbable Vascular Wrap—Vascular Wrap is a trademark of Angiotech Pharmaceuticals, Inc. paclitaxel-eluting mesh. <i>Journal of Vascular Surgery</i> , 2007, 45, 1029-1038.e3.	0.6	61
646	Revascularization in Heart Failure: The Role of Percutaneous Coronary Intervention. <i>Heart Failure Clinics</i> , 2007, 3, 229-235.	1.0	2
647	Rapid Desensitization Protocols for Patients with Cardiovascular Disease and Aspirin Hypersensitivity in an Era of Dual Antiplatelet Therapy. <i>Annals of Pharmacotherapy</i> , 2007, 41, 61-67.	0.9	27
648	Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351.	1.6	4,993
649	Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. <i>European Heart Journal</i> , 2007, 28, 1304-1309.	1.0	114
650	Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). <i>European Heart Journal</i> , 2007, 28, 719-725.	1.0	74
651	New percutaneous approaches for chronic total occlusion of coronary arteries. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 231-241.	0.6	20
652	Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2007, 356, 998-1008.	13.9	1,776
653	Bio-nanowebs Based on Poly(styrene- <i>l</i> ² -isobutylene- <i>l</i> ² -styrene) (SIBS) Containing Single-Wall Carbon Nanotubes. <i>Chemistry of Materials</i> , 2007, 19, 2721-2723.	3.2	29
654	Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents. <i>New England Journal of Medicine</i> , 2007, 356, 1020-1029.	13.9	1,338
655	Therapy Insight: diabetes and drug-eluting stents. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 143-150.	3.3	14
656	Drug-eluting stent technologies for vascular regeneration. <i>International Journal of Materials Research</i> , 2007, 98, 637-642.	0.1	8
657	Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden. <i>New England Journal of Medicine</i> , 2007, 356, 1009-1019.	13.9	1,113
658	Drug delivery via nano-, micro and macroporous coronary stent surfaces. <i>Expert Opinion on Drug Delivery</i> , 2007, 4, 287-295.	2.4	49

#	ARTICLE	IF	CITATIONS
659	A Cause for Concern. <i>Circulation</i> , 2007, 115, 1440-1455.	1.6	724
660	Pathology of Atherosclerosis and Stenting. <i>Neuroimaging Clinics of North America</i> , 2007, 17, 285-301.	0.5	39
663	Glucocorticoids in the Prevention of Restenosis After Coronary Angioplasty. <i>Drugs</i> , 2007, 67, 1243-1255.	4.9	18
664	Janus [®] Tacrolimus-Eluting Carbestent. Immediate and Medium-Term Clinical Results. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2007, 60, 197-200.	0.4	3
665	Mechanisms of vascular injury from drug-eluting stents. <i>Drug Discovery Today Disease Mechanisms</i> , 2007, 4, 141-146.	0.8	1
666	Contemporary Treatment of In-Stent Restenosis and the Incidence of Recurrent In-Stent Restenosis in the Era of Drug-Eluting Stents. <i>Heart Lung and Circulation</i> , 2007, 16, 269-273.	0.2	4
667	The Vascular Therapist. <i>Heart Lung and Circulation</i> , 2007, 16, 193-199.	0.2	10
668	Coronary Collateral Function Long After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2007, 49, 15-20.	1.2	70
669	Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2007, 49, 616-623.	1.2	149
670	Incidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1043-1051.	1.2	121
671	Polymer-Based, Paclitaxel-Eluting TAXUS Libert [®] Stent in De Novo Lesions. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1676-1683.	1.2	104
672	Percutaneous Coronary Intervention of Functionally Nonsignificant Stenosis. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2105-2111.	1.2	1,377
673	Usefulness of 64-Slice Multislice Computed Tomography Coronary Angiography to Assess In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2204-2210.	1.2	137
674	Perioperative Management of Patients With Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2145-2150.	1.2	188
675	Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2320-2328.	1.2	48
677	Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 138-145.	1.2	78
679	Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions. <i>Journal of the American College of Cardiology</i> , 2007, 50, 463-470.	1.2	229
680	Comparative Clinical Outcomes of Paclitaxel- and Sirolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1214-1222.	1.2	60

#	ARTICLE	IF	CITATIONS
682	Clopidogrel Desensitization After Drug-Eluting Stent Placement. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2039-2043.	1.2	45
683	Drug-Eluting Coronary Stents. , 0, , 335-353.		0
684	Treatment with Drug-Eluting Stents. , 2007, , 135-156.		0
685	Avaliaç�o do custo do implante programado de m�ltiplos stents em mais de uma intervenç�o percut�nea em pacientes com doenç�a coron�ria multiarterial. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2007, 15, 249-254.	0.1	3
686	Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. <i>Thrombosis and Haemostasis</i> , 2007, 97, 1003-1012.	1.8	48
688	Stents in interventional cardiology. <i>Medicina (Lithuania)</i> , 2007, 43, 183.	0.8	2
689	Comparison of the Predictors of Coronary Restenosis after Drug-Eluting Stent Implantation in Diabetic and Nondiabetic Patients. <i>Korean Circulation Journal</i> , 2007, 37, 530.	0.7	3
690	Evoluç�o cl�nica tardia dos stents farmacol�gicos: seguranç�a e efic�cia at� cinco anos do Registro DESIRE. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2007, 15, 221-227.	0.1	11
691	Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent?. <i>Sao Paulo Medical Journal</i> , 2007, 125, 242-245.	0.4	3
692	An�lise de impacto do stent farmacol�gico no orç�samento do sistema �nico de sa�de. <i>Arquivos Brasileiros De Cardiologia</i> , 2007, 88, 458-463.	0.3	8
693	Comparison of the Clinical and Angiographic Outcomes of Compromised Side Branches (Stent Jail) after Percutaneous Coronary Intervention between Sirolimus-Eluting Stents and Paclitaxel-Eluting Stents. <i>Korean Circulation Journal</i> , 2007, 37, 630.	0.7	1
694	Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. <i>Korean Circulation Journal</i> , 2007, 37, 135.	0.7	7
695	Effects of Cilostazol on the Drug-Eluting Stent in Native Coronary Arteries. <i>Korean Circulation Journal</i> , 2007, 37, 304.	0.7	3
696	Pacientes com angina inst�vel tratados por meio de intervenç�es coronarianas percut�neas no novo mil�nio: o que os caracteriza?. <i>Arquivos Brasileiros De Cardiologia</i> , 2007, 88, 26-30.	0.3	1
697	Comparison of immediate and followup results between transradial and transfemoral approach for percutaneous coronary intervention in true bifurcational lesions. <i>Chinese Medical Journal</i> , 2007, 120, 539-544.	0.9	16
699	Long-term outcomes following drug-eluting stent implantation in unprotected left main bifurcation lesions. <i>Chinese Medical Journal</i> , 2007, 120, 545-551.	0.9	7
701	Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction. <i>Chinese Medical Journal</i> , 2007, 120, 863-867.	0.9	18
703	Determination of adequate coronary stent expansion using StentBoost, a novel fluoroscopic image processing technique. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 84-93.	0.7	48

#	ARTICLE	IF	CITATIONS
704	Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: Insight into the RESEARCH and T-SEARCH registries. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 94-103.	0.7	39
705	Concurrent implantation of sirolimus- and paclitaxel-eluting stents in the same vessel. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 109-114.	0.7	1
706	Stent fracture associated with drug-eluting stents: Clinical characteristics and implications. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 387-394.	0.7	160
707	Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 790-798.	0.7	30
708	Mycotic pseudoaneurysm of the left circumflex coronary artery: A fatal complication following drug-eluting stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 508-512.	0.7	26
709	Stent fracture: An unusual cause of late restenosis after sirolimus-eluting stent placement. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 988-991.	0.7	16
710	Stent thrombosis with drug-eluting stents: A re-examination of the evidence. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 782-789.	0.7	25
711	Revascularization in severe left ventricular dysfunction: Outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 26-33.	0.7	53
712	Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 1-8.	0.7	17
713	Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 9-14.	0.7	53
714	Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 167-172.	0.7	8
715	Transition from bare metal to drug eluting stenting in contemporary US practice: Effect on incidence and predictors of clinically driven target lesion revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 175-183.	0.7	6
716	Clinical outcomes of dexamethasone-eluting stent implantation in ST-elevation acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 492-497.	0.7	15
717	Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 515-523.	0.7	137
718	Stent thrombosis after sirolimus- and paclitaxel-eluting stent implantation in daily clinical practice: Analysis of a single center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 415-421.	0.7	6
719	The SIRIUS-DIRECT trial: A multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 505-512.	0.7	18
720	Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: The TAXI-LATE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 163-166.	0.7	14
721	Drug eluting stents versus coronary artery bypass surgery in patients with isolated proximal lesion in left anterior descending artery suffering from chronic stable angina. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 832-837.	0.7	16

#	ARTICLE	IF	CITATIONS
722	Three-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: Insights from the rapamycin-eluting stent evaluated at rotterdam cardiology hospitalâ€”(RESEARCH) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 635-639.	0.7	32
723	Late stent thrombosisâ€”The â€œvulnerableâ€”stent. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 54-56.	0.7	4
724	Clinical and angiographic results of percutaneous coronary revascularization using a trilayer stainless steelâ€”tantalumâ€”stainless steel phosphorylcholineâ€”coated stent: The TriMaxx trial. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 914-919.	0.7	21
725	Pimecrolimus and dual pimecrolimusâ€”paclitaxel eluting stents decrease neointimal proliferation in a porcine model. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 871-879.	0.7	14
726	Prospective randomized study of the restenotic process in small coronary arteries using a Carbofilmâ„¢ coated stent in comparison with plain old balloon angioplasty:. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 920-927.	0.7	4
727	Vascular delivery of c-myc antisense from cationically modified phosphorylcholine coated stents. <i>Biomaterials</i> , 2007, 28, 1218-1224.	5.7	16
728	Prognostic significance of asymptomatic coronary artery disease in patients with diabetes and need for early revascularization therapy. <i>Diabetic Medicine</i> , 2007, 24, 1003-1011.	1.2	26
729	High frequency of contact allergy to gold in patients with endovascular coronary stents. <i>British Journal of Dermatology</i> , 2007, 157, 730-738.	1.4	49
730	The Costs and Quality-of-Life Outcomes of Drug-Eluting Coronary Stents: A Systematic Review. <i>Journal of Interventional Cardiology</i> , 2007, 20, 1-9.	0.5	28
731	Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention with Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease. <i>Journal of Interventional Cardiology</i> , 2007, 20, 10-16.	0.5	34
732	Drug-Eluting Stents Versus Bare Metal Stents Following Rotational Atherectomy for Heavily Calcified Coronary Lesions: Late Angiographic and Clinical Follow-Up Results. <i>Journal of Interventional Cardiology</i> , 2007, 20, 100-106.	0.5	78
733	Percutaneous Treatment of Coronary Bifurcations: Lesion Preparation Before Provisional Bare Metal Stenting and Subsequent Immunosuppression with Oral Prednisone. The IMPRESS-Y Study. <i>Journal of Interventional Cardiology</i> , 2007, 20, 114-121.	0.5	9
734	Neutropenia in Patients Treated With Thienopyridines and High-Dose Oral Prednisone after Percutaneous Coronary Interventions. <i>Journal of Interventional Cardiology</i> , 2007, 20, 209-213.	0.5	10
735	Single-Center Randomized Evaluation of Paclitaxel-Eluting Versus Conventional Stent in Acute Myocardial Infarction (SELECTION). <i>Journal of Interventional Cardiology</i> , 2007, 20, 282-291.	0.5	55
736	FDA Advisory Panel on the Safety and Efficacy of Drug-Eluting Stents: Summary of Findings and Recommendations. <i>Journal of Interventional Cardiology</i> , 2007, 20, 425-446.	0.5	23
737	Comparison of outcomes of percutaneous coronary intervention on proximal versus non-proximal left anterior descending coronary artery, proximal left circumflex, and proximal right coronary artery: A cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2007, 7, 7.	0.7	11
738	Treatment of unprotected left main disease with drug-eluting stents in patients at high risk for coronary artery bypass grafting. <i>Cardiovascular Revascularization Medicine</i> , 2007, 8, 84-89.	0.3	8
739	Early vascular response to overlapped paclitaxel-eluting stents in swine coronary arteries. <i>Cardiovascular Revascularization Medicine</i> , 2007, 8, 251-258.	0.3	15

#	ARTICLE	IF	CITATIONS
740	Vascular injury and modulation of MAPKs: A targeted approach to therapy of restenosis. Cellular Signalling, 2007, 19, 1359-1371.	1.7	26
741	Left Main Coronary Artery Stenosis: State-of-the-Art. Current Problems in Cardiology, 2007, 32, 103-193.	1.1	70
742	Comparison of Drug-Eluting Versus Bare Metal Stents on Later Frequency of Acute Myocardial Infarction and Death. American Journal of Cardiology, 2007, 99, 333-338.	0.7	28
743	Cypher Versus Taxus: All Smoke and No Fire: Lessons for Future Comparative Drug-Eluting Stent Trials in Interventional Cardiology. American Journal of Cardiology, 2007, 99, 424-427.	0.7	2
744	Frequency, Etiology, Treatment, and Outcomes of Drug-Eluting Stent Thrombosis During One Year of Follow-Up. American Journal of Cardiology, 2007, 99, 465-469.	0.7	24
745	Comparison of Effectiveness of Bare Metal Stents Versus Drug-Eluting Stents in Large (≥ 3.5 mm) Coronary Arteries. American Journal of Cardiology, 2007, 99, 599-602.	0.7	55
746	Long-Term Clinical Outcomes and Thrombosis Rates of Sirolimus-Eluting Versus Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease (REWARDS Registry). American Journal of Cardiology, 2007, 100, 45-51.	0.7	59
747	Meta-Analysis of Angiographic Versus Intravascular Ultrasound Parameters of Drug-Eluting Stent Efficacy (from TAXUS IV, V, and VI). American Journal of Cardiology, 2007, 100, 621-626.	0.7	19
748	Predictors of In-stent Restenosis and Patient Outcome After Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. American Journal of Cardiology, 2007, 100, 777-780.	0.7	33
749	Detailed Intravascular Ultrasound Analysis of Zotarolimus-Eluting Phosphorylcholine-Coated Cobalt-Chromium Alloy Stent in de Novo Coronary Lesions (Results from the ENDEAVOR II) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5 Kuntz is currently an employee of Medtronic Vascular.. American Journal of Cardiology, 2007, 100, 818-822.	0.7	42
750	Safety of Drug-Eluting Stents in the Coronary Artery in ST-Elevation Myocardial Infarction at a Single High-Volume Medical Center. American Journal of Cardiology, 2007, 100, 949-952.	0.7	8
751	Correlates of Clinical Restenosis Following Intracoronary Implantation of Drug-Eluting Stents. American Journal of Cardiology, 2007, 100, 965-969.	0.7	33
752	Impact of In-Stent Restenosis on Death and Myocardial Infarction. American Journal of Cardiology, 2007, 100, 1109-1113.	0.7	20
753	The Significance of Preclinical Evaluation of Sirolimus-, Paclitaxel-, and Zotarolimus-Eluting Stents. American Journal of Cardiology, 2007, 100, S36-S44.	0.7	114
755	Limites des stents actifs. Annales De Cardiologie Et D'Angeiologie, 2007, 56, S48-S52.	0.3	1
756	Poly(ethylene carbonate): A thermoelastic and biodegradable biomaterial for drug eluting stent coatings?. Journal of Controlled Release, 2007, 117, 312-321.	4.8	45
757	Release profiles in drug-eluting stents: Issues and uncertainties. Journal of Controlled Release, 2007, 120, 149-160.	4.8	154
758	Does off-pump or minimally invasive coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with percutaneous coronary intervention? A meta-analysis of randomized trials. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 623-631.	0.4	42

#	ARTICLE	IF	CITATIONS
759	Situación actual de los stents liberadores de fármacos: nuevos desafíos y nuevas dudas. Introducción. Revista Española De Cardiología Suplementos, 2007, 7, 1E-7E.	0.2	0
761	Stents recubiertos de fármacos para el tratamiento de lesiones complejas: enfoque sobre las lesiones largas y los pequeños vasos. Revista Española De Cardiología Suplementos, 2007, 7, 29E-40E.	0.2	0
763	Seguridad a largo plazo de los stents recubiertos. El fenómeno de la trombosis tardía. Revista Española De Cardiología Suplementos, 2007, 7, 80E-90E.	0.2	1
764	Systemic Nanoparticle Paclitaxel (nab-Paclitaxel) for In-stent Restenosis I (SNAPIST-I): A First-in-Human Safety and Dose-finding Study. Clinical Cardiology, 2007, 30, 165-170.	0.7	81
765	Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. Netherlands Heart Journal, 2007, 15, 382-386.	0.3	8
766	Matrices and scaffolds for drug delivery in vascular tissue engineering. Advanced Drug Delivery Reviews, 2007, 59, 360-373.	6.6	77
767	Late thrombosis with drug-eluting stents: Anatomy of a controversy and lessons learned. Current Cardiology Reports, 2007, 9, 429-431.	1.3	1
769	Drug-Eluting Stents, Restenosis and Revascularization. Herz, 2007, 32, 287-295.	0.4	14
771	Drug eluting stents for ST-elevation myocardial infarction: risk and benefit. Journal of Thrombosis and Thrombolysis, 2007, 24, 293-299.	1.0	5
772	Comparison of the slow-release polymerbased paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clinical Research in Cardiology, 2007, 96, 70-76.	1.5	51
773	The Sirolimus-eluting coronary stent in daily routine practice in Germany. Clinical Research in Cardiology, 2007, 96, 548-556.	1.5	24
774	The Paclitaxel-Eluting Coroflex® Please Stent Pilot Study (PECOPS I). Clinical Research in Cardiology, 2007, 96, 803-811.	1.5	10
775	Utility of drug-eluting stents in complex lesions and high-risk patients. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 11-28.	0.4	4
776	Drug-eluting stents: What is the balance of risks and benefits?. Current Cardiovascular Risk Reports, 2007, 1, 279-283.	0.8	0
778	Diagnostic accuracy of 64-slice CT in the assessment of coronary stents. Radiologia Medica, 2007, 112, 526-537.	4.7	14
779	Comparison of Percutaneous Coronary Intervention With Bare-Metal and Drug-Eluting Stents for Cardiac Allograft Vasculopathy. JACC: Cardiovascular Interventions, 2008, 1, 710-715.	1.1	57
780	Facile synthesis of diphenylethylene end-functional polyisobutylene and its applications for the synthesis of block copolymers containing poly(methacrylate)s. Polymer, 2008, 49, 386-393.	1.8	17
781	Angiographic and 3D intravascular ultrasound assessment of overlapping bare metal stent and three different formulations of drug-eluting stents in patients with diabetes mellitus. International Journal of Cardiovascular Imaging, 2008, 24, 125-132.	0.7	8

#	ARTICLE	IF	CITATIONS
782	The lack of endothelialization after drug-eluting stent implantation as a cause of fatal late stent thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 154-158.	1.0	8
786	Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 227-232.	0.8	1
787	Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention. <i>Heart and Vessels</i> , 2008, 23, 75-82.	0.5	36
788	Standortbestimmung der Drug-Eluting-Stents ein Jahr nach Beginn der Sicherheitsdiskussion. <i>Clinical Research in Cardiology Supplements</i> , 2008, 3, 85-89.	2.0	0
789	Clopidogrel and coronary stents: Risks and benefits. <i>Current Atherosclerosis Reports</i> , 2008, 10, 303-308.	2.0	0
790	Late adverse events after drug-eluting stent implantation. <i>Current Cardiology Reports</i> , 2008, 10, 253-262.	1.3	1
791	The risks and benefits of drug-eluting stents in the setting of STEMI. <i>Current Cardiology Reports</i> , 2008, 10, 402-406.	1.3	6
792	Multi-slice CT coronary angiography for the detection of in-stent restenosis. <i>Current Cardiovascular Imaging Reports</i> , 2008, 1, 119-124.	0.4	1
793	Drug-eluting stents: Are they still the answer?. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 334-341.	0.8	0
794	Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 333-339.	0.7	27
795	Infrapopliteal drug-eluting stents for chronic limb ischemia. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 108-111.	0.7	31
796	Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis?. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 614-618.	0.7	96
797	Outcomes of nonagenarians who undergo percutaneous coronary intervention with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 526-530.	0.7	17
798	Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: A prospective multicenter registry. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 51-57.	0.7	30
799	Prospective randomized comparison of sirolimus-versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 25-32.	0.7	33
800	Novel guidewire-based stent delivery system: Examination by intravascular ultrasound. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 47-51.	0.7	8
801	Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 13-20.	0.7	44
802	Usage patterns and 2-year outcomes with the TAXUS express stent: Results of the US ARRIVE 1 registry. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 433-445.	0.7	39

#	ARTICLE	IF	CITATIONS
803	An evidence-based approach to the use of rotational and directional coronary atherectomy in the era of drug-eluting stents: When does it make sense?. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 650-662.	0.7	41
804	The off-versus on-label use of medical devices in interventional cardiovascular medicine: Clarifying the ambiguity between regulatory labeling and clinical decision-making, Part 1: PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 500-504.	0.7	8
805	High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 470-478.	0.7	25
806	A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: The DECODE study. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 591-600.	0.7	33
807	Impact of diabetes and acute coronary syndrome on survival in patients treated with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 909-914.	0.7	14
808	Native vessel PCI in the diabetic: DES whenever feasible. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 608-609.	0.7	4
809	Paclitaxel-eluting composite fibers: Drug release and tensile mechanical properties. <i>Journal of Biomedical Materials Research - Part A</i> , 2008, 84A, 313-323.	2.1	14
810	Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. <i>Journal of Biomedical Materials Research - Part A</i> , 2008, 85A, 1064-1071.	2.1	59
811	Coronary Artery Aneurysms After Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 14-21.	1.1	175
812	Drug-Eluting Stenting. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 22-31.	1.1	65
813	Unprotected Left Main Intervention. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 5-13.	1.1	17
814	Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 161-167.	1.1	9
815	Direct Stenting With the TAXUS Libert ^Å Drug-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 150-160.	1.1	24
816	Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 494-503.	1.1	84
817	A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus-Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 524-532.	1.1	31
818	Reduced Risk of Restenosis in Small Vessels and Reduced Risk of Myocardial Infarction in Long Lesions With the New Thin-Strut TAXUS Libert ^Å Stent. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 699-709.	1.1	74
819	Biostability and biological performance of a PDMS-based polyurethane for controlled drug release. <i>Biomaterials</i> , 2008, 29, 2987-2995.	5.7	104
820	Drug delivery from gold and titanium surfaces using self-assembled monolayers. <i>Biomaterials</i> , 2008, 29, 4561-4573.	5.7	94

#	ARTICLE	IF	CITATIONS
821	Improved endothelial cell adhesion and proliferation on patterned titanium surfaces with rationally designed, micrometer to nanometer features. <i>Acta Biomaterialia</i> , 2008, 4, 192-201.	4.1	251
822	Development of surface-functionalized drug-eluting stent with diamond-like carbon nanocoated by using PECVD method. <i>Surface and Coatings Technology</i> , 2008, 202, 5750-5752.	2.2	24
823	Clinical Impact of Drug-Eluting Stents in an Unselected Population of Diabetic Patients. <i>Clinical Cardiology</i> , 2008, 31, 165-171.	0.7	7
824	Multilayered polyelectrolyte assemblies as platforms for the delivery of DNA and other nucleic acid-based therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 979-999.	6.6	286
825	Effect of Paclitaxel-Eluting Versus Sirolimus-Eluting Stents on Coronary Restenosis in Korean Diabetic Patients. <i>Journal of Interventional Cardiology</i> , 2008, 21, 225-231.	0.5	24
826	Long-Term Clinical Outcomes of the Drug-Eluting Stents in the Real World (DESIRE) Registry. <i>Journal of Interventional Cardiology</i> , 2008, 21, 307-314.	0.5	27
827	Clinical Outcomes Following Drug-Eluting versus Bare Metal Stent Implantation for Lesion Subsets Excluded from Pivotal Clinical Trials: Findings from the GHOST Study (Guthrie Health System Off-Label). <i>TJ ETQq0 0.6 rgBT / Overlock 10</i>	0.6	10
828	Everolimus- and Zotarolimus-Eluting Stents for Bare Metal Stent In-Stent Restenosis Treatment: A Prospective Study. <i>Journal of Interventional Cardiology</i> , 2008, 21, 388-394.	0.5	5
829	An Intravascular Ultrasound Study of Cypher, Taxus, and Endeavor Stents on Relation between Neointimal Proliferation and Residual Plaque Burden. <i>Journal of Interventional Cardiology</i> , 2008, 21, 519-527.	0.5	2
830	A cardiologist view of vascular disease in diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 279-292.	2.2	18
831	Irreversible Electroporation Attenuates Neointimal Formation After Angioplasty. <i>IEEE Transactions on Biomedical Engineering</i> , 2008, 55, 2268-2274.	2.5	39
832	Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings. <i>American Journal of Cardiology</i> , 2008, 101, 58-62.	0.7	162
833	Impact of "Off-Label" Utilization of Drug-Eluting Stents on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2008, 101, 293-299.	0.7	40
834	Factors Associated With Off-Label Use of Drug-Eluting Stents in Patients With ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2008, 101, 286-292.	0.7	15
835	Usefulness of 64-Detector Computed Tomographic Angiography for Diagnosing In-Stent Restenosis in Native Coronary Arteries. <i>American Journal of Cardiology</i> , 2008, 101, 820-824.	0.7	34
836	Long-Term Outcomes With Drug-Eluting Stents Versus Bare Metal Stents in the Treatment of Saphenous Vein Graft Disease (Results from the REGistro Regionale AngiopLastiche Emilia-Romagna) <i>Tj ETQq1 1 0.784314 rgBT / Overlock</i>	0.784314	10
837	Outcomes After Sirolimus- and Paclitaxel-Eluting Stent Implantation in Patients With Insulin-Treated Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 101, 1253-1258.	0.7	19
838	<i>Meta-analysis of the Effects of Paclitaxel-Eluting Stents Versus Bare Metal Stents on Volumetric Intravascular Ultrasound in Patients With Versus Without Diabetes Mellitus</i> —Conflict of interest: Drs. Weissman, Dawkins, Grube, Ellis, and Cannon have received research grants from Boston Scientific Corporation. Drs. Mintz, Ellis, and Cannon are on the speaker's bureau of and have received honoraria from Boston Scientific Corporation. Drs. Ellis, Cannon, and Stone are consultants for and are on the advisory board. <i>American Journal of Cardiology</i> , 2008, 101, 1263-1268.	0.7	12

#	ARTICLE	IF	CITATIONS
839	Comparison of Stent Thrombosis, Myocardial Infarction, and Mortality Following Drug-Eluting Versus Bare-Metal Stent Coronary Intervention in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 102, 165-172.	0.7	31
840	Two-Year Outcome of Patients Treated With Sirolimus- Versus Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease (from the REWARDS Registry). <i>American Journal of Cardiology</i> , 2008, 102, 292-297.	0.7	13
841	Drug-Eluting Stents Versus Bare Metal Stents for Narrowing in Saphenous Vein Grafts. <i>American Journal of Cardiology</i> , 2008, 102, 530-534.	0.7	42
842	Effect of Prolonged Thienopyridine Use After Drug-Eluting Stent Implantation (from the TAXUS) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	15
843	Impact of Mild or Moderate Renal Insufficiency on the Intravascular Ultrasonic Analysis of Chronic Vascular Response to Paclitaxel-Eluting and Bare-Metal Stents (from the TAXUS IV, V, and VI Trials). <i>American Journal of Cardiology</i> , 2008, 102, 1009-1016.	0.7	3
844	Clinical and Angiographic Follow-Up of Small Vessel Lesions Treated With Paclitaxel-Eluting Stents (from the TRUE Registry). <i>American Journal of Cardiology</i> , 2008, 102, 1002-1008.	0.7	33
845	Meta-Analysis Comparison (Nine Trials) of Outcomes With Drug-Eluting Stents Versus Bare Metal Stents in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 102, 1328-1334.	0.7	33
847	Assessing the Landscape of Stent Thrombosis: The Drug-Eluting Versus Bare-Metal Stent Controversy. <i>American Journal of Cardiology</i> , 2008, 102, 4J-11J.	0.7	3
848	The Question of Drug-Eluting Stent Safety: Then and Now. <i>American Journal of Cardiology</i> , 2008, 102, 12J-17J.	0.7	8
849	Endovascular procedures for below the knee arteries in diabetics. <i>Annales De Cardiologie Et D'Angeiologie</i> , 2008, 57, 352-358.	0.3	6
850	Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. <i>Cardiovascular Revascularization Medicine</i> , 2008, 9, 24-28.	0.3	17
851	Very late thrombosis of paclitaxel-eluting stent. <i>Cardiovascular Revascularization Medicine</i> , 2008, 9, 275-277.	0.3	4
852	Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. <i>Cardiovascular Revascularization Medicine</i> , 2008, 9, 156-165.	0.3	62
853	Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents. <i>Cardiovascular Revascularization Medicine</i> , 2008, 9, 218-223.	0.3	26
854	Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. <i>European Journal of Pharmacology</i> , 2008, 590, 343-354.	1.7	78
855	Impact of Obesity on the Pathogenesis and Prognosis of Coronary Heart Disease. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 162-167.	1.7	44
856	Drug-Eluting Stents for Left Main Coronary Artery Stenosis: Case Selection and Technical Issues. <i>The American Heart Hospital Journal</i> , 2008, 6, 21-29.	0.2	2
857	Reperfusion Strategies in Acute ST-Elevation Myocardial Infarction: An Overview of Current Status. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 352-382.	1.6	72

#	ARTICLE	IF	CITATIONS
858	Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures. <i>Journal of Controlled Release</i> , 2008, 126, 139-148.	4.8	30
859	Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents. <i>Journal of Controlled Release</i> , 2008, 130, 2-8.	4.8	44
860	Results of provisional stenting with a Sirolimus-eluting stent for bifurcation lesion: Multicenter study in Japan. <i>Journal of Cardiology</i> , 2008, 51, 89-94.	0.8	7
861	Biofunctionalization of Biomaterials for Accelerated in Situ Endothelialization: A Review. <i>Biomacromolecules</i> , 2008, 9, 2969-2979.	2.6	319
862	The future of drug-eluting stents. <i>Pharmacological Research</i> , 2008, 57, 171-180.	3.1	100
864	Short- and long-term outcomes of single bare metal stent versus drug eluting stent in nondiabetic patients with a simple de novo lesion in the middle and large vessel. <i>Journal of Translational Medicine</i> , 2008, 6, 42.	1.8	7
865	Clinical and angiographic results of angioplasty with a paclitaxel-eluting stent for unprotected left main coronary artery disease (a study of 101 consecutive patients). <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 11-17.	0.7	5
866	Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 100-107.	0.7	8
867	Angiographic Surrogate End Points in Drug-Eluting Stent Trials. <i>Journal of the American College of Cardiology</i> , 2008, 51, 23-32.	1.2	153
868	Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction: 9-Month Angiographic and Intravascular Ultrasound Results and 12-Month Clinical Outcome. <i>Journal of the American College of Cardiology</i> , 2008, 51, 618-626.	1.2	148
869	The Problem With Composite End Points in Cardiovascular Studies. <i>Journal of the American College of Cardiology</i> , 2008, 51, 701-707.	1.2	272
870	Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2008, 51, 708-715.	1.2	106
871	A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1543-1552.	1.2	109
872	Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1844-1853.	1.2	66
873	Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2011-2016.	1.2	51
874	Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2220-2227.	1.2	110
875	Clinical Efficacy of Drug-Eluting Stents in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2385-2395.	1.2	69
876	Acute Coronary Syndrome: Where We Are, How We Got Here, and Where We Are Going. , 2008, , 1-8.		0

#	ARTICLE	IF	CITATIONS
877	Intravascular ultrasound findings in patients with restenosis of sirolimus- and paclitaxel-eluting stents. <i>International Journal of Cardiology</i> , 2008, 125, 11-15.	0.8	19
878	Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. <i>International Journal of Cardiology</i> , 2008, 126, 37-44.	0.8	121
879	A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. <i>International Journal of Cardiology</i> , 2008, 128, 53-61.	0.8	1
880	Two-year outcome of the use of paclitaxel-eluting stents in aorto-ostial lesions. <i>International Journal of Cardiology</i> , 2008, 129, 348-353.	0.8	10
881	Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents. <i>International Journal of Cardiology</i> , 2008, 130, 444-448.	0.8	16
882	Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry. <i>International Journal of Cardiology</i> , 2008, 130, 374-379.	0.8	20
883	Current Clinical Outcomes of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. <i>Annals of Thoracic Surgery</i> , 2008, 86, 496-503.	0.7	30
884	Simultaneous "hybrid" percutaneous coronary intervention and minimally invasive surgical bypass grafting: Feasibility, safety, and clinical outcomes. <i>American Heart Journal</i> , 2008, 155, 661-667.	1.2	111
885	The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. <i>American Heart Journal</i> , 2008, 156, 44-56.	1.2	152
886	Correlates of late and very late thrombosis of drug eluting stents. <i>American Heart Journal</i> , 2008, 156, 141-147.	1.2	31
887	Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. <i>American Heart Journal</i> , 2008, 156, 513-519.	1.2	36
888	Disparity in drug-eluting stent utilization by insurance type. <i>American Heart Journal</i> , 2008, 156, 1133-1140.	1.2	21
889	Local catheter-based delivery of antithrombotic or antiproliferative drugs: A new concept for prevention of restenosis. <i>Thrombosis Research</i> , 2008, 123, 236-243.	0.8	13
890	Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents. <i>Diabetes and Metabolism</i> , 2008, 34, 62-67.	1.4	7
891	Short-term Follow-up Results of Drug-eluting Stenting in Premature Coronary Artery Disease Patients with Multiple Atherosclerotic Risk Factors. <i>Journal of the Chinese Medical Association</i> , 2008, 71, 342-346.	0.6	5
892	Drug-Eluting Stents: Patient Understanding of the Risks of Premature Cessation of Antiplatelet Drugs. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2008, 22, 806-810.	0.6	8
893	A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. <i>Lancet, The</i> , 2008, 371, 899-907.	6.3	655
894	Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. <i>Lancet, The</i> , 2008, 371, 1353-1363.	6.3	420

#	ARTICLE	IF	CITATIONS
895	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. <i>Lancet, The</i> , 2008, 372, 1163-1173.	6.3	607
896	Drug-eluting stents: is new necessarily better?. <i>Lancet, The</i> , 2008, 372, 1126-1128.	6.3	5
897	Safety of drug-coated stents. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 597-606.	1.0	8
898	Comparison of one-year clinical outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice. <i>Canadian Journal of Cardiology</i> , 2008, 24, 771-775.	0.8	4
899	Safety and Feasibility of Drug-eluting Stent Implantation at Vertebral Artery Origin: The First Case Series in Asians. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 253-258.	0.8	21
900	Endovascular Techniques for Stroke Prevention. <i>Neurologic Clinics</i> , 2008, 26, 1099-1127.	0.8	1
901	Current Status of Off-Pump Coronary Artery Bypass Surgery. <i>Asian Cardiovascular and Thoracic Annals</i> , 2008, 16, 164-178.	0.2	28
903	Off-label use of stents: bare-metal versus drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1095-1106.	0.6	1
904	Cost comparison of four revascularisation procedures for the treatment of multivessel coronary artery disease. <i>Journal of Medical Economics</i> , 2008, 11, 119-134.	1.0	4
905	Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometry. <i>Analyst, The</i> , 2008, 133, 1742.	1.7	17
906	Multivessel Disease: Percutaneous Coronary Intervention for Classic Coronary Artery Bypass Grafting Indications. <i>Angiology</i> , 2008, 59, 83S-88S.	0.8	5
907	Safety of drug-eluting stents. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 316-328.	3.3	18
908	The Effects of Vinblastine on Endothelial Cells. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2008, 15, 9-15.	1.7	15
909	Meta-Analysis Shows Similar Risk of Thrombosis After Drug-Eluting Stent, Bare-Metal Stent, or Angioplasty. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2008, 15, 93-100.	1.7	6
910	Impact of vessel size, lesion length and diabetes mellitus on angiographic restenosis outcomes: Insights from the NIRTOP study. <i>Acute Cardiac Care</i> , 2008, 10, 104-110.	0.2	14
911	Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions. <i>Acute Cardiac Care</i> , 2008, 10, 88-92.	0.2	22
912	Clinical results of drug eluting stents compared to bare metal stents for patients with ST elevation acute myocardial infarction. <i>Acute Cardiac Care</i> , 2008, 10, 167-172.	0.2	3
913	Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study. <i>Acute Cardiac Care</i> , 2008, 10, 93-99.	0.2	6

#	ARTICLE	IF	CITATIONS
914	Effectiveness of Drug-Eluting Stents in Real-World Patients. JAMA - Journal of the American Medical Association, 2008, 299, 454-5.	3.8	10
915	Current Status of Percutaneous Coronary Intervention With Drug-Eluting Stents in Asia. Circulation, 2008, 118, 2730-2737.	1.6	18
916	Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus. Circulation, 2008, 118, 2277-2285.	1.6	121
917	Long-Term Outcomes of Coronary-Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Multivessel Coronary Artery Disease in the Bare-Metal Stent Era. Circulation, 2008, 118, S199-209.	1.6	101
918	Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 137-146.	1.0	6
919	Very Late Stent Thrombosis After Dual Antiplatelet Therapy Discontinuation in a Patient with a History of Acute Stent Thrombosis. Annals of Pharmacotherapy, 2008, 42, 708-712.	0.9	8
920	The Appropriate Role Of Cost-Effectiveness In Determining Device Coverage: A Case Study Of Drug-Eluting Stents. Health Affairs, 2008, 27, 1577-1586.	2.5	8
921	Primary Percutaneous Coronary Intervention. Fundamental and Clinical Cardiology, 2008, , 91-117.	0.0	0
922	Cardiovascular Toxicology. , 0, , .		0
923	Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. European Heart Journal, 2008, 29, 1625-1634.	1.0	54
924	The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. European Heart Journal, 2008, 29, 1851-1857.	1.0	265
925	Biodegradable coating for drug-eluting stents--more than a facelift?. European Heart Journal, 2008, 29, 1930-1931.	1.0	21
926	Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. European Heart Journal, 2008, 29, 2733-2741.	1.0	39
928	Aspirin following PCI: too much of a good thing?. European Heart Journal, 2008, 30, 882-884.	1.0	8
929	Thrombosis after stent implantation: how much of a problem is there?. Future Cardiology, 2008, 4, 261-267.	0.5	9
930	Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2008, 299, 1903.	3.8	535
931	Intravascular irreversible electroporation: Theoretical and experimental feasibility study. , 2008, 2008, 2051-4.		8
932	Intramural Delivery of Rapamycin With $\hat{\pm}$ $\hat{2}$ $\hat{3}$ -Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 820-826.	1.1	92

#	ARTICLE	IF	CITATIONS
933	Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients. <i>Circulation</i> , 2008, 118, 1138-1145.	1.6	818
934	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 226-232.	1.4	3
935	Impact of In-Stent Minimal Lumen Area at 9 Months Poststent Implantation on 3-Year Target Lesion Revascularization-Free Survival. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 111-118.	1.4	21
936	Review: The safety of drug-eluting stents. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 43-52.	1.0	6
937	Drug-Eluting or Bare-Metal Stents for ST Elevation Myocardial Infarction Can Observational Data Balance the Risk Benefit Equation?. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 161-163.	1.4	0
938	Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds. <i>Redox Report</i> , 2008, 13, 48-59.	1.4	22
939	Acute Brain and Spinal Cord Injury. , 0, , .		1
940	Acute Thrombosis of a Mesenteric Artery Drug-Eluting Stent Following Clopidogrel Cessation. <i>Vascular and Endovascular Surgery</i> , 2008, 41, 564-567.	0.3	0
942	Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 20-27.	1.4	33
943	Long-Term Mortality After Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Artery Disease. <i>Circulation</i> , 2008, 117, 2079-2086.	1.6	83
944	Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 103-110.	1.4	40
945	Management of Coronary Artery Disease in Type 2 Diabetes Mellitus. , 2008, , 289-319.		1
946	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 217-225.	1.4	15
947	Studies of Drug-Eluting Stents. <i>Circulation</i> , 2008, 117, 2047-2050.	1.6	15
948	Drug-eluting stents: do the risks really outweigh the benefits?. <i>Heart</i> , 2008, 94, 127-128.	1.2	7
949	Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions: A prospective, randomized, multicenter study. <i>Diabetes Care</i> , 2008, 31, 15-19.	4.3	38
950	Late Angiographic Stent Thrombosis: The LAST Straw for Drug-Eluting Stents?. <i>Angiology</i> , 2008, 59, 667-675.	0.8	2
951	Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. <i>European Heart Journal</i> , 2008, 30, 932-939.	1.0	44

#	ARTICLE	IF	CITATIONS
952	Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. <i>European Heart Journal</i> , 2008, 29, 718-725.	1.0	64
953	Drug-eluting stent safety: findings from preclinical studies. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1379-1391.	0.6	72
954	Drug-Eluting Stents "Pushing the Envelope beyond the Labels?". <i>New England Journal of Medicine</i> , 2008, 358, 405-407.	13.9	8
955	A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications. <i>New England Journal of Medicine</i> , 2008, 358, 342-352.	13.9	250
956	Drug-Eluting or Bare-Metal Stents for Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 359, 1330-1342.	13.9	482
957	Do percutaneous coronary interventions protect the surgical patient?. <i>Southern African Journal of Anaesthesia and Analgesia</i> , 2008, 14, 102-106.	0.1	0
958	Preprocedural Statin Administration can Reduce Thrombotic Reaction After Stent Implantation. <i>Circulation Journal</i> , 2008, 72, 232-237.	0.7	20
959	Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. <i>Annals of Internal Medicine</i> , 2008, 148, 234.	2.0	48
960	Management of Antiplatelet Therapy for Non-Cardiac Surgery. , 0, , 251-264.		0
961	Antiplatelet Therapy and Coronary Stents. , 0, , 265-279.		0
962	The role of coronary artery stents in PCI. <i>British Journal of Cardiac Nursing</i> , 2008, 3, 24-30.	0.0	0
963	Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. <i>Anesthesia and Analgesia</i> , 2008, 107, 552-569.	1.1	62
964	Systemic Immunosuppressive Therapy with Oral Sirolimus after Bare Metal Stent Implantation: The Missing Alternative in the Prevention of Coronary Restenosis after Percutaneous Coronary Interventions. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2008, 3, 201-208.	1.5	5
965	Idraparinux for the prevention of thromboembolism in patients with atrial fibrillation. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 139-144.	0.2	0
966	CURRENT CONCEPTS IN THE MANAGEMENT OF INTRACRANIAL ATHEROSCLEROTIC DISEASE. <i>Neurosurgery</i> , 2008, 62, S210-S218.	0.6	2
967	Strut fracture: a further concern with drug-eluting stents. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 949-952.	0.6	4
968	Drug-eluting stents for the treatment of coronary lesions in cardiac transplant vasculopathy: acute and mid-term clinical and angiographic outcomes. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 396-402.	0.6	6
969	Intimal Hyperplasia in Murine Models. <i>Current Drug Targets</i> , 2008, 9, 251-260.	1.0	69

#	ARTICLE	IF	CITATIONS
970	Incidence of thrombosis after implantation of drug-eluting stents in patients with coronary artery disease. Chinese Medical Journal, 2008, 121, 2144-2147.	0.9	2
971	Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2™ stent. Chinese Medical Journal, 2008, 121, 492-497.	0.9	8
972	Is adjunctive balloon postdilatation necessary with drug-eluting stents? One center experience in Chinese patients. Chinese Medical Journal, 2008, 121, 513-517.	0.9	9
974	Computerized two-lead resting ECG analysis for the detection of coronary artery stenosis after coronary revascularization. International Journal of Medical Sciences, 2008, 5, 50-61.	1.1	9
975	Importância da interação entre a integrina Mac-1 dos leucócitos e a glicoproteína Iba das plaquetas para o recrutamento de leucócitos pelas plaquetas e para a resposta inflamatória à lesão vascular. Arquivos Brasileiros De Cardiologia, 2008, 90, 54-63.	0.3	13
976	Drug-eluting stents. , 2008, , 83-99.		0
977	Stents farmacológicos no mundo real: impacto de sua disponibilidade no perfil de pacientes tratados por meio de intervenção coronária percutânea em um hospital público. Revista Brasileira De Cardiologia Invasiva, 2008, 16, 31-36.	0.1	2
978	Reparação vascular após implante de stents não-farmacológicos e farmacológicos em modelo experimental de fibroateroma de capa fina em coelhos. Revista Brasileira De Cardiologia Invasiva, 2008, 16, 474-481.	0.1	3
979	Novel Coronary Stent Platforms. Korean Circulation Journal, 2008, 38, 393.	0.7	2
980	Impact of Drug-Eluting Stents on Clinical Outcomes in Patients With Diffuse Coronary Lesions. Korean Circulation Journal, 2008, 38, 612.	0.7	2
981	Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry. Medical Journal of Australia, 2008, 189, 423-428.	0.8	23
982	Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V™). Vascular Health and Risk Management, 0, Volume 4, 31-38.	1.0	0
983	Venous Angioplasty; How does it Work (or not Work)!. Journal of Vascular Access, 2009, 10, 249-251.	0.5	0
984	Deficiency of Clusterin Inhibits Neointimal Hyperplasia After Vascular Injury. Journal of Atherosclerosis and Thrombosis, 2009, 16, 772-781.	0.9	12
985	Stents bioabsorvíveis: já é hora de "absorvermos" esse conceito?. Revista Brasileira De Cardiologia Invasiva, 2009, 17, 110-116.	0.1	1
986	Stents liberadores de sirolimus com e sem cobertura polimérica: análise seriada com angiografia e ultrassom intracoronariano tridimensional. Revista Brasileira De Cardiologia Invasiva, 2009, 17, 20-30.	0.1	5
987	Até que ponto a complexidade angiográfica influi nos resultados tardios de pacientes tratados com stents farmacológicos?: comparação entre indicações on-label e off-label no Registro DESIRE. Revista Brasileira De Cardiologia Invasiva, 2009, 17, 31-38.	0.1	1
988	Long-Term Effects of Novel Biodegradable, Polymer-Coated, Sirolimus-Eluting Stents on Neointimal Formation in a Porcine Coronary Model. International Heart Journal, 2009, 50, 811-822.	0.5	15

#	ARTICLE	IF	CITATIONS
989	Role of E2F1-Cyclin E1-Cyclin E2 Circuit in Human Coronary Smooth Muscle Cell Proliferation and Therapeutic Potential of Its Downregulation by siRNAs. <i>Molecular Medicine</i> , 2009, 15, 297-306.	1.9	39
990	FORMATION MECHANISM OF POROUS STRUCTURE ON 316L STAINLESS STEEL BY ANODIZATION. <i>International Journal of Modern Physics B</i> , 2009, 23, 1047-1052.	1.0	1
991	Percutaneous Revascularization Is the Preferred Strategy for Patients With Significant Left Main Coronary Stenosis. <i>Circulation</i> , 2009, 119, 1021-1033.	1.6	23
992	Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1047-1058.	0.9	18
993	Xience Vâ„¢ everolimus-eluting coronary stent. <i>Expert Review of Medical Devices</i> , 2009, 6, 219-229.	1.4	32
994	Diminished Benefits of Drug-Eluting Stents versus Bare Metal Stents in Patients with Severe Renal Insufficiency. <i>Nephron Clinical Practice</i> , 2009, 113, c198-c202.	2.3	15
995	Long-Term Follow-Up on a Large Cohort of "Full-Metal Jacket" Percutaneous Coronary Intervention Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 416-422.	1.4	54
996	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused) <i>Tj ETQq1 1 0.784314 rgt /Overlo</i>	1.6	1073
997	<i>></i><i>></i>-4-Tert-Butyl Benzyl Haloperidol Chloride Suppresses Ca<sup>2+</sup>-dependent Egr-1 Expression and Subsequently Inhibits Vascular Smooth Muscle Cell Proliferation Induced by Angiotensin II. <i>Cellular Physiology and Biochemistry</i> , 2009, 23, 295-304.	1.1	8
998	Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. <i>Heart</i> , 2009, 95, 970-975.	1.2	21
999	Treatment of Stenoses of Vertebral Artery Origin Using Short Drug-Eluting Coronary Stents: Improved Follow-Up Results. <i>American Journal of Neuroradiology</i> , 2009, 30, 1653-1656.	1.2	57
1000	Drug-Eluting Stents Compared with Bare Metal Stents Improve Late Outcome after Saphenous Vein Graft but Not after Large Native Vessel Interventions. <i>Cardiology</i> , 2009, 112, 49-55.	0.6	57
1001	Restenosis and Gene Polymorphisms. <i>Cardiology</i> , 2009, 112, 260-262.	0.6	1
1002	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. <i>European Heart Journal</i> , 2009, 30, 2714-2721.	1.0	224
1003	Deformations During and Post Stenting of a Diseased Coronary Artery Phantom: An In Vitro Study. , 2009, , .		0
1004	Endovascular Treatment of Isolated PICA Insufficiency. <i>Neuroradiology Journal</i> , 2009, 22, 482-485.	0.6	1
1005	Evolution of stents: past, present and future. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 443-446.	0.6	8
1006	Better results with the new generation bare metal stents. <i>Scandinavian Cardiovascular Journal</i> , 2009, 43, 84-86.	0.4	1

#	ARTICLE	IF	CITATIONS
1007	Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras. <i>Circulation</i> , 2009, 119, 952-961.	1.6	47
1008	Long-term outcomes of patients receiving drug-eluting stents. <i>Cmaj</i> , 2009, 180, 167-174.	0.9	9
1009	Restenosis Revisited. <i>Circulation Research</i> , 2009, 104, 823-825.	2.0	7
1010	Long-Term Clinical Outcome After a First Angiographically Confirmed Coronary Stent Thrombosis. <i>Circulation</i> , 2009, 119, 828-834.	1.6	154
1011	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>European Heart Journal</i> , 2009, 30, 2441-2449.	1.0	207
1012	Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. <i>Heart</i> , 2009, 95, 1579-1586.	1.2	31
1013	Drug-Eluting Stent Thrombosis in Routine Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 285-293.	1.4	77
1014	Barriers to clopidogrel adherence following placement of drug-eluting stents. <i>Annals of Pharmacotherapy</i> , 2009, 43, 259-67.	0.9	24
1015	Long-Term Paclitaxel-Eluting Stent Outcomes in Elderly Patients. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 178-187.	1.4	20
1016	Mid-term angiographic benefit of sirolimus-eluting stents compared with paclitaxel-eluting stents in patients with acute myocardial infarction. <i>Journal of Cardiology</i> , 2009, 54, 80-85.	0.8	1
1017	Bare-metal stents versus drug-eluting stents in large (≥3.5mm) single coronary artery: Angiographic and clinical outcomes at 6 months. <i>Journal of Cardiology</i> , 2009, 54, 108-114.	0.8	12
1018	On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: An in vitro study. <i>Vascular Pharmacology</i> , 2009, 51, 50-56.	1.0	12
1019	The Problem of Stent Thrombosis Associated With Drug-Eluting Stents and the Optimal Duration of Dual Antiplatelet Therapy. <i>Preventive Cardiology</i> , 2009, 12, 59-64.	1.1	1
1020	Frequency of Coronary Artery Bypass Grafting Following Implantation of a Paclitaxel-Eluting or a Bare-Metal Stent Into a Single Coronary Artery. <i>American Journal of Cardiology</i> , 2009, 103, 11-16.	0.7	14
1021	Paclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) Study. <i>American Journal of Cardiology</i> , 2009, 103, 199-202.	0.7	12
1022	Three-Year Survival Following Multivessel Percutaneous Coronary Intervention With Bare-Metal or Drug-Eluting Stents in Unselected Patients. <i>American Journal of Cardiology</i> , 2009, 103, 203-211.	0.7	12
1023	Comparison of the Sirolimus-Eluting Versus Paclitaxel-Eluting Coronary Stent in Patients With Diabetes Mellitus: The Diabetes and Drug-Eluting Stent (DiabeDES) Randomized Angiography Trial—A list of participating centers and investigators appears in the Appendix.. <i>American Journal of Cardiology</i> , 2009, 103, 345-349.	0.7	55
1024	Outcome Differences With the Use of Drug-Eluting Stents for the Treatment of In-Stent Restenosis of Bare-Metal Stents Versus Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2009, 103, 491-495.	0.7	90

#	ARTICLE	IF	CITATIONS
1025	An Integrated TAXUS IV, V, and VI Intravascular Ultrasound Analysis of the Predictors of Edge Restenosis After Bare Metal or Paclitaxel-Eluting Stents. <i>American Journal of Cardiology</i> , 2009, 103, 501-506.	0.7	69
1026	Comparison of Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in Nonstent Proximal Left Anterior Descending Coronary Arteries. <i>American Journal of Cardiology</i> , 2009, 103, 496-500.	0.7	6
1027	Classification and Potential Mechanisms of Intravascular Ultrasound Patterns of Stent Fracture. <i>American Journal of Cardiology</i> , 2009, 103, 818-823.	0.7	90
1028	Comparison of Long-Term Outcomes of Bare Metal or Drug-Eluting Stent Implantation in Standard Versus Off-Label Coronary Narrowings. <i>American Journal of Cardiology</i> , 2009, 103, 1537-1545.	0.7	10
1029	Two-Year Results of Paclitaxel-Eluting Stents in Patients With Medically Treated Diabetes Mellitus from the TAXUS ARRIVE Program. <i>American Journal of Cardiology</i> , 2009, 103, 1663-1671.	0.7	21
1030	Comparison of Outcomes Using Bare Metal Versus Drug-Eluting Stents in Coronary Artery Disease Patients With and Without Human Immunodeficiency Virus Infection. <i>American Journal of Cardiology</i> , 2009, 104, 216-222.	0.7	39
1031	Clinical Outcomes After Sirolimus-Eluting, Paclitaxel-Eluting, and Bare Metal Stents (from the First) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 104, 1362-1369.	0.7	33
1032	Effect of Drug-Eluting Stents on Frequency of Repeat Revascularization in Patients With Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2009, 104, 1654-1659.	0.7	15
1034	Metal allergic reaction in chronic refractory in-stent restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 17-22.	0.3	43
1035	Drug-eluting or bare-metal stents in subjects over 75 years of age: what is the best therapeutic strategy? Data from 460 consecutive patients with 1-year outcome. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 94-102.	0.3	5
1036	Tormentric acid reduces vascular smooth muscle cell proliferation and survival. <i>European Journal of Pharmacology</i> , 2009, 615, 50-54.	1.7	24
1037	Drug-Eluting Stents in Patients With ESRD on Dialysis: A Small Step Forward. <i>American Journal of Kidney Diseases</i> , 2009, 54, 197-200.	2.1	0
1038	Highly Porous Nano- and Microstructured Films Loaded with Bioactive Agents for Biomedical Applications: Structure-Release Profile Effects. <i>Advanced Engineering Materials</i> , 2009, 11, B122.	1.6	0
1039	Real world safety and efficacy of the Janus tacrolimus-eluting stent: Long-term clinical outcome and angiographic findings from the tacrolimus-eluting stent (TEST) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 243-248.	0.7	23
1040	Impact of a prolonged delivery inflation time for optimal drug-eluting stent expansion. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 205-211.	0.7	32
1041	A novel 0.010-inch guidewire for crossing jailed sidebranches. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 346-349.	0.7	6
1042	Prognostic value of the syntax score in patients undergoing coronary artery bypass grafting for three-vessel coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 612-617.	0.7	52
1043	Treatment of drug-eluting stent restenosis: An emerging challenge. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 108-116.	0.7	26

#	ARTICLE	IF	CITATIONS
1044	A novel paclitaxel-eluting dedicated bifurcation stent: A case report from the first human use Taxus Petal trial. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 637-640.	0.7	8
1045	The incidence and predictors of postprocedural incomplete stent apposition after angiographically successful drug-eluting stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 58-63.	0.7	16
1046	Defining a new standard for IVUS optimized drug eluting stent implantation: The PRAVIO study. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 348-356.	0.7	22
1047	Comparing long-term outcomes between drug-eluting and bare-metal stents in the treatment of cardiac allograft vasculopathy. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 543-549.	0.7	17
1048	The paclitaxel-eluting coroflex, please stent study (PECOPS I): The 3-year clinical follow-up. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 674-682.	0.7	6
1049	Antiplatelet therapy discontinuation following drug-eluting stent placement: Dangers, reasons, and management recommendations. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 1047-1054.	0.7	37
1050	Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: Results from the Prairie - Real World Stent Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 93-100.	0.7	27
1051	Clinical safety and efficacy of a novel thin-strut cobalt-chromium coronary stent system: Results of the real world Coroflex Blue Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 78-85.	0.7	17
1052	Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 317-325.	0.7	18
1053	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused) Tj ETQq1 1 0.784314 rgbT /Overlo	0.7	56
1054	Controlled delivery of paclitaxel from stent coatings using novel styrene maleic anhydride copolymer formulations. <i>Journal of Biomedical Materials Research - Part A</i> , 2009, 90A, 522-532.	2.1	11
1055	Development of transgenic endothelial progenitor cell-seeded stents. <i>Journal of Biomedical Materials Research - Part A</i> , 2009, 91A, 623-628.	2.1	10
1056	<i>In vitro</i> and <i>In vivo</i> studies of local arterial gene delivery and transfection using lipopolyplexes-embedded stents. <i>Journal of Biomedical Materials Research - Part A</i> , 2010, 93A, 325-336.	2.1	14
1057	Absorbable polymer stent technologies for vascular regeneration. <i>Journal of Chemical Technology and Biotechnology</i> , 2010, 85, 744-751.	1.6	50
1058	The risk of definitive stent thrombosis is increased after off-label stent implantation irrespective of drug-eluting stent or bare-metal stent use. <i>Clinical Research in Cardiology</i> , 2009, 98, 549-554.	1.5	18
1059	A Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 428-434.	1.1	109
1060	Impact of Target Lesion and Nontarget Lesion Cardiac Events on 5-Year Clinical Outcomes After Sirolimus-Eluting or Bare-Metal Stenting. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 498-503.	1.1	36
1061	The Risk of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Bare-Metal and Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 534-541.	1.1	134

#	ARTICLE	IF	CITATIONS
1062	In-Hospital and 1-Year Outcomes Among Unselected Percutaneous Coronary Intervention Patients Treated With Either Sirolimus- or Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 767-775.	1.1	12
1063	Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1142-1148.	1.1	20
1065	Long-Term Clinical and Economic Analysis of the Endeavor Drug-Eluting Stent Versus the Driver Bare-Metal Stent. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1178-1187.	1.1	36
1066	Correlation between quantitative angiographic and intravascular ultrasound parameters in patients treated with sirolimus analogous-eluting stents. <i>International Journal of Cardiovascular Imaging</i> , 2009, 25, 345-351.	0.7	1
1067	Early Systemic Inflammatory Response to Drug-Eluting Stents Implantation: The Heart of the Difference?. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 103-105.	1.3	0
1068	Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 365-378.	1.0	12
1069	Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 200-210.	1.0	24
1070	In vitro and in vivo evaluation of the safety and stability of the TAXUS [®] Paclitaxel-Eluting Coronary Stent. <i>Journal of Materials Science: Materials in Medicine</i> , 2009, 20, 1553-1562.	1.7	25
1071	Medical and catheter-based therapies for managing stable coronary disease: Lessons from the COURAGE trial. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 45-53.	0.4	2
1072	Drug-eluting stents versus bypass surgery for multivessel coronary disease. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 331-338.	0.8	1
1073	Emergent coronary artery bypass grafting for cardiogenic shock caused by very late drug-eluting stent thrombosis. <i>General Thoracic and Cardiovascular Surgery</i> , 2009, 57, 609-611.	0.4	1
1074	Die Behandlung der koronaren Mehrgefäßkrankung: Bypassoperation oder perkutane Katheterintervention?. <i>Clinical Research in Cardiology Supplements</i> , 2009, 4, 154-159.	2.0	0
1075	Advances in percutaneous coronary intervention. <i>Current Cardiology Reports</i> , 2009, 11, 245-251.	1.3	6
1076	Drug-eluting stent coatings. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2009, 1, 451-462.	3.3	53
1077	Polymers for targeted and/or sustained drug delivery. <i>Polymers for Advanced Technologies</i> , 2009, 20, 595-606.	1.6	48
1078	Efficacies of the new Paclitaxel-eluting Coroflex Please [®] , [®] Stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please [®] , [®] and Taxus [®] , [®] (ECO-PLEASANT) trial: study rationale and design. <i>Trials</i> , 2009, 10, 98.	0.7	1
1079	Comparison of the Systemic Levels of Inflammatory Markers after Percutaneous Coronary Intervention with Bare Metal versus Sirolimus-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2009, 22, 169-174.	0.5	6
1080	Head-to-Head and Extrapolated Comparisons of Different Drug-Eluting Stents: Differences in Late Loss, Restenosis, and Clinical Outcomes. <i>Journal of Interventional Cardiology</i> , 2009, 22, .	0.5	1

#	ARTICLE	IF	CITATIONS
1081	Long-Term Clinical Follow-Up after Sirolimus-Eluting Stent versus Bare Metal Stent Implantation in Patients with Acute Coronary Syndrome. <i>Journal of Interventional Cardiology</i> , 2009, 22, 216-221.	0.5	4
1082	Performance of Everolimus-Eluting Stents: Pooled Analysis from the SPIRIT Trials. <i>Journal of Interventional Cardiology</i> , 2009, 22, .	0.5	3
1083	Choice of DES: A US Clinician's Perspective. <i>Journal of Interventional Cardiology</i> , 2009, 22, .	0.5	0
1084	Nationwide Trends in the Utilization of Multivessel Percutaneous Coronary Intervention (MVPCI) in the United States across Different Gender and Ethnicities. <i>Journal of Interventional Cardiology</i> , 2009, 22, 247-251.	0.5	10
1085	Incomplete Stent Apposition after Coronary Stent Implantation: Myth or Reality?. <i>Journal of Interventional Cardiology</i> , 2009, 22, 341-349.	0.5	9
1086	A correlation found between contact allergy to stent material and restenosis of the coronary arteries. <i>Contact Dermatitis</i> , 2009, 60, 158-164.	0.8	81
1087	Diffusion of a fluid through a spherical elastic solid undergoing large deformations. <i>International Journal of Engineering Science</i> , 2009, 47, 50-63.	2.7	10
1088	Endothelium-Dependent Vasomotor Dysfunction in Pig Coronary Arteries With Paclitaxel-Eluting Stents Is Associated With Inflammation and Oxidative Stress. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 253-262.	1.1	60
1089	First-in-Man 1-Year Clinical Outcomes of the Catania Coronary Stent System With Nanothin Polyzene-F in De Novo Native Coronary Artery Lesions. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 197-204.	1.1	30
1090	TAXUS Libert� Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 240-252.	1.1	27
1092	The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 515-523.	1.1	72
1093	Characterization of Post-Operative Risk Associated With Prior Drug-Eluting Stent Use. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 542-549.	1.1	76
1094	Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients With Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 614-621.	1.1	31
1095	2-Year Results of the AUTAX (Austrian Multivessel TAXUS-Stent) Registry. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 718-727.	1.1	13
1096	Clinical Presentation and Angiographic Characteristics of Saphenous Vein Graft Failure After Stenting. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 855-860.	1.1	45
1097	Feasibility, Safety, and Efficacy of a Novel Polymeric Pimecrolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1017-1024.	1.1	7
1098	No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1149-1155.	1.1	29
1099	Long-Term Safety and Efficacy With Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1248-1259.	1.1	122

#	ARTICLE	IF	CITATIONS
1100	Impact of Post-Intervention Minimal Stent Area on 9-Month Follow-Up Patency of Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1269-1275.	1.1	173
1101	Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1208-1218.	1.1	57
1102	Mathematical modelling of NABD release from endoluminal gel paved stent. <i>Computational Biology and Chemistry</i> , 2009, 33, 33-40.	1.1	14
1103	Update on multidetector coronary CT angiography of coronary stents: in vitro evaluation of 29 different stent types with dual-source CT. <i>European Radiology</i> , 2009, 19, 42-49.	2.3	80
1104	Carbon-coated Stents in Patients with Acute Coronary Syndromes. <i>Clinical Cardiology</i> , 2009, 32, E1-6.	0.7	8
1105	Long-Term Clinical Efficacy of Cutting Balloon Angioplasty Followed by Bare Metal Stent Implantation for Treating Ostial Left Anterior Descending Artery Lesions. <i>Clinical Cardiology</i> , 2009, 32, E31-5.	0.7	1
1106	Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice. <i>Clinical Cardiology</i> , 2009, 32, E33-9.	0.7	7
1107	Comparison of Long-Term Outcomes Following Sirolimus-eluting Stent vs Paclitaxel-eluting Stent Implantation in Patients with Long Calcified Coronary Lesions. <i>Clinical Cardiology</i> , 2009, 32, 633-638.	0.7	2
1108	Safety and Efficacy of Drug-Eluting and Bare Metal Stents. <i>Circulation</i> , 2009, 119, 3198-3206.	1.6	794
1109	Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Libertel Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 188-195.	1.4	144
1110	Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents. <i>Circulation</i> , 2009, 119, 680-686.	1.6	282
1111	Acrylic Copolymers as Candidates for Drug-Eluting Coating of Vascular Stents. <i>Journal of Biomaterials Applications</i> , 2009, 24, 353-383.	1.2	5
1112	An angiographic evaluation of restenosis rate at a six-month follow-up of patients with ST-elevation myocardial infarction submitted to primary percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2009, 131, 362-369.	0.8	7
1113	Clinical characteristics of stent fracture after sirolimus-eluting stent implantation. <i>International Journal of Cardiology</i> , 2009, 131, 212-216.	0.8	40
1114	Predictors of death after coronary stenting with sirolimus-eluting stent in high-risk patients. <i>International Journal of Cardiology</i> , 2009, 132, 342-347.	0.8	3
1115	Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2009, 133, 213-222.	0.8	89
1116	Impressive sirolimus-eluting stent fracture immediately after stent implantation: A case report. <i>International Journal of Cardiology</i> , 2009, 134, e113-e116.	0.8	6
1117	Reduction in mortality and target-lesion revascularisation at 2 years: A comparison between drug-eluting stents and conventional bare-metal stents in the "real world". <i>International Journal of Cardiology</i> , 2009, 132, 398-404.	0.8	10

#	ARTICLE	IF	CITATIONS
1118	Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: The sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT). <i>International Journal of Cardiology</i> , 2009, 137, 16-21.	0.8	17
1119	Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 13-21.e5.	2.4	122
1120	The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. <i>American Heart Journal</i> , 2009, 157, 899-907.	1.2	35
1121	Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: Four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angioplasty (PASEO) randomized trial. <i>American Heart Journal</i> , 2009, 158, e43-e50.	1.2	74
1122	SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. <i>American Heart Journal</i> , 2009, 158, 520-526.e2.	1.2	41
1123	Drug-eluting stents: A study of international practice. <i>American Heart Journal</i> , 2009, 158, 576-584.	1.2	14
1124	Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: A post hoc analysis of the SPIRIT III randomized trial. <i>American Heart Journal</i> , 2009, 158, 1005-1010.	1.2	36
1125	Rationale and design of the Patient Related Outcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. <i>American Heart Journal</i> , 2009, 158, 902-909.e5.	1.2	42
1126	Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up. <i>American Journal of Medicine</i> , 2009, 122, 581.e1-581.e10.	0.6	77
1127	Intravascular ultrasound-guided percutaneous coronary interventions in contemporary practice. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 143-151.	0.7	12
1128	Comparative analysis of neointimal coverage with paclitaxel and zotarolimus drug-eluting stents, using optical coherence tomography 6 months after implantation. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 617-624.	0.7	17
1129	Medical Therapy Versus Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 528-529.	1.2	2
1130	2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2009, 53, 658-664.	1.2	316
1131	Temporal Pattern of Ischemic Events in Relation to Dual Antiplatelet Therapy in Patients With Unprotected Left Main Coronary Artery Stenosis Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1176-1181.	1.2	16
1132	Safety and Effectiveness of Drug-Eluting and Bare-Metal Stents for Patients With Off- and On-Label Indications. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1773-1782.	1.2	50
1133	Clinical Effectiveness of Coronary Stents in Elderly Persons. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1629-1641.	1.2	135
1134	Use of Drug-Eluting Stents in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1677-1689.	1.2	398
1135	The Everolimus-Eluting Stent in Real-World Patients. <i>Journal of the American College of Cardiology</i> , 2009, 54, 269-276.	1.2	63

#	ARTICLE	IF	CITATIONS
1136	Incidence and Predictors of Drug-Eluting Stent Fracture in Human Coronary Artery. Journal of the American College of Cardiology, 2009, 54, 1924-1931.	1.2	229
1137	Stent Gap by 64-Detector Computed Tomographic Angiography. Journal of the American College of Cardiology, 2009, 54, 1949-1959.	1.2	41
1138	Atherosclerotic and Thrombogenic Neointima Formed Over Sirolimus Drug-Eluting Stent. JACC: Cardiovascular Imaging, 2009, 2, 616-624.	2.3	151
1139	Clinical characteristics and early mortality of patients undergoing coronary artery bypass grafting compared to percutaneous coronary intervention: Insights from the Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and the Melbourne Interventional Group (MIG) Registries. Heart Lung and Circulation, 2009, 18, 184-190.	0.2	35
1140	Drug-Eluting Stents in Percutaneous Coronary Intervention. Drug Safety, 2009, 32, 749-770.	1.4	63
1141	Interventional Treatment of Advanced Ischemic Heart Disease. , 2009, , .		0
1142	A review of current devices and a look at new technology: drug-eluting stents. Expert Review of Medical Devices, 2009, 6, 33-42.	1.4	60
1143	MAD (Multiagent Delivery) Nanolayer: Delivering Multiple Therapeutics from Hierarchically Assembled Surface Coatings. Langmuir, 2009, 25, 14086-14092.	1.6	91
1144	Poly(ester amide) Co-polymers Promote Blood and Tissue Compatibility. Journal of Biomaterials Science, Polymer Edition, 2009, 20, 1495-1511.	1.9	56
1145	Preparation of a dual-drug-eluting stent by grafting of ALA with abciximab on a bare metal stent. Journal of Materials Chemistry, 2009, 19, 8135.	6.7	9
1146	Predicting risk of complications following a drug eluting stent procedure: A SVM approach for imbalanced data. , 2009, , .		6
1147	Drug-eluting stents for acute myocardial infarction. Expert Opinion on Pharmacotherapy, 2009, 10, 19-34.	0.9	2
1148	Angiographic results of the cobalt chromium Vision and Mini-Vision stents. Canadian Journal of Cardiology, 2009, 25, 581-584.	0.8	7
1149	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused) Tj ETQq1 1 0.784314 rgt /Ove	1.2	1,378
1150	A New Wave in Treatment of Vascular Occlusive Disease: Biodegradable Stentsâ€”Clinical Experience and Scientific Principles. Journal of Vascular and Interventional Radiology, 2009, 20, 315-324.	0.2	42
1151	Diagnosis and treatment of acquired coronary artery disease in adults. Postgraduate Medical Journal, 2009, 85, 364-365.	0.9	1
1152	TREATMENT OF SYMPTOMATIC MIDDLE CEREBRAL ARTERY STENOSIS WITH BALLOON-MOUNTED STENTS. Neurosurgery, 2009, 64, 79-85.	0.6	52
1153	Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry. Journal of Cardiovascular Medicine, 2009, 10, 322-329.	0.6	3

#	ARTICLE	IF	CITATIONS
1154	Comparison between balloon angioplasty and additional coronary stent implantation for the treatment of drug-eluting stent restenosis: 18-month clinical outcomes. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 469-473.	0.6	11
1155	A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) – study design and rationale. <i>Journal of Cardiovascular Medicine</i> . 2009, 10, 192-199.	0.6	5
1156	Advanced Neointimal Growth is Not Associated With a Low Risk of In-Stent Thrombus Optical Coherence Tomographic Findings After First-Generation Drug-Eluting Stent Implantation. <i>Circulation Journal</i> , 2009, 73, 1627-1634.	0.7	26
1157	Latest on the pathology of drug-eluting stents. <i>Interventional Cardiology</i> , 2009, 1, 165-174.	0.0	3
1158	Angiographic Patterns of Restenosis After Sirolimus-Eluting Stent Implantation. <i>Circulation Journal</i> , 2009, 73, 508-511.	0.7	14
1159	Silent Very Late Thrombotic Occlusion of Sirolimus-Eluting Stent Confirmed by Directional Coronary Atherectomy. <i>Circulation Journal</i> , 2009, 73, 1762-1764.	0.7	3
1160	Factors That Influence Measurements and Accurate Evaluation of Stent Apposition by Optical Coherence Tomography Assessment Using a Phantom Model. <i>Circulation Journal</i> , 2009, 73, 1841-1847.	0.7	46
1161	Routine stenting vs. balloon angioplasty in ST-segment elevation myocardial infarction due to proximal left anterior descending coronary artery occlusion. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 22-26.	0.6	2
1162	Drug-eluting balloon: Very short-term exposure and overlapping. <i>Thrombosis and Haemostasis</i> , 2009, 101, 201-206.	1.8	94
1163	Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues. <i>Current Opinion in Lipidology</i> , 2009, 20, 227-235.	1.2	38
1164	Severe multivessel coronary spasm after sirolimus-eluting stent implantation. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 485-488.	0.6	4
1165	Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure. <i>Current Pharmaceutical Design</i> , 2009, 15, 1107-1122.	0.9	15
1166	Clinical Studies with Paclitaxel - Eluting Stent Systems. <i>Current Pharmaceutical Design</i> , 2010, 16, 4025-4036.	0.9	4
1167	Anti-Proliferative Compounds for the Prevention of Restenosis: Anti-Restenotic Mechanisms of Paclitaxel Action. <i>Current Pharmaceutical Design</i> , 2010, 16, 3989-4001.	0.9	11
1168	Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. <i>Coronary Artery Disease</i> , 2010, 21, 46-56.	0.3	65
1169	Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems. <i>Current Pharmaceutical Design</i> , 2010, 16, 4012-4024.	0.9	10
1170	Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) trial: rationale, objectives and design. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 53-58.	0.6	5
1171	A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the EXECUTIVE trial. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 299-309.	0.6	3

#	ARTICLE	IF	CITATIONS
1172	Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dl on clinical outcomes in very high-risk patients treated with drug-eluting stents. <i>Coronary Artery Disease</i> , 2010, 21, 182-188.	0.3	7
1173	Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: Drug-Eluting Stents or Bare Metal Stents?. <i>American Journal of Therapeutics</i> , 2010, 17, 516-522.	0.5	0
1174	Zotarolimus-eluting versus sirolimus-eluting coronary stent implantation. <i>Interventional Cardiology</i> , 2010, 2, 807-812.	0.0	2
1175	Long-Term Clinical Outcome of Chronic Total Occlusive Lesions Treated With Drug-Eluting Stents: - Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents -. <i>Circulation Journal</i> , 2010, 74, 693-700.	0.7	23
1176	ISAR - A Story of Trials With Impact on Practice -. <i>Circulation Journal</i> , 2010, 74, 1771-1778.	0.7	6
1177	In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report. <i>Cases Journal</i> , 2010, 3, 68.	0.4	6
1178	Real World' Comparison of Drug-Eluting Stents vs Bare Metal Stents in the Treatment of Unselected Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation Journal</i> , 2010, 74, 1111-1120.	0.7	20
1179	Intravascular Ultrasound Criteria for Determination of Optimal Longitudinal Positioning of Sirolimus-Eluting Stents. <i>Circulation Journal</i> , 2010, 74, 1609-1616.	0.7	48
1180	Impact of Drug-Eluting Stents on Treatment Option Mix for Coronary Artery Disease in Japan. <i>Circulation Journal</i> , 2010, 74, 1635-1643.	0.7	22
1181	Three-Month Dual Antiplatelet Therapy After Implantation of Zotarolimus-Eluting Stents - The DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) Registry -. <i>Circulation Journal</i> , 2010, 74, 2314-2321.	0.7	28
1182	Drug-Eluting Stents Are Not Indicated for Patients With Acute Coronary Syndrome - Should Drug-Eluting Stents Be Indicated for Patients With Acute Coronary Syndrome? (Con) -. <i>Circulation Journal</i> , 2010, 74, 2232-2238.	0.7	9
1183	What Is the Effectiveness of Drug-Eluting Stents in the Treatment of ST-Elevation Myocardial Infarction? - Should Drug-Eluting Stents Be Indicated for Patients With Acute Coronary Syndrome? (Pro) -. <i>Circulation Journal</i> , 2010, 74, 2225-2231.	0.7	8
1184	Application of Drug Eluting Stents to Clinical Practice in Japan. <i>Circulation Journal</i> , 2010, 74, 1532-1533.	0.7	0
1185	STELLIUM 1: First-In-Man Follow-up Evaluation of Bioabsorbable Polymer-Coated Paclitaxel-Eluting Stent. <i>Circulation Journal</i> , 2010, 74, 2089-2096.	0.7	8
1186	Liposomal Simvastatin Attenuates Neointimal Hyperplasia in Rats. <i>AAPS Journal</i> , 2010, 12, 181-187.	2.2	24
1187	Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 1339-1356.	1.2	12
1189	Long-term Clinical Outcomes of Drug-Eluting Stents Vs Bare-Metal Stents in Chinese Patients. <i>Clinical Cardiology</i> , 2010, 33, E22-9.	0.7	4
1190	Clinical and Angiographic Outcomes of Drug-Eluting Stents in Patients With Large Vessel and Single Coronary Artery Lesion. <i>Clinical Cardiology</i> , 2010, 33, 340-344.	0.7	3

#	ARTICLE	IF	CITATIONS
1191	Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictor of Restenosis Following Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2010, 33, 678-685.	0.7	42
1192	Acceptance, Panic, and Partial Recovery. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 902-910.	1.1	35
1193	Influence of Sex on Long-Term Outcomes After Percutaneous Coronary Intervention With the Paclitaxel-Eluting Coronary Stent. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1250-1259.	1.1	53
1194	Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents. <i>Acta Biomaterialia</i> , 2010, 6, 534-546.	4.1	76
1195	Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry. <i>Clinical Research in Cardiology</i> , 2010, 99, 99-106.	1.5	4
1197	Diagnostic accuracy of 64-slice computed tomography coronary angiography for the detection of in-stent restenosis: A meta-analysis. <i>Journal of Nuclear Cardiology</i> , 2010, 17, 470-478.	1.4	57
1198	Paclitaxel-polyurethane film for anti-cancer drug delivery: Film characterization and preliminary in vivo study. <i>Macromolecular Research</i> , 2010, 18, 680-685.	1.0	37
1199	Biodegradable Stents: Biomechanical Modeling Challenges and Opportunities. <i>Cardiovascular Engineering and Technology</i> , 2010, 1, 52-65.	0.7	46
1200	Drug-Eluting Stents in the Elderly. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 76-83.	0.4	7
1201	Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb/IIIa inhibitors and BMS or DES. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 133-141.	1.0	22
1202	Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: Internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. <i>Journal of Controlled Release</i> , 2010, 146, 182-195.	4.8	87
1203	Autonomic Denervation Using Magnetic Nanoparticles. <i>Trends in Cardiovascular Medicine</i> , 2010, 20, 268-272.	2.3	2
1204	Comparison by Meta-Analysis of Drug-Eluting Stents and Bare Metal Stents for Saphenous Vein Graft Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 1076-1082.	0.7	49
1205	Three-Year Outcome of Sirolimus-Eluting Versus Bare-Metal Stents for the Treatment of ST-Segment Elevation Myocardial Infarction (from the MISSION! Intervention Study). <i>American Journal of Cardiology</i> , 2010, 106, 4-12.	0.7	45
1206	Incidence and Risk Factors of Late Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation (3-Year Follow-Up of the j-Cypher Registry). <i>American Journal of Cardiology</i> , 2010, 106, 329-336.	0.7	95
1207	Effect of Coronary Target Lesion Revascularization on Late Cardiac Events After Insertion of Sirolimus-Eluting or Bare Metal Stents. <i>American Journal of Cardiology</i> , 2010, 106, 774-779.	0.7	3
1208	Comparison of Five-Year Outcome of Octogenarians Undergoing Percutaneous Coronary Intervention With Drug-Eluting Versus Bare-Metal Stents (from the RESEARCH and T-SEARCH Registries). <i>American Journal of Cardiology</i> , 2010, 106, 1376-1381.	0.7	11
1209	Percutaneous coronary intervention for small vessel coronary artery disease. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 189-198.	0.3	64

#	ARTICLE	IF	CITATIONS
1210	Vascular responses to the multiple overlapped paclitaxel-eluting stents for the treatment of bare-metal in-stent restenotic lesions: angiographic and intravascular ultrasound analysis from the TAXUS-V ISR Trial. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 140-148.	0.3	1
1211	<i>In vivo</i> and <i>in vitro</i> characterization of poly(styrene- <i>co</i> -isobutylene- <i>co</i> -styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. <i>Journal of Biomedical Materials Research - Part A</i> , 2010, 92A, 773-782.	2.1	43
1212	Combined drug release from biodegradable bilayer coating for endovascular stents. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2010, 93B, 375-385.	1.6	15
1213	Drug-eluting stent fracture: Incidence, contributing factors, and clinical implications. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 237-245.	0.7	76
1214	Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 578-583.	0.7	149
1215	Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 179-186.	0.7	12
1216	Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with <i>de novo</i> coronary artery lesions: The SPIRIT FIRST trial. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 997-1003.	0.7	54
1217	Limitations of stints: A good, albeit imperfect, therapy; For a less than perfect world. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 343-344.	0.7	0
1218	The EXTREME registry: Titanium-nitride-coated stents in small coronary arteries. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 281-287.	0.7	7
1219	Impact of chronic renal insufficiency on clinical outcomes in patients undergoing saphenous vein graft intervention with drug-eluting stents: A multicenter Southern Californian Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 272-278.	0.7	9
1220	A novel three-dimensional quantitative coronary angiography system: <i>In vivo</i> comparison with intravascular ultrasound for assessing arterial segment length. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 291-298.	0.7	42
1221	A comparative analysis of major clinical outcomes using drug-eluting stents versus bare-metal stents in a large consecutive patient cohort. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 374-380.	0.7	21
1222	Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 257-262.	0.7	18
1223	Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 41-49.	0.7	11
1224	Drug-eluting stents in patients with end-stage renal disease: Meta-analysis and systematic review of the literature. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 942-948.	0.7	28
1225	The Relationship and Threshold of Stent Length With Regard to Risk of Stent Thrombosis After Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 383-389.	1.1	111
1226	Serial Angiography and Intravascular Ultrasound: Results of the SISC Registry (Stents In Small) Tj ETQq0 0 0 r gBT /Overlock 10 Tf 50 102	1.1	13
1227	A Novel Paclitaxel-Eluting Stent With an Ultrathin Abluminal Biodegradable Polymer. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 431-438.	1.1	48

#	ARTICLE	IF	CITATIONS
1228	The Clinical Impact of Routine Angiographic Follow-Up in Randomized Trials of Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2010, 3, 403-411.	1.1	89
1229	Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy. JACC: Cardiovascular Interventions, 2010, 3, 378-382.	1.1	18
1230	Long-Term Impact of Routinely Detected Early and Late Incomplete Stent Apposition. JACC: Cardiovascular Interventions, 2010, 3, 486-494.	1.1	72
1232	Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2010, 3, 1220-1228.	1.1	45
1233	Long-Term Clinical Outcomes With Zotarolimus-Eluting Versus Bare-Metal Coronary Stents. JACC: Cardiovascular Interventions, 2010, 3, 1240-1249.	1.1	42
1234	A mixture model for water uptake, degradation, erosion and drug release from polydisperse polymeric networks. Biomaterials, 2010, 31, 3032-3042.	5.7	64
1235	In vitro and in vivo changes to PLGA/sirolimus coating on drug eluting stents. Biomaterials, 2010, 31, 5151-5158.	5.7	59
1236	A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: Design and statistical methods of the PERSEUS clinical program. Trials, 2010, 11, 1.	0.7	56
1237	Layer-by-Layer Assembled Capsules and Films for Therapeutic Delivery. Small, 2010, 6, 1836-52.	5.2	280
1238	Coronary Stenting with the Sirolimus-Eluting Stent in Clinical Practice: Final Results from the Prospective Multicenter <i>German Cypher Stent Registry</i>. Journal of Interventional Cardiology, 2010, 23, 18-25.	0.5	18
1239	Paclitaxel-Eluting Stents for Chronically Occluded Saphenous Vein Grafts (EOS) Study. Journal of Interventional Cardiology, 2010, 23, 40-45.	0.5	9
1240	Paclitaxel-Eluting Stents for Chronically Occluded Saphenous Vein Grafts (EOS) Study. Journal of Interventional Cardiology, 2010, , .	0.5	0
1241	The Paclitaxel-Eluting Coroflex, Stent Study II (PECOPS II) Acute and 6-Month Clinical and Angiographic Follow-Up, 1-Year Clinical Follow-Up. Journal of Interventional Cardiology, 2010, 23, 160-166.	0.5	7
1242	Real World, Long-Term Outcomes Comparison Between Paclitaxel-Eluting and Sirolimus-Eluting Stent Platforms. Journal of Interventional Cardiology, 2010, 23, 167-175.	0.5	4
1243	Rotablation in the Drug Eluting Era: Immediate and Long-Term Results from a Single Center Experience. Journal of Interventional Cardiology, 2010, 23, 249-253.	0.5	49
1244	Aggressive Plaque Modification with Rotational Atherectomy and/or Cutting Balloon before Drug-Eluting Stent Implantation for the Treatment of Calcified Coronary Lesions. Journal of Interventional Cardiology, 2010, 23, 240-248.	0.5	53
1245	Effects of an Alpha-4 Integrin Inhibitor on Restenosis in a New Porcine Model Combining Endothelial Denudation and Stent Placement. PLoS ONE, 2010, 5, e14314.	1.1	4
1246	Drug-Eluting Stents in Patients with Chronic Kidney Disease: A Prospective Registry Study. PLoS ONE, 2010, 5, e15070.	1.1	30

#	ARTICLE	IF	CITATIONS
1247	New stent design for use in small coronary arteries during percutaneous coronary intervention. <i>Medical Devices: Evidence and Research</i> , 2010, 3, 57.	0.4	2
1248	Impacto de stents farmacológicos em pacientes com doença arterial coronária estável submetidos a intervenção coronária percutânea na prática diária do mundo real. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2010, 18, 392-399.	0.1	0
1249	Aspectos contemporâneos da intervenção coronária percutânea no tratamento eletivo de estenoses localizadas no tronco não-protetido da artéria coronária esquerda. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2010, 18, 456-467.	0.1	0
1250	Avaliação angiográfica do volume de placa e eventos cardiovasculares após implante de stents coronarianos. <i>Arquivos Brasileiros De Cardiologia</i> , 2010, 95, 679-684.	0.3	1
1251	Percutaneous Coronary Intervention (PCI) in Patients with Chronic Total Occlusion (CTO): A Single Center Experiences. <i>Cardiovascular Journal</i> , 2010, 2, 168-174.	0.0	0
1252	Efficacy of Sirolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease: 24-Month Outcomes of Patients in a Prospective Non-randomized Registry in Southern Turkey. <i>International Journal of Medical Sciences</i> , 2010, 7, 191-196.	1.1	3
1253	Sirolimus Eluting Stents. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2094.	0.4	7
1254	Rationale and Design of a Randomized Clinical Comparison of Everolimus-Eluting (Xience V/Promus) and Sirolimus-Eluting (Cypher Select+) Coronary Stents in Unselected Patients with Coronary Heart Disease. <i>Cardiology</i> , 2010, 116, 73-78.	0.6	18
1255	The role of CABG in the era of drug-eluting stents: a surgeon's viewpoint. <i>Heart Asia</i> , 2010, 2, 7-10.	1.1	0
1256	Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Drug-eluting Stents. <i>Critical Pathways in Cardiology</i> , 2010, 9, 203-206.	0.2	8
1257	Long-Term Outcome of Adjunctive Celecoxib Treatment After Paclitaxel-Eluting Stent Implantation for the Complex Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 243-248.	1.4	8
1258	Drug-Eluting or Bare Metal Stents for the Treatment of Saphenous Vein Graft Disease. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 565-576.	1.4	29
1259	Role of the Paclitaxel-Eluting Stent and Tirofiban in Patients With ST-Elevation Myocardial Infarction Undergoing Postfibrinolysis Angioplasty. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 297-307.	1.4	46
1260	Review of Registry and Randomised Comparisons of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents in Western Denmark. <i>The European Journal of Cardiovascular Medicine</i> , 2010, 1, .	1.0	0
1261	Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents?. <i>The European Journal of Cardiovascular Medicine</i> , 2010, 1, 20-24.	1.0	11
1262	Why Observational Studies Should Be Among The Tools Used In Comparative Effectiveness Research. <i>Health Affairs</i> , 2010, 29, 1818-1825.	2.5	183
1263	Development of lipid-rich plaque inside bare metal stent: possible mechanism of late stent thrombosis? An optical coherence tomography study. <i>Heart</i> , 2010, 96, 1187-1190.	1.2	47
1264	Strut Coverage and Vessel Wall Response to a New-Generation Paclitaxel-Eluting Stent With an Ultrathin Biodegradable Abluminal Polymer. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 367-375.	1.4	64

#	ARTICLE	IF	CITATIONS
1265	Is direct stenting superior to stenting with predilation in patients treated with percutaneous coronary intervention? results from a meta-analysis of 24 randomised controlled trials. Heart, 2010, 96, 588-594.	1.2	36
1266	Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. , 2010, , CD004587.		64
1267	Development and performance of the zotarolimus-eluting Endeavor® coronary stent. Expert Review of Medical Devices, 2010, 7, 449-459.	1.4	8
1268	Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial. Circulation: Cardiovascular Interventions, 2010, 3, 556-564.	1.4	55
1269	Initial experience with an everolimus-eluting, second-generation drug-eluting stent for treatment of intracranial atherosclerosis. Journal of NeuroInterventional Surgery, 2010, 2, 104-109.	2.0	23
1270	Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice. Circulation: Cardiovascular Interventions, 2010, 3, 327-334.	1.4	76
1271	Comparison of the Effect of Preinterventional Arterial Remodeling on Intimal Hyperplasia after Implantation of a Sirolimus- or Paclitaxel-Eluting Stent. Cardiology, 2010, 116, 117-122.	0.6	4
1272	Polymers for Drug Eluting Stents. Current Pharmaceutical Design, 2010, 16, 3978-3988.	0.9	38
1273	Computed tomography angiography, perfusion computed tomography, and a drug-eluting stent for the treatment of in-stent restenosis of the middle cerebral artery. Journal of Neurosurgery, 2010, 112, 729-733.	0.9	3
1274	Percutaneous Coronary Intervention in Chronic Stable Angina. American Journal of the Medical Sciences, 2010, 339, 568-572.	0.4	1
1275	Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2010, 38, S1-S52.	0.6	405
1276	The role of vessel geometry and material properties on the mechanics of stenting in the coronary and peripheral arteries. Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, 2010, 224, 465-476.	1.0	16
1277	Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation. Current Pharmaceutical Design, 2010, 16, 4064-4071.	0.9	35
1278	LVADs—“from an imaginative leap to clinical decision making. Nature Reviews Cardiology, 2010, 7, 246-248.	6.1	2
1279	Current status of the Xience V [®] everolimus-eluting coronary stent system. Expert Review of Cardiovascular Therapy, 2010, 8, 1363-1374.	0.6	11
1280	Endovascular treatment of vertebral artery stenosis. Nature Reviews Cardiology, 2010, 7, 245-246.	6.1	2
1281	Nano- and Biotechnological Approaches in Current and Future Generation of Cardiovascular Stents. Current Nanoscience, 2010, 6, 469-478.	0.7	8
1282	Decision-making: stenting in acute myocardial infarction. Future Cardiology, 2010, 6, 301-314.	0.5	1

#	ARTICLE	IF	CITATIONS
1283	Percutaneous coronary intervention for small-vessel coronary disease: highlight on the everolimus-eluting stent. Expert Review of Cardiovascular Therapy, 2010, 8, 1239-1245.	0.6	4
1284	Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials. Expert Review of Cardiovascular Therapy, 2010, 8, 1207-1210.	0.6	2
1285	High-Pitch 128-Slice Dual-Source CT for the Assessment of Coronary Stents in a Phantom Model. Academic Radiology, 2010, 17, 1366-1374.	1.3	13
1286	Controlling the drug release rate from biocompatible polymers with micro-patterned diamond-like carbon (DLC) coating. Diamond and Related Materials, 2010, 19, 806-813.	1.8	39
1287	Coronary Stents. Journal of the American College of Cardiology, 2010, 56, S43-S78.	1.2	278
1288	A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions. Journal of the American College of Cardiology, 2010, 55, 543-554.	1.2	217
1289	Intravascular Ultrasound Findings in Patients With Very Late Stent Thrombosis After Either Drug-Eluting or Bare-Metal Stent Implantation. Journal of the American College of Cardiology, 2010, 55, 1936-1942.	1.2	132
1290	Pathological Findings at Bifurcation Lesions. Journal of the American College of Cardiology, 2010, 55, 1679-1687.	1.2	228
1291	Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations. Journal of the American College of Cardiology, 2010, 55, 1743-1750.	1.2	58
1292	Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization. Journal of the American College of Cardiology, 2010, 56, 1187-1195.	1.2	143
1293	Clinical and Angiographic Outcomes After Treatment of De Novo Coronary Stenoses With a Novel Platinum Chromium Thin-Strut Stent. Journal of the American College of Cardiology, 2010, 56, 264-271.	1.2	66
1294	Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2010, 56, 641-645.	1.2	75
1295	Coronary Stents. Journal of the American College of Cardiology, 2010, 56, S1-S42.	1.2	447
1296	In-Stent Restenosis in the Drug-Eluting Stent Era. Journal of the American College of Cardiology, 2010, 56, 1897-1907.	1.2	663
1297	Effect of Stent Thrombosis on the Risk-Benefit Balance of Drug-Eluting Stents and Bare Metal Stents. Revista Espanola De Cardiologia (English Ed), 2010, 63, 528-535.	0.4	1
1298	Drug-eluting Stents for the Treatment of Acute Myocardial Infarction: The View to the HORIZONS. Heart Lung and Circulation, 2010, 19, 11-18.	0.2	1
1299	Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. International Journal of Cardiology, 2010, 144, 42-46.	0.8	21
1300	Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound. American Heart Journal, 2010, 159, 271-277.	1.2	22

#	ARTICLE	IF	CITATIONS
1301	Intracoronary thrombus formation after drug-eluting stents implantation: Optical coherence tomographic study. <i>American Heart Journal</i> , 2010, 159, 278-283.	1.2	44
1302	Rapid adoption of drug-eluting stents: Clinical practices and outcomes from the early drug-eluting stent era. <i>American Heart Journal</i> , 2010, 160, 767-774.e1.	1.2	15
1303	Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. <i>American Heart Journal</i> , 2010, 160, 1035-1041.e1.	1.2	158
1304	REVIEW: Stent Thrombosis – Risk Assessment and Prevention. <i>Cardiovascular Therapeutics</i> , 2010, 28, e92-100.	1.1	18
1305	CORONARY REVASCULARISATION IN CHRONIC KIDNEY DISEASE PART 1: STABLE CORONARY ARTERY DISEASE. <i>Journal of Renal Care</i> , 2010, 36, 106-117.	0.6	6
1306	Noninvasive quantitative evaluation of coronary artery stent patency using 64-row multidetector computed tomography. <i>Journal of Cardiovascular Computed Tomography</i> , 2010, 4, 29-37.	0.7	21
1307	Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model. <i>Atherosclerosis</i> , 2010, 208, 97-103.	0.4	27
1308	Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation. <i>Atherosclerosis</i> , 2010, 210, 503-509.	0.4	22
1309	Influencia de la trombosis del stent en la relación riesgo-beneficio de los stents farmacoactivos y los stents convencionales. <i>Revista Espanola De Cardiología</i> , 2010, 63, 528-535.	0.6	3
1311	Nuevos avances en cardiología intervencionista. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2010, 22, 42-47.	0.4	0
1312	Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. <i>Lancet, The</i> , 2010, 375, 201-209.	6.3	641
1313	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. <i>Lancet, The</i> , 2010, 375, 1090-1099.	6.3	198
1314	Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: A Canadian experience. <i>Canadian Journal of Cardiology</i> , 2010, 26, e40-e44.	0.8	8
1315	Late outcomes following percutaneous coronary interventions: Results from a large, observational registry. <i>Canadian Journal of Cardiology</i> , 2010, 26, e218-e224.	0.8	12
1316	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	1.0	2,649
1317	Controversies in the Use of Drug-Eluting Stents for Acute Myocardial Infarction: A Critical Appraisal of the Data. <i>Annual Review of Medicine</i> , 2010, 61, 215-231.	5.0	6
1318	Titanium-nitride-oxide-coated Titan-2 bioactive coronary stent: a new horizon for coronary intervention. <i>Expert Review of Medical Devices</i> , 2010, 7, 599-604.	1.4	6
1319	Pharmacological prevention and management of restenosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1855-1872.	0.9	4

#	ARTICLE	IF	CITATIONS
1320	Preparation of a drug-eluting stent using a TiO ₂ film deposited by plasma enhanced chemical vapour deposition as a drug-combining matrix. <i>Journal of Materials Chemistry</i> , 2010, 20, 4792.	6.7	29
1321	The comparative safety of bare-metal and drug-eluting intracoronary stents. <i>Expert Review of Medical Devices</i> , 2010, 7, 611-624.	1.4	4
1322	Nanostructured polymer assemblies formed at interfaces: applications from immobilization and encapsulation to stimuli-responsive release. <i>Physical Chemistry Chemical Physics</i> , 2011, 13, 4782.	1.3	82
1325	Paclitaxel Inhibits Ureteral Smooth Muscle Cell Proliferation and Collagen Production in the Absence of Cell Toxicity. <i>Journal of Urology</i> , 2011, 185, 335-340.	0.2	15
1326	Coronary Responses and Differential Mechanisms of Late Stent Thrombosis Attributed to First-Generation Sirolimus- and Paclitaxel-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2011, 57, 390-398.	1.2	283
1327	Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2143-2151.	1.2	92
1328	The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2221-2232.	1.2	101
1329	Disruption of Platelet-Derived Growth Factor-Dependent Phosphatidylinositol 3-Kinase and Phospholipase C β 1 Activity Abolishes Vascular Smooth Muscle Cell Proliferation and Migration and Attenuates Neointima Formation In Vivo. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2527-2538.	1.2	44
1330	Clinical Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1778-1783.	1.2	131
1331	2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 887-895.	1.1	32
1332	1-Year Outcome of TRIAS HR (TRI-Stent Adjudication Study-“High Risk of Restenosis). <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 896-904.	1.1	49
1333	Long-Term Safety and Effectiveness of Drug-Eluting Stents for the Treatment of Saphenous Vein Grafts Disease. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 965-973.	1.1	14
1334	Assessing the Temporal Course of Neointimal Hyperplasia Formation After Different Generations of Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1067-1074.	1.1	23
1335	Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation? Editorials published in <i>JACC: Cardiovascular Interventions</i> reflect the views of the authors and do not necessarily represent the views of <i>JACC: Cardiovascular Interventions</i> or the American College of Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1129-1132.	1.1	15
1336	Second-Generation Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1216-1217.	1.1	0
1337	Correlation of Angiographic Late Loss With Neointimal Proliferation in Stents Evaluated by OCT and Histology in Porcine Coronary Arteries. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 1002-1010.	2.3	13
1338	Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 147-154.	0.7	3
1339	Novel Coating Technologies of Drug Eluting Stents. <i>Studies in Mechanobiology, Tissue Engineering and Biomaterials</i> , 2011, , 87-125.	0.7	4

#	ARTICLE	IF	CITATIONS
1340	Active Implants and Scaffolds for Tissue Regeneration. Studies in Mechanobiology, Tissue Engineering and Biomaterials, 2011, , .	0.7	15
1341	Nitric Oxide: A Guardian for Vascular Grafts?. Chemical Reviews, 2011, 111, 5742-5767.	23.0	157
1342	Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical) Tj ETQqO 0 0 rgBT. # Overlock 10 Tf 50	0.7	15
1343	Immunosuppressive Therapy with Oral Prednisone to Prevent Restenosis after PCI. A Multicenter Randomized Trial. American Journal of Medicine, 2011, 124, 434-443.	0.6	29
1344	Progress Towards a National Cardiac Procedure Databaseâ€”Development of the Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and Melbourne Interventional Group (MIG) Registries. Heart Lung and Circulation, 2011, 20, 10-18.	0.2	78
1345	Meta-analysis of long-term outcomes of drug-eluting stent implantations for chronic total coronary occlusions. Heart and Lung: Journal of Acute and Critical Care, 2011, 40, e32-e40.	0.8	13
1346	Usefulness of a 0.010-inch guidewire compatible balloon for crossing stent-jailed sidebranches. International Journal of Cardiology, 2011, 148, 228-231.	0.8	2
1347	Optical frequency domain imaging guided crossing of a stumpless chronic total occlusion. International Journal of Cardiology, 2011, 148, 231-233.	0.8	9
1348	Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. International Journal of Cardiology, 2011, 147, 253-257.	0.8	27
1349	Determining clinical benefits of drug-eluting coronary stents according to the population risk profile: A meta-regression from 31 randomized trials. International Journal of Cardiology, 2011, 148, 23-29.	0.8	7
1350	Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. International Journal of Cardiology, 2011, 149, 174-181.	0.8	24
1351	Comparison of efficacy between paclitaxel-eluting stents with different polymers in terms of major adverse cardiac events and stent thrombosis up to 12months of clinical follow-up. International Journal of Cardiology, 2011, 152, 392-395.	0.8	0
1352	First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. Journal of Vascular Surgery, 2011, 54, 394-401.	0.6	144
1353	Local Drug Delivery for Treatment of Coronary and Peripheral Artery Disease. Cardiovascular Therapeutics, 2011, 29, e54-e66.	1.1	18
1354	Prognosis of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafts for Ostial Right Coronary Lesions in Propensity-Matched Individuals. Cardiovascular Therapeutics, 2011, 29, 395-403.	1.1	4
1355	Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet, The, 2011, 377, 1241-1247.	6.3	216
1356	Fatigue behavior and coating failure of polymer coated drug eluting stent. Strength, Fracture and Complexity, 2011, 7, 195-203.	0.2	1
1357	Drug-eluting coronary stents – focus on improved patient outcomes. Patient Related Outcome Measures, 2011, 2, 161.	0.7	12

#	ARTICLE	IF	CITATIONS
1358	Drug eluting stent or drug eluting balloon? Which is the better device to treat instent restenosis?. Postepy W Kardiologii Interwencyjnej, 2011, 2, 147-155.	0.1	0
1359	Hemodialysis Vascular Access Dysfunction. , 2011, , .		0
1360	Proliferation unleashed: The role of Skp2 in vascular smooth muscle cell proliferation. Frontiers in Bioscience - Landmark, 2011, 16, 1517.	3.0	12
1361	Effectiveness of Drug-Eluting Stents versus Bare-Metal Stents in Large Coronary Arteries in Patients with Acute Myocardial Infarction. Journal of Korean Medical Science, 2011, 26, 521.	1.1	23
1362	Late Stent Thrombosis After Drug-Eluting Stent Implantation: A Rare Case of Accelerated Neo-Atherosclerosis and Early Manifestation of Neointimal Rupture. Korean Circulation Journal, 2011, 41, 409.	0.7	3
1363	Stents farmacolÃ³gicos liberadores de Everolimus Xience™ V no tratamento de pacientes com lesÃµes coronÃ¡rias complexas na prÃ¡tica diÃ¡ria: resultados iniciais do registro brasileiro BRAVO. Revista Brasileira De Cardiologia Invasiva, 2011, 19, 357-366.	0.1	3
1364	ComparaÃ§Ã£o randomizada entre o stent eluidor de paclitaxel de nova geraÃ§Ã£o sem polÃmero e o stent eluidor de paclitaxel com polÃmero durÃ¡vel em pacientes com doenÃa arterial coronÃ¡ria: resultados da anÃlise angiogrÃfica e ultrassonogrÃfica seriada do estudo PAX-A. Revista Brasileira De Cardiologia Invasiva, 2011, 19, 379-391.	0.1	4
1365	Everolimus-eluting stents: update on current clinical studies. Medical Devices: Evidence and Research, 2011, 4, 91.	0.4	3
1366	Advantages and disadvantages of biodegradable platforms in drug eluting stents. World Journal of Cardiology, 2011, 3, 84.	0.5	32
1367	Association on cardiovascular interventions of PCS Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease: An expert consensus document of the Association for Percutaneous Cardiovascular Interventions and Polish Cardiac Society. Postepy W Kardiologii Interwencyjnej, 2011, 1, 20-55.	0.1	0
1368	Serum Levels of Bilirubin as an Independent Predictor of Coronary In-Stent Restenosis: A New Look at an Old Molecule. Journal of Atherosclerosis and Thrombosis, 2011, 18, 574-583.	0.9	20
1369	Pathogenesis of Neointima Formation Following Vascular Injury. Cardiovascular & Hematological Disorders Drug Targets, 2011, 11, 30-39.	0.2	67
1370	Drug-Eluting Stents. , 2011, , 427-448.		6
1371	Predictors of edge stenosis after paclitaxel-eluting stent implantation. Coronary Artery Disease, 2011, 22, 59-63.	0.3	1
1372	Survival Benefit With Drug-Eluting Stents in Observational Studies. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 587-594.	0.9	29
1373	Predictors of stent fracture in patients treated with closed-cell design stents. Coronary Artery Disease, 2011, 22, 40-44.	0.3	7
1374	Local Delivery of Therapeutics for Percutaneous Coronary Intervention. Current Drug Delivery, 2011, 8, 534-556.	0.8	9
1375	Coronary stent thrombosis: incidence, predictors and triggering mechanisms. Interventional Cardiology, 2011, 3, 581-588.	0.0	2

#	ARTICLE	IF	CITATIONS
1376	Six-Year Clinical Follow-up After Treatment of Diffuse In-Stent Restenosis With Cutting Balloon Angioplasty Followed by Intracoronary Brachytherapy With Liquid Rhenium-188-Filled Balloon via Transradial Approach. <i>Circulation Journal</i> , 2011, 75, 113-120.	0.7	2
1377	Lipid-Rich Plaques Predict Non-Target-Lesion Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2011, 75, 157-166.	0.7	43
1378	Long-Term Benefit of the TAXUS Liberte Stent in Small Vessels and Long Lesions - TAXUS ATLAS Program -. <i>Circulation Journal</i> , 2011, 75, 1120-1129.	0.7	9
1379	Efficacy of Paclitaxel-Eluting Stent in Patients With Impaired Glucose Tolerance - Comparison With Sirolimus-Eluting Stent -. <i>Circulation Journal</i> , 2011, 75, 868-873.	0.7	2
1380	Beneficial Effects of Valsartan on Target Lesion Revascularization After Percutaneous Coronary Interventions With Bare-Metal Stents. <i>Circulation Journal</i> , 2011, 75, 1641-1648.	0.7	6
1381	Mechanisms of Smooth Muscle Cell Proliferation and Endothelial Regeneration After Vascular Injury and Stenting - Approach to Therapy -. <i>Circulation Journal</i> , 2011, 75, 1287-1296.	0.7	223
1382	Drug-Eluting vs. Bare-Metal Stents for Treatment of Acute Myocardial Infarction With Renal Insufficiency. <i>Circulation Journal</i> , 2011, 75, 2798-2804.	0.7	11
1383	Clinical Outcomes and the Risk Factors of Coronary Artery Aneurysms That Developed After Drug-Eluting Stent Implantation. <i>Circulation Journal</i> , 2011, 75, 861-867.	0.7	28
1384	TAXUS [®] Elementa, ϕ stent system. <i>Interventional Cardiology</i> , 2011, 3, 641-648.	0.0	2
1385	The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial. <i>Interventional Cardiology</i> , 2011, 3, 451-460.	0.0	1
1386	Review of the everolimus-eluting coronary stent system. <i>Interventional Cardiology</i> , 2011, 3, 299-307.	0.0	0
1387	Prevalence and predictors of premature discontinuation of dual antiplatelet therapy after drug-eluting stent implantation: importance of social factors in Asian patients. <i>Internal Medicine Journal</i> , 2011, 41, 623-629.	0.5	11
1388	Five-Year Clinical Outcome of Titanium-Nitride-Oxide-Coated Bioactive Stent Implantation in a Real-World Population: A Comparison with Paclitaxel-eluting Stents: The PORI Registry. <i>Journal of Interventional Cardiology</i> , 2011, 24, 1-8.	0.5	28
1389	Late Catch-Up Phenomenon Associated with Stent Fracture after Sirolimus-Eluting Stent Implantation: Incidence and Outcome. <i>Journal of Interventional Cardiology</i> , 2011, 24, 165-171.	0.5	7
1390	Two-Year Clinical Outcomes with Paclitaxel-Eluting Coronary Stents in Patients with Chronic Total Occlusions: Analysis from the TAXUS ARRIVE Program. <i>Journal of Interventional Cardiology</i> , 2011, 24, 232-240.	0.5	3
1391	Low Stent Thrombosis Risk with the XIENCE V [®] Everolimus-Eluting Coronary Stent: Evidence from Randomized and Single-Arm Clinical Trials. <i>Journal of Interventional Cardiology</i> , 2011, 24, 326-341.	0.5	10
1392	Two-Year Outcomes after Utilization of the TAXUS Paclitaxel-Eluting Stent in Bifurcations and Multivessel Stenting in the ARRIVE Registries. <i>Journal of Interventional Cardiology</i> , 2011, 24, 342-350.	0.5	2
1393	Performance of Everolimus-Eluting versus Paclitaxel-Eluting Coronary Stents in Small Vessels: Results from the SPIRIT III and SPIRIT IV Clinical Trials. <i>Journal of Interventional Cardiology</i> , 2011, 24, 505-513.	0.5	23

#	ARTICLE	IF	CITATIONS
1394	Long-Term Clinical Outcome of Thin-Strut Cobalt-Chromium Stents in the Drug-Eluting Stent Era: Results of the COBALT (Comparison of Bare-Metal Stents in All-Comers™ Lesion Treatment) Registry. <i>Journal of Interventional Cardiology</i> , 2011, 24, 496-504.	0.5	12
1395	Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data. <i>Biometrics</i> , 2011, 67, 1163-1170.	0.8	60
1396	Influence of Antiplatelet Medications on Bleeding Events in Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2011, 15, 454-459.	0.4	10
1397	Total sleep deprivation augments balloon angioplasty-induced neointimal hyperplasia in rats. <i>Experimental Physiology</i> , 2011, 96, 1239-1247.	0.9	2
1398	Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2011, 57, 231-238.	0.8	23
1399	Stent thrombosis and drug-eluting stents. <i>Journal of Cardiology</i> , 2011, 58, 92-98.	0.8	28
1400	Stent thrombosis of drug eluting stent: Pathological perspective. <i>Journal of Cardiology</i> , 2011, 58, 84-91.	0.8	70
1401	Long-term Clinical Outcomes Following Drug-Eluting or Bare-Metal Stent Placement in Patients With Severely Reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. <i>American Journal of Kidney Diseases</i> , 2011, 57, 202-211.	2.1	28
1402	Treatment of Vertebral Disease: Appropriate Use of Open and Endovascular Techniques. <i>Seminars in Vascular Surgery</i> , 2011, 24, 24-30.	1.1	9
1403	Mathematical modeling of simultaneous drug release and in vivo absorption. <i>International Journal of Pharmaceutics</i> , 2011, 418, 130-141.	2.6	55
1404	Impact of Coronary Calcium on Outcome Following Sirolimus-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2011, 108, 514-517.	0.7	18
1405	Everolimus-Eluting Versus Paclitaxel-Eluting Stents for Treatment of Bare Metal Stent Restenosis. <i>American Journal of Cardiology</i> , 2011, 108, 518-522.	0.7	14
1406	Patency of Paclitaxel-Eluting Versus Bare Metal Stents Long Term After Implantation in Acute ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2011, 108, 1214-1219.	0.7	1
1407	Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion?. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 105-110.	0.3	3
1408	Improved strut coverage and less late incomplete apposition with thin-strut TAXUS LibertÃ© vs. TAXUS Express: the importance of stent platform design for drug-eluting stents. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 247-257.	0.3	7
1409	The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 273-279.	0.3	3
1410	Influence of Low-Dose Aspirin (81 mg) on the Incidence of Definite Stent Thrombosis in Patients Receiving Bare-Metal and Drug-Eluting Stents. <i>Clinical Cardiology</i> , 2011, 34, 567-571.	0.7	3
1411	Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. <i>Clinical Cardiology</i> , 2011, 34, 706-713.	0.7	27

#	ARTICLE	IF	CITATIONS
1412	Mechanism and in Vitro Release Kinetic Study of Sirolimus from a Biodegradable Polymeric Matrix Coated Cardiovascular Stent. <i>Industrial & Engineering Chemistry Research</i> , 2011, 50, 9539-9549.	1.8	60
1413	Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation. <i>Netherlands Heart Journal</i> , 2011, 19, 412-417.	0.3	24
1414	Investigation of PLLA/PCL Blends and Paclitaxel Release Profiles. <i>AAPS PharmSciTech</i> , 2011, 12, 1442-1453.	1.5	45
1415	Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late ϵ -phenomenon after cypher [®] sirolimus-eluting stent implantation. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 867-874.	0.7	8
1416	Long-term (2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 875-881.	0.7	25
1417	Optical coherence tomography endpoints in stent clinical investigations: strut coverage. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 271-287.	0.7	36
1418	Fusion of 3D QCA and IVUS/OCT. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 197-207.	0.7	66
1419	Berberine cooperates with adrenal androgen dehydroepiandrosterone sulfate to attenuate PDGF-induced proliferation of vascular smooth muscle cell A7r5 through Skp2 signaling pathway. <i>Molecular and Cellular Biochemistry</i> , 2011, 355, 127-134.	1.4	13
1420	Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. <i>Clinical Research in Cardiology</i> , 2011, 100, 191-200.	1.5	16
1421	Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2011, 100, 561-570.	1.5	38
1422	Effect of intravascular ultrasound-guided adjuvant high-pressure non-compliant balloon post-dilation after drug-eluting stent implantation. <i>Heart and Vessels</i> , 2011, 26, 565-571.	0.5	12
1423	Utility of myocardial fractional flow reserve for prediction of restenosis following sirolimus-eluting stent implantation. <i>Heart and Vessels</i> , 2011, 26, 572-581.	0.5	20
1424	Nanotechnology and its Relationship to Interventional Radiology. Part II: Drug Delivery, Thermotherapy, and Vascular Intervention. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 676-690.	0.9	18
1425	Pathogenesis of implant-associated infection: the role of the host. <i>Seminars in Immunopathology</i> , 2011, 33, 295-306.	2.8	183
1427	Delivery of plasmid DNA to vascular tissue in vivo using catheter balloons coated with polyelectrolyte multilayers. <i>Biomaterials</i> , 2011, 32, 610-618.	5.7	38
1429	The potential of surgical strategy for incomplete stent apposition after implantation of a sirolimus eluting stent. <i>Cardiovascular Intervention and Therapeutics</i> , 2011, 26, 157-161.	1.2	0
1430	Clinical usefulness of the Driver [®] stent in a retrospective, collaborative, multicenter, open-label study in Japanese real-world patients with coronary artery disease and the drug-eluting stent era. <i>Cardiovascular Intervention and Therapeutics</i> , 2011, 26, 131-137.	1.2	0
1431	Efficacy of dual antiplatelet therapy combined with Naoxintong Capsules (è,,‘à;fěššèf‘à›Š) following coronary microembolization induced by homologous microthrombi in rats. <i>Chinese Journal of Integrative Medicine</i> , 2011, 17, 917-924.	0.7	16

#	ARTICLE	IF	CITATIONS
1432	Bare-Metal Stents Versus Drug-Eluting Stents for Primary Angioplasty: Long-Term Outcome. <i>Current Cardiology Reports</i> , 2011, 13, 459-464.	1.3	2
1433	Triple therapy in hospitalized patients: Facts and controversies. <i>Journal of Hospital Medicine</i> , 2011, 6, 537-545.	0.7	1
1435	Long-term stability of self-assembled monolayers on electropolished L605 cobalt chromium alloy for stent applications. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2011, 98B, 280-289.	1.6	22
1436	Synergistic effect of resveratrol and quercetin released from drug-eluting polymer coatings for endovascular devices. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2011, 99B, 266-275.	1.6	26
1437	Sirolimus versus paclitaxel coronary stents in clinical practice. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 5-12.	0.7	9
1438	Percutaneous coronary intervention of moderate to severe calcified coronary lesions: Insights from the National Heart, Lung, and Blood Institute Dynamic Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 22-28.	0.7	73
1439	Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: Rationale and safety. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 193-200.	0.7	2
1440	Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 494-501.	0.7	17
1441	One-year clinical outcome in an unselected patient population treated with the Genous [®] endothelial progenitor cell capturing stent. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 809-817.	0.7	12
1442	Usage patterns and 1-year outcomes with the TAXUS Libert [®] stent: Results of the TAXUS OLYMPIA registry. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 979-992.	0.7	2
1443	Drug eluting versus bare metal stents in cardiac allograft vasculopathy. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 962-969.	0.7	38
1444	Long-term outcome after drug-eluting stent implantation in unselected population: ROME and UDINE Experience (The RUDI Registry). <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 1068-1075.	0.7	1
1445	A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 710-717.	0.7	16
1446	Drug-eluting stents for coronary artery disease: A review. <i>Medical Engineering and Physics</i> , 2011, 33, 148-163.	0.8	104
1447	Vasomotor Function After Paclitaxel-Coated Balloon Post-Dilation in Porcine Coronary Stent Model. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 247-255.	1.1	17
1448	Role of Pioglitazone in the Prevention of Restenosis and Need for Revascularization After Bare-Metal Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 353-360.	1.1	26
1449	5-Year Follow-Up After Primary Percutaneous Coronary Intervention With a Paclitaxel-Eluting Stent Versus a Bare-Metal Stent in Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 24-29.	1.1	116
1450	Randomized Comparison of a Polymer-Free Sirolimus-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent in Patients With Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 452-459.	1.1	30

#	ARTICLE	IF	CITATIONS
1451	Comparison of Titanium-Nitride-Oxide-Coated Stents With Zotarolimus-Eluting Stents for Coronary Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 672-682.	1.1	25
1452	Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 530-542.	1.1	57
1453	Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention with Drug-Eluting Stent Implantation: A Review of the Current Guidelines and Literature. <i>Hospital Practice (1995)</i> , 2011, 39, 32-40.	0.5	11
1454	Endovascular management of vertebral artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 575-578.	0.6	5
1455	Comparing the use of cobalt chromium stents to stainless steel stents in primary percutaneous coronary intervention for acute myocardial infarction: A prospective registry. <i>Acute Cardiac Care</i> , 2011, 13, 219-222.	0.2	6
1456	Incidence, Risk Factors, and Clinical Sequelae of Angiographic Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation. <i>Circulation</i> , 2011, 123, 2382-2391.	1.6	117
1457	Bioactive materials in drug delivery systems. , 2011, , 247-265.		3
1458	Polymer-Free Sirolimus- and Probucol-Eluting Versus New Generation Zotarolimus-Eluting Stents in Coronary Artery Disease. <i>Circulation</i> , 2011, 124, 624-632.	1.6	126
1459	Vascular Smooth Muscle Cell Proliferation in Restenosis. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 104-111.	1.4	270
1460	Five-Year Outcomes of Sirolimus-Eluting and Paclitaxel-Eluting Stents in Routine Clinical Practice. <i>Circulation</i> , 2011, 123, 2779-2781.	1.6	3
1461	Stent Coated With Antibody Against Vascular Endothelial-Cadherin Captures Endothelial Progenitor Cells, Accelerates Re-Endothelialization, and Reduces Neointimal Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2798-2805.	1.1	64
1462	Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. <i>Heart</i> , 2011, 97, 1338-1342.	1.2	73
1463	Coronary Revascularization Trends in the United States, 2001-2008. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1769.	3.8	454
1464	Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use. <i>Circulation</i> , 2011, 124, 1028-1037.	1.6	41
1465	Vascular Responses to Drug-Eluting and Bare Metal Stents in Diabetic/Hypercholesterolemic and Nonatherosclerotic Porcine Coronary Arteries. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 438-446.	1.4	18
1466	The role of mitosis in LDL transport through cultured endothelial cell monolayers. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H769-H776.	1.5	37
1467	Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 9-14.	1.4	166
1468	Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents. <i>Circulation</i> , 2011, 123, 2819-2828.	1.6	169

#	ARTICLE	IF	CITATIONS
1469	Long-term clinical outcomes of overlapping heterogeneous drug-eluting stents compared with homogeneous drug-eluting stents. <i>Heart</i> , 2011, 97, 1501-1506.	1.2	16
1470	Computational structural modelling of coronary stent deployment: a review. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2011, 14, 331-348.	0.9	67
1471	Peptide-Mediated Disruption of Calmodulin-Cyclin E Interactions Inhibits Proliferation of Vascular Smooth Muscle Cells and Neointima Formation. <i>Circulation Research</i> , 2011, 108, 1053-1062.	2.0	19
1472	Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-19.	0.5	7
1474	Impact of Drug-Eluting Stents on Distal Vessels. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 211-219.	1.4	9
1475	Stent Selection in Patients with Myocardial Infarction: Drug Eluting, Biodegradable Polymers or Bare Metal Stents?. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2012, 7, 105-120.	1.5	2
1476	Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis. <i>Coronary Artery Disease</i> , 2012, 23, 492-496.	0.3	9
1477	Comparison of 5-Year Clinical Outcomes Between Sirolimus-Versus Paclitaxel-Eluting Stent. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 174-184.	1.4	14
1478	Impact of Chronic Kidney Disease on Long-term Clinical Outcomes After Percutaneous Coronary Intervention With Drug-eluting or Bare-metal Stents. <i>Critical Pathways in Cardiology</i> , 2012, 11, 152-159.	0.2	9
1479	First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip. <i>Science Translational Medicine</i> , 2012, 4, 122ra21.	5.8	360
1480	Two-Year Follow-up of Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Acute Myocardial Infarction. <i>International Journal of Angiology</i> , 2012, 21, 053-058.	0.2	5
1481	Engineering Biomaterials for Regenerative Medicine. , 2012, , .		16
1482	Endovascular treatment of extracranial atherosclerotic disease involving the vertebral artery origins: a comparison of drug-eluting and bare-metal stents. <i>Journal of NeuroInterventional Surgery</i> , 2012, 4, 206-210.	2.0	21
1483	Edge Effect From Drug-Eluting Stents as Assessed With Serial Intravascular Ultrasound. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 305-311.	1.4	15
1484	Hybrid Procedures Have Proven Clinical Utility and Are the Wave of the Future. <i>Circulation</i> , 2012, 125, 2492-2503.	1.6	17
1485	Drug-eluting versus bare-metal coronary stents: where are we now?. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 501-508.	0.6	1
1486	Short- and Long-Term Outcomes of Coronary Stenting in Women Versus Men. <i>Circulation</i> , 2012, 126, 2190-2199.	1.6	77
1487	Drug-Eluting vs Bare-Metal Stents in Primary Angioplasty. <i>Archives of Internal Medicine</i> , 2012, 172, 611-21; discussion 621-2.	4.3	218

#	ARTICLE	IF	CITATIONS
1488	Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 125, 1246-1255.	1.6	149
1489	Long-term treatment with nifedipine suppresses coronary hyperconstricting responses and inflammatory changes induced by paclitaxel-eluting stent in pigs in vivo: possible involvement of Rho-kinase pathway. <i>European Heart Journal</i> , 2012, 33, 791-799.	1.0	29
1490	Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina. <i>European Heart Journal</i> , 2012, 33, 2653-2661.	1.0	18
1492	The HEART study. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 775-782.	0.6	1
1493	Characterization of Porous TiO ₂ Surfaces Formed on 316L Stainless Steel by Plasma Electrolytic Oxidation for Stent Applications. <i>Journal of Functional Biomaterials</i> , 2012, 3, 349-360.	1.8	15
1494	Natural History of Stent Edge Dissection, Tissue Protrusion and Incomplete Stent Apposition Detectable Only on Optical Coherence Tomography After Stent Implantation. <i>Circulation Journal</i> , 2012, 76, 698-703.	0.7	87
1495	Paclitaxel-Induced Endothelial Dysfunction in Living Rats Is Prevented by Nicorandil via Reduction of Oxidative Stress. <i>Journal of Pharmacological Sciences</i> , 2012, 119, 349-358.	1.1	24
1496	Accelerating endothelialization of coronary stents by capturing circulating endothelial progenitor cells. <i>Interventional Cardiology</i> , 2012, 4, 169-181.	0.0	7
1498	Clinical review of the Resolute [®] zotarolimus-eluting stent for the treatment of coronary artery disease. <i>Interventional Cardiology</i> , 2012, 4, 33-43.	0.0	2
1499	Techniques for the diagnosis of vertebral artery origin stenosis and considerations for determining treatment and timing. <i>Interventional Cardiology</i> , 2012, 4, 419-427.	0.0	1
1500	Nobori [®] drug-eluting stent system: current data on a novel stent. <i>Interventional Cardiology</i> , 2012, 4, 309-318.	0.0	0
1501	Three-Year Follow-up of Sirolimus-Eluting Stents vs. Bare Metal Stents for Acute Myocardial Infarction. <i>Circulation Journal</i> , 2012, 76, 65-70.	0.7	13
1502	First-in-Man Study of Simvastatin-Eluting Stent in De Novo Coronary Lesions. <i>Circulation Journal</i> , 2012, 76, 1109-1114.	0.7	16
1503	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. <i>Lancet, The</i> , 2012, 379, 1393-1402.	6.3	854
1504	Back to the Future: How Biology and Technology Could Change the Role of PTFE Grafts in Vascular Access Management. <i>Seminars in Dialysis</i> , 2012, 25, 495-504.	0.7	17
1505	Drug-Eluting Stents. , 2012, , 383-407.		2
1506	Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents. <i>Circulation</i> , 2012, 125, 505-513.	1.6	555
1507	Stent Thrombosis With Everolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 357-364.	1.4	140

#	ARTICLE	IF	CITATIONS
1508	Choice of drug-eluting stentâ€”evidence-based or empirical. Journal of Indian College of Cardiology, 2012, 2, 22-28.	0.1	1
1509	Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry. Clinical Research in Cardiology, 2012, 101, 709-716.	1.5	10
1510	Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9Âmonths after stent implantation. International Journal of Cardiovascular Imaging, 2012, 28, 1281-1287.	0.7	19
1511	Evaluation of in-stent neointimal tissue components using integrated backscatter intravascular ultrasound: comparison of drug-eluting stents and bare-metal stents. International Journal of Cardiovascular Imaging, 2012, 28, 1635-1641.	0.7	10
1512	Neointimal tissue characteristics following sirolimus-eluting stent implantation: OCT quantitative tissue property analysis. International Journal of Cardiovascular Imaging, 2012, 28, 1879-1886.	0.7	19
1513	Simultaneous stent obstruction of triple vessels with very late stent thrombosis after implantation of sirolimus-eluting stents. Journal of Cardiology Cases, 2012, 5, e87-e91.	0.2	1
1514	The Generations of Drug-Eluting Stents and Outcomes in Women. Interventional Cardiology Clinics, 2012, 1, 183-195.	0.2	0
1515	Impact of the first-generation drug-eluting stent implantation on periprocedural myocardial injury in patients with stable angina pectoris. Journal of Cardiology, 2012, 60, 264-269.	0.8	7
1516	CaracterizaciÃ³n de la restenosis de stents coronarios convencionales y liberadores de medicamentos en pacientes incluidos en el registro DRug Eluting STent (DREST). Revista Colombiana De Cardiologia, 2012, 19, 121-131.	0.1	2
1517	Radiation Therapy for Dialysis Access Stenosis: Unfulfilled Promise or False Expectations. Seminars in Dialysis, 2012, 25, 464-469.	0.7	3
1518	Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation. Circulation: Cardiovascular Interventions, 2012, 5, 381-391.	1.4	43
1519	ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). American Heart Journal, 2012, 163, 601-607.	1.2	44
1520	Rationale and design of the TAXUS LibertÃ© Post-Approval Study: Examination of patients receiving the TAXUS LibertÃ© stent with concomitant prasugrel therapy in routine interventional cardiology practice. American Heart Journal, 2012, 163, 142-148.e6.	1.2	4
1521	Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT). American Heart Journal, 2012, 163, 1011-1018.	1.2	4
1522	Long-term clinical and angiographic outcomes of patients with sirolimus-eluting stent fracture. International Journal of Cardiology, 2012, 158, 83-87.	0.8	6
1523	â€œAngiographic late catch-upâ€•phenomenon after sirolimus-eluting stent implantation. International Journal of Cardiology, 2012, 160, 48-52.	0.8	23
1524	Comparison of the safety between first- and second-generation drug eluting stents. International Journal of Cardiology, 2012, 160, 181-186.	0.8	8
1525	A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: Final results of the ZoMaxx II trial. International Journal of Cardiology, 2012, 157, 96-101.	0.8	4

#	ARTICLE	IF	CITATIONS
1526	Clinical outcomes of zotarolimus-eluting stents versus the first generation sirolimus-eluting stents and paclitaxel-eluting stents: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2012, 157, 152-156.	0.8	3
1527	Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 84.	0.7	2
1528	Microrough Cobalt-Chromium Alloy Surfaces for Paclitaxel Delivery: Preparation, Characterization, and <i>In Vitro</i> Drug Release Studies. <i>Langmuir</i> , 2012, 28, 11511-11526.	1.6	24
1529	Vinopocetine Suppresses Pathological Vascular Remodeling by Inhibiting Vascular Smooth Muscle Cell Proliferation and Migration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 479-488.	1.3	46
1530	Stent thrombosis in patients with chronic kidney disease. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 617-626.	0.6	0
1531	French Ministry of Health prospective multicentre study using bio-active stents coated with titanium nitride oxide: The EVIDENCE Registry. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 60-67.	0.7	11
1532	Evaluating the effectiveness of a rapidly adopted cardiovascular technology with administrative data: The case of drug-eluting stents for acute coronary syndromes. <i>American Heart Journal</i> , 2012, 164, 207-214.	1.2	8
1533	Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) Trial: Rationale and design of a large-scale, randomized, multicenter study. <i>American Heart Journal</i> , 2012, 164, 810-816.e3.	1.2	18
1534	Primary Endpoint Results of the EVOLVE Trial. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1362-1370.	1.2	188
1535	Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus-Eluting Stents in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 381-387.	1.2	124
1536	Examination of the In Vivo Mechanisms of Late Drug-Eluting Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 12-20.	1.1	305
1537	Pathology of Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Bypass Graft Lesions. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 666-674.	1.1	54
1538	3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 812-818.	1.1	43
1539	Unrestricted Use of 2 New-Generation Drug-Eluting Stents in Patients With Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 936-945.	1.1	19
1540	Clinical Impact of Second-Generation Everolimus-Eluting Stent Compared With First-Generation Drug-Eluting Stents in Diabetes Mellitus Patients. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1141-1149.	1.1	52
1541	Ex Vivo Assessment of Vascular Response to Coronary Stents by Optical Frequency Domain Imaging. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 71-82.	2.3	113
1542	Quantitative and Qualitative Changes in DES-Related Neointimal Tissue Based on Serial OCT. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 1147-1155.	2.3	64
1543	Comparison of Bare-Metal Stents and Drug-Eluting Stents in Coronary Ostial Lesions (from the Tj ETQq1 1 0.784314 rgBT /Overlock 1113-1118.	0.7	7

#	ARTICLE	IF	CITATIONS
1544	Current perspectives of biodegradable drug-eluting stents for improved safety. <i>Biotechnology and Bioprocess Engineering</i> , 2012, 17, 912-924.	1.4	7
1545	Microelectromechanical Systems and Nanotechnology. <i>Vascular and Endovascular Surgery</i> , 2012, 46, 605-609.	0.3	13
1546	Drug-Coated Balloons for Coronary and Peripheral Interventional Procedures. <i>Current Cardiology Reports</i> , 2012, 14, 635-641.	1.3	21
1547	Long Acting Injections and Implants. , 2012, , .		24
1551	Drug-eluting stent coatings. <i>Interventional Cardiology</i> , 2012, 4, 73-83.	0.0	25
1552	Rapamycin Regulates the Expression and Activity of KrÄppel-Like Transcription Factor 2 in Human Umbilical Vein Endothelial Cells. <i>PLoS ONE</i> , 2012, 7, e43315.	1.1	5
1553	Pathological Perspective of Drug-Eluting Stent Thrombosis. <i>Thrombosis</i> , 2012, 2012, 1-8.	1.4	11
1554	Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement. <i>Thrombosis</i> , 2012, 2012, 1-16.	1.4	52
1555	Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1161-1171.	1.8	50
1557	study of glutathione metabolism oxidative stress and the effect of vitamin E supplementation in COPD .. <i>International Journal of Biomedical Research</i> , 2012, 3, .	0.1	0
1558	Comparison of safety and efficacy of paclitaxel-eluting stents with durable versus biodegradable polymer implanted in saphenous vein graft lesions. Nine-month angiographic and intravascular ultrasound follow-up. <i>Postepy W Kardiologii Interwencyjnej</i> , 2012, 4, 269-274.	0.1	0
1559	Mid-Term Clinical Outcomes of ACS and Non-ACS Patients Treated With Everolimus-Eluting Stents. <i>International Heart Journal</i> , 2012, 53, 215-220.	0.5	1
1560	Rotablation in the Drug Eluting Syent Era. , 2012, , .		0
1561	Comparison of Long-Term Clinical Outcomes Between Sirolimus-Eluting Stents and Paclitaxel-Eluting Stents Following Rotational Atherectomy. <i>International Heart Journal</i> , 2012, 53, 149-153.	0.5	35
1562	Coronary Stent Thrombosis: Current Insights into New Drug-Eluting Stent Designs. <i>Chonnam Medical Journal</i> , 2012, 48, 141.	0.5	6
1563	Everolimus-eluting stents in interventional cardiology. <i>Vascular Health and Risk Management</i> , 2012, 8, 393.	1.0	15
1564	Comparison of Optical Coherence Tomographic Assessment between First- and Second-Generation Drug-Eluting Stents. <i>Yonsei Medical Journal</i> , 2012, 53, 524.	0.9	31
1565	Effectiveness and Efficiency of Drug Eluting Stents. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
1566	Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents. <i>Circulation</i> , 2012, 125, 2873-2891.	1.6	521
1567	Predictors for Neoatherosclerosis. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 660-666.	1.3	143
1568	The importance of the endothelium in atherothrombosis and coronary stenting. <i>Nature Reviews Cardiology</i> , 2012, 9, 439-453.	6.1	314
1569	Decreased risk of stent fracture-related restenosis between paclitaxel-eluting stents and sirolimus eluting stents: Results of long-term follow-up. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 559-565.	0.7	3
1570	Randomized comparison of the nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 789-796.	0.7	45
1571	Frequency and impact of bleeding in elective coronary stent clinical trials—Utility of three commonly used definitions. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, E23-9.	0.7	3
1572	Incidence of periprocedural myocardial infarction following stent implantation: Comparison between first- and second-generation drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 524-530.	0.7	10
1573	Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: Three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 385-394.	0.7	12
1574	Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: A randomized PIPA trial. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 799-806.	0.7	2
1575	In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: A report from the EVENT registry. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 1127-1136.	0.7	8
1576	The impact of preprocedural hemoglobin A1c on the efficacy of sirolimus-eluting and paclitaxel-eluting stents. <i>Cardiovascular Intervention and Therapeutics</i> , 2012, 27, 72-83.	1.2	3
1577	In vivo evaluation of stent patency by 64-slice multidetector CT coronary angiography: shall we do it or not?. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 651-658.	0.7	19
1578	Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 715-723.	0.7	26
1579	Coronary Stent Choice in Patients with Acute Myocardial Infarction. <i>Current Cardiology Reports</i> , 2012, 14, 477-485.	1.3	2
1580	Late Stent Thrombosis: The Last Remaining Obstacle in Coronary Interventional Therapy. <i>Current Cardiology Reports</i> , 2012, 14, 408-417.	1.3	15
1581	How Do OCT and IVUS Compare to Histology in Coronary Atherosclerosis and Stenting?. <i>Current Cardiovascular Imaging Reports</i> , 2012, 5, 249-263.	0.4	1
1582	Titanium-nitride-oxide-coated stents multicenter registry in diabetic patients: the TIBET registry. <i>Heart and Vessels</i> , 2012, 27, 151-158.	0.5	12
1583	Concurrent drug eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up. <i>Clinical Research in Cardiology</i> , 2012, 101, 281-288.	1.5	7

#	ARTICLE	IF	CITATIONS
1584	Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. <i>Clinical Research in Cardiology</i> , 2012, 101, 469-476.	1.5	68
1585	Long-Term Safety and Effectiveness of Drug-Eluting Stents Compared to Bare Metal Stents following Successful PCI in Non-ST-Elevation Myocardial Infarction: Findings from the Guthrie Health Off-Label StenT (GHOST) Registry. <i>Journal of Interventional Cardiology</i> , 2012, 25, 28-36.	0.5	6
1586	Rotational atherectomy: A "survivor" in the drug-eluting stent era. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 185-192.	0.3	27
1587	Efficacy of Drug-Eluting Stents for Treating In-Stent Restenosis of Drug-Eluting Stents (from the Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	19
1588	Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years. <i>American Journal of Cardiology</i> , 2012, 110, 21-29.	0.7	20
1589	Effects of Thiazolidinediones on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After Drug-Eluting Stent Implantation: A Retrospective Cohort Study Using the National Health Insurance Database in Taiwan. <i>Clinical Therapeutics</i> , 2012, 34, 885-893.	1.1	6
1590	Beta blocker therapy is associated with reduced depressive symptoms 12 months post percutaneous coronary intervention. <i>Journal of Affective Disorders</i> , 2012, 136, 751-757.	2.0	11
1591	Dual roles of hyaluronic acids in multilayer films capturing nanocarriers for drug-eluting coatings. <i>Biomaterials</i> , 2012, 33, 5468-5477.	5.7	29
1592	Coronary stent use in New York State in the drug-eluting stent era. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 18, 872-877.	0.9	0
1593	The FDA review process for cardiac medical devices in children: A review for the clinician. <i>Progress in Pediatric Cardiology</i> , 2012, 33, 105-109.	0.2	4
1594	Liposomal alendronate for the treatment of restenosis. <i>Journal of Controlled Release</i> , 2012, 161, 619-627.	4.8	32
1595	Drug eluting stents: Developments and current status. <i>Journal of Controlled Release</i> , 2012, 161, 703-712.	4.8	156
1596	An analytical solution for the stress state at stent-coating interfaces. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2012, 10, 183-196.	1.5	10
1597	Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1047-1054.	1.7	10
1598	In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 969-985.	1.2	33
1599	Third in-stent restenosis in sirolimus eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 91-96.	0.7	6
1600	Molecular imaging of drug-eluting coronary stents: method development, optimization and selected applications. <i>Journal of Mass Spectrometry</i> , 2012, 47, 155-162.	0.7	17
1601	Nanoparticle Shape Improves Delivery: Rational Coarse Grain Molecular Dynamics (rCGMD) of Taxol in Worm-Like PEG-PCL Micelles. <i>Advanced Materials</i> , 2012, 24, 3823-3830.	11.1	136

#	ARTICLE	IF	CITATIONS
1602	Short-term effects of fully bioabsorbable PLLA coronary stents in a porcine model. <i>Polymer Bulletin</i> , 2012, 68, 1171-1181.	1.7	17
1603	Choice of stent and outcomes after treatment of drug-eluting stent restenosis in highly complex lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, E16-22.	0.7	4
1604	Long-term luminal change after drug-eluting stent implantation: Serial angiographic follow-up study of the ZEST randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 274-282.	0.7	4
1605	Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTimal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 56.	0.7	13
1606	Eluting combination drugs from stents. <i>International Journal of Pharmaceutics</i> , 2013, 454, 4-10.	2.6	25
1607	<i>In Vitro</i> Drug Release and Hemocompatibility of Biodegradable Plga/Peg Coated Paclitaxel-Eluting Stents. <i>Advanced Materials Research</i> , 2013, 651, 49-53.	0.3	0
1608	Applications of Electrochemistry in Medicine. <i>Modern Aspects of Electrochemistry</i> , 2013, , .	0.2	6
1609	The Pathogenesis of Vasospastic Angina. , 2013, , 91-99.		0
1610	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 271-273.	0.7	3
1611	Management of cardiovascular disease in patients with kidney disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 261-273.	6.1	98
1612	Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 977-988.	0.7	4
1613	Progress in Treatment by Percutaneous Coronary Intervention: The Stent of the Future. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 483-496.	0.4	34
1614	Thin Films and Coatings in Biology. <i>Biological and Medical Physics Series</i> , 2013, , .	0.3	6
1615	Modelos animales de reparaci3n vascular y reendotelizaci3n. <i>Revista Espanola De Cardiologia Suplementos</i> , 2013, 13, 20-28.	0.2	0
1616	Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. <i>American Heart Journal</i> , 2013, 165, 704-709.	1.2	63
1617	Clinical outcomes with Biolimus (A9) eluting stent, BioMatrix™ in diabetic patients – interim results from multicenter post market surveillance registry in India. <i>Indian Heart Journal</i> , 2013, 65, 586-592.	0.2	6
1618	Temporal trends in percutaneous coronary intervention outcomes among older patients in the United States. <i>American Heart Journal</i> , 2013, 166, 273-281.e4.	1.2	35
1620	Evaluation of neointimal coverage and apposition with various drug-eluting stents over 12months after implantation by optical coherence tomography. <i>International Journal of Cardiology</i> , 2013, 162, 166-171.	0.8	15

#	ARTICLE	IF	CITATIONS
1621	Poly(L-lactic acid) and citric acid crosslinked gelatin composite matrices as a drug-eluting stent coating material with endothelialization, antithrombogenic, and drug release properties. <i>Journal of Biomedical Materials Research - Part A</i> , 2013, 101A, 2049-2057.	2.1	9
1622	Usefulness of Intravascular Ultrasound to Predict Outcomes in Short-Length Lesions Treated With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2013, 112, 642-646.	0.7	17
1623	Two-year clinical outcomes of patients with the second-generation cobalt-chromium sirolimus-eluting stents from the real-world FOCUS registry. <i>International Journal of Cardiology</i> , 2013, 166, 750-752.	0.8	2
1624	The Paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: An angiographic follow up study. <i>Indian Heart Journal</i> , 2013, 65, 510-517.	0.2	11
1625	Macroscale delivery systems for molecular and cellular payloads. <i>Nature Materials</i> , 2013, 12, 1004-1017.	13.3	251
1626	Coronary stents: historical development, current status and future directions. <i>British Medical Bulletin</i> , 2013, 106, 193-211.	2.7	234
1627	Comparison of edge vascular response after sirolimus- and paclitaxel-eluting stent implantation. <i>International Journal of Cardiology</i> , 2013, 165, 46-50.	0.8	2
1628	Device Development for Cardiovascular Therapeutics. , 2013, , 41-52.		2
1629	Stent Thrombosis With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1915-1921.	1.2	119
1630	A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1012-1022.	1.1	28
1631	First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1026-1034.	1.1	32
1632	Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 398.	0.7	6
1633	Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 1693-1703.	0.7	19
1634	A highly flexible paclitaxel-loaded poly(μ -caprolactone) electrospun fibrous-membrane-covered stent for benign cardia stricture. <i>Acta Biomaterialia</i> , 2013, 9, 8328-8336.	4.1	58
1635	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. <i>Interventional Cardiology</i> , 2013, 5, 179-201.	0.0	0
1636	The end of ENDEAVOR IV: the stent comparison trial's final follow-up. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 941-943.	0.6	0
1637	In-stent restenosis of drug-eluting stents. <i>Future Cardiology</i> , 2013, 9, 721-731.	0.5	15
1638	Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease. <i>The Cochrane Library</i> , 2013, , CD009581.	1.5	8

#	ARTICLE	IF	CITATIONS
1639	In vitro mutagenicity and blood compatibility of paclitaxel and curcumin in poly (dl-lactide-co-glycolide) films. <i>Toxicology in Vitro</i> , 2013, 27, 198-203.	1.1	10
1640	Do Statins have a Role in Reduction/Prevention of Post-PCI Restenosis?. <i>Cardiovascular Therapeutics</i> , 2013, 31, 12-26.	1.1	25
1641	Racial Differences in Long-Term Outcomes after Percutaneous Coronary Intervention with Paclitaxel-Eluting Coronary Stents. <i>Journal of Interventional Cardiology</i> , 2013, 26, 49-57.	0.5	20
1642	Angiographic patterns of in-stent restenosis classified by computed tomography in patients with drug-eluting stents: correlation with invasive coronary angiography. <i>European Radiology</i> , 2013, 23, 101-107.	2.3	19
1643	A propensity score matched analysis to determine if second-generation drug-eluting stents outperform first-generation drug-eluting stents in a complex patient population. <i>International Journal of Cardiology</i> , 2013, 170, 43-48.	0.8	6
1644	The 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 325-333.	1.1	72
1645	What is an acceptable risk of major adverse cardiac event in chest pain patients soon after discharge from the Emergency Department?. <i>International Journal of Cardiology</i> , 2013, 166, 752-754.	0.8	324
1646	Improving endothelialization on 316L stainless steel through wettability controllable coating by sol-gel technology. <i>Applied Surface Science</i> , 2013, 268, 73-78.	3.1	25
1647	Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2013, 167, 2250-2258.	0.8	23
1648	Effects of plasma treatments on the controlled drug release from poly(ethylene-co-vinyl acetate). <i>Surface and Coatings Technology</i> , 2013, 216, 318-323.	2.2	41
1649	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , 2013, 382, 1879-1888.	6.3	127
1650	One-year clinical outcomes of BioMatrix [®] Biolimus A9 [®] eluting stent: The e-BioMatrix multicenter post marketing surveillance registry in India. <i>Indian Heart Journal</i> , 2013, 65, 593-599.	0.2	12
1651	In stent restenosis and thrombosis assessment after EP224283 injection in a rat model. <i>Atherosclerosis</i> , 2013, 229, 462-468.	0.4	9
1653	Characterization of tissue responses and degradation behavior of heparin-immobilized copolymer for drug-eluting stents. <i>Polymer Degradation and Stability</i> , 2013, 98, 1015-1021.	2.7	13
1654	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. <i>Lancet, The</i> , 2013, 381, 661-669.	6.3	173
1655	The impact of industry representative's visits on utilization of coronary stents. <i>American Heart Journal</i> , 2013, 166, 258-265.	1.2	19
1656	Stent thrombosis distal to the segment showing early in-stent restenosis with everolimus-eluting stent. <i>Journal of Cardiology Cases</i> , 2013, 8, e20-e23.	0.2	3
1657	Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 166, 118-125.	0.8	8

#	ARTICLE	IF	CITATIONS
1658	Frequency, Mechanisms, and Implications of Late Peri-Stent Contrast Staining: Analysis (from the Tj ETQq0 0 0 rgBTJ/Overlock 10 Tf 50	0.7	10
1659	Evaluation of a Policy of Selective Drug-eluting Stent Implantation for Patients at High Risk of Restenosis. Heart Lung and Circulation, 2013, 22, 523-532.	0.2	7
1660	How and When to Decide on Revascularization in Stable Ischemic Heart Disease. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 79-92.	0.4	6
1661	Antiplatelet Therapy After Coronary Stenting. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 1-10.	0.4	15
1662	Platelets, photosensitizers, and PDT. Photodiagnosis and Photodynamic Therapy, 2013, 10, 1-16.	1.3	33
1663	Intracoronary Stents: Medical Devices at the Interface of Biology and Electrochemistry. Modern Aspects of Electrochemistry, 2013, , 55-82.	0.2	0
1664	Drug-Eluting Coronary-Artery Stents. New England Journal of Medicine, 2013, 368, 254-265.	13.9	618
1665	A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimusâ€•vs. Paclitaxelâ€•eluting stents in de novo occlusive lesions in coronary arteries: Fiveâ€•year results from the ZOMAXX I trial. Catheterization and Cardiovascular Interventions, 2013, 82, 1039-1047.	0.7	6
1666	High-Speed Rotational Atherectomy Before Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions. JACC: Cardiovascular Interventions, 2013, 6, 10-19.	1.1	373
1667	Randomized trial comparing the efficacy between different types of paclitaxel-eluting stents: The comparison of Efficacy between COroflex PLEASE AND Taxus stent (ECO-PLEASANT) randomized controlled trial. American Heart Journal, 2013, 165, 733-743.	1.2	4
1668	Optimal Stenting in Saphenous Vein Graft Intervention. Interventional Cardiology Clinics, 2013, 2, 307-313.	0.2	0
1669	Bareâ€•metal stent versus drugâ€•eluting stent in large coronary arteries. Catheterization and Cardiovascular Interventions, 2013, 81, 1087-1094.	0.7	9
1670	Study Design and Rationale of â€œA Multicenter, Open-Labeled, Randomized Controlled Trial Comparing Three 2nd-Generation Drug-Eluting Stents in Real-World Practiceâ€•(CHOICE trial). American Heart Journal, 2013, 166, 224-229.	1.2	4
1671	Taxol Producing Fungi. , 2013, , 2797-2812.		13
1672	Randomized Comparison of Clinical Outcomes Between Intravascular Ultrasound and Angiography-Guided Drug-Eluting Stent Implantation for Long Coronary Artery Stenoses. JACC: Cardiovascular Interventions, 2013, 6, 369-376.	1.1	154
1673	Vascular access in haemodialysis: strengthening the Achilles' heel. Nature Reviews Nephrology, 2013, 9, 348-357.	4.1	127
1674	Reduction of intimal hyperplasia in injured rat arteries promoted by catheter balloons coated with polyelectrolyte multilayers that contain plasmid DNA encoding PKCÎ¶. Biomaterials, 2013, 34, 226-236.	5.7	28
1675	Improved biocompatibility of poly (styrene-b-(ethylene-co-butylene)-b-styrene) elastomer by a surface graft polymerization of hyaluronic acid. Colloids and Surfaces B: Biointerfaces, 2013, 102, 210-217.	2.5	37

#	ARTICLE	IF	CITATIONS
1676	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. <i>Heart</i> , 2013, 99, 1267-1274.	1.2	36
1677	Polyelectrolyte Multilayers Promote Stent-Mediated Delivery of DNA to Vascular Tissue. <i>Biomacromolecules</i> , 2013, 14, 1696-1704.	2.6	48
1678	Long-term safety of drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1359-1378.	0.6	5
1679	Biolimus-eluting stent with biodegradable polymer (Nobori®): an overview of recent clinical results, SORT OUT V and COMPARE II trials. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1293-1296.	0.6	4
1680	When is evidence sufficient for decision-making? A framework for understanding the pace of evidence adoption. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 383-391.	0.6	14
1681	Outcomes of Patients Treated with the Everolimus- versus the Paclitaxel-Eluting Stents in a Consecutive Cohort of Patients at a Tertiary Medical Center. <i>International Journal of Angiology</i> , 2013, 22, 165-170.	0.2	3
1682	Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification. <i>European Heart Journal</i> , 2013, 34, 3378-3388.	1.0	58
1683	Cost-Effectiveness of Percutaneous Coronary Intervention With Drug Eluting Stents Versus Bypass Surgery for Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 820-831.	1.6	107
1684	Anti-Inflammatory Effects of Arsenic Trioxide Eluting Stents in a Porcine Coronary Model. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	10
1685	Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents. <i>Coronary Artery Disease</i> , 2013, 24, 165-170.	0.3	3
1686	Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Libert® paclitaxel-eluting stent in de-novo coronary artery lesions. <i>Coronary Artery Disease</i> , 2013, 24, 61-68.	0.3	8
1687	Long-term outcome of drug-eluting stenting for stenoses of the intracranial vertebrobasilar artery and vertebral ostium. <i>Journal of NeuroInterventional Surgery</i> , 2013, 5, 435-439.	2.0	7
1688	Advances in Coronary Revascularization. , 2013, , 214-239.		0
1689	Six-year clinical outcomes of first-generation drug-eluting stents. <i>Coronary Artery Disease</i> , 2013, 24, 440-448.	0.3	3
1690	Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease. <i>ISRN Cardiology</i> , 2013, 2013, 1-7.	1.6	4
1691	External Adjustment Sensitivity Analysis for Unmeasured Confounding: An Application to Coronary Stent Outcomes, Pennsylvania 2004-2008. <i>Health Services Research</i> , 2013, 48, 1191-1214.	1.0	6
1692	World Safety and Effectiveness Outcomes of a Zotarolimus-Eluting Stent: Final Year Report of the RESOLUTE International Study. <i>Journal of Interventional Cardiology</i> , 2013, 26, 515-523.	0.5	11
1693	Finite element analysis of balloon-expandable coronary stent deployment: Influence of angioplasty balloon configuration. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2013, 29, 1161-1175.	1.0	48

#	ARTICLE	IF	CITATIONS
1694	Long term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E856-63.	0.7	7
1695	Long-term efficacy and safety of zotarolimus-eluting stent in patients with diabetes mellitus: Pooled 5-year results from the ENDEAVOR III and IV trials. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 1031-1038.	0.7	11
1696	Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. <i>BMJ</i> , The, 2013, 347, f6625-f6625.	3.0	257
1697	Predictors of Early and Late Target Lesion Revascularization after Drug-Eluting Stent Implantation. <i>Journal of Interventional Cardiology</i> , 2013, 26, 137-144.	0.5	8
1698	Long-Term Clinical Follow-up after Drug-Eluting Stent Implantation for Bare Metal Stent Restenosis. <i>Journal of Interventional Cardiology</i> , 2013, 26, 271-277.	0.5	1
1699	Outcomes of Overlapping Heterogeneous Drug-Eluting Stents Versus Homogeneous Drug-Eluting Stents for Diffuse Lesions in Small Coronary Arteries. <i>Journal of Interventional Cardiology</i> , 2013, 26, 264-270.	0.5	2
1700	In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E777-87.	0.7	9
1701	Combined Paclitaxel-Eluting Balloon and Genous Cobalt-Chromium Alloy Stent Utilization in De Novo Coronary Stenoses (PEGASUS). <i>Journal of Interventional Cardiology</i> , 2013, 26, 556-560.	0.5	3
1702	Nine-Month Angiographic and Intravascular Ultrasound Outcomes After Resolute Zotarolimus-Eluting Stent Implantation for the Treatment of In-Stent Restenosis. <i>Journal of Interventional Cardiology</i> , 2013, 26, 543-549.	0.5	0
1703	Impact of Diabetes on Long-Term Outcome After Primary Angioplasty. <i>Diabetes Care</i> , 2013, 36, 1020-1025.	4.3	91
1704	Coronary Arterial Remodeling and Out-Stent Plaque Change After Drug-Eluting Stent Implantation. <i>Circulation Journal</i> , 2013, 77, 363-371.	0.7	9
1705	Difference in Clinical and Angiographic Characteristics of Very Late Stent Thrombosis Between Drug-Eluting and Bare-Metal Stent Implantations. <i>Circulation Journal</i> , 2013, 77, 1453-1460.	0.7	11
1706	Long-Term Outcome of Drug-Eluting vs. Bare-Metal Stents in Patients With Acute Myocardial Infarction. <i>Circulation Journal</i> , 2013, 77, 2024-2031.	0.7	10
1707	Seven-Year Clinical Outcomes of Unprotected Left Main Coronary Artery Stenting With Drug-Eluting Stent and Bare-Metal Stent. <i>Circulation Journal</i> , 2013, 77, 2497-2504.	0.7	15
1708	Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 793-799.	0.7	38
1709	In Vitro Dissolution Testing of Drug-Eluting Stents. <i>Current Pharmaceutical Biotechnology</i> , 2013, 14, 67-75.	0.9	7
1710	Is there a Role for Antioxidants in the Treatment of Stable Angina?. <i>Current Pharmaceutical Design</i> , 2013, 19, 1601-1615.	0.9	1
1711	Patient preferences for coronary artery bypass graft surgery or percutaneous intervention in multivessel coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 212-218.	0.7	55

#	ARTICLE	IF	CITATIONS
1712	Minimizing complications following stent implantation: outcomes and follow-up. <i>Interventional Cardiology</i> , 2013, 5, 301-317.	0.0	3
1713	Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 438-445.	0.6	32
1714	Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: From Western Denmark heart registry. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 260-265.	0.7	13
1715	Low-dose paclitaxel modulates tumour fibrosis in gastric cancer. <i>International Journal of Oncology</i> , 2013, 42, 1167-1174.	1.4	42
1716	Effect of Atorvastatin-Eluting Stents in a Rabbit Iliac Artery Restenosis Model. <i>Chonnam Medical Journal</i> , 2013, 49, 118.	0.5	7
1717	Bioresorbable scaffolds in the treatment of coronary artery disease. <i>Medical Devices: Evidence and Research</i> , 2013, 6, 37.	0.4	17
1718	Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology. <i>Clinical Epidemiology</i> , 2013, 5, 357.	1.5	21
1719	Comparison of Drug-eluting Coronary Stents, Bare Coronary Stents and Self-expanding Stents in Angioplasty of Middle Cerebral Artery Stenoses. <i>Journal of Cerebrovascular and Endovascular Neurosurgery</i> , 2013, 15, 85.	0.2	12
1720	Predictors of diffuse-type in-stent restenosis following drug-eluting stent implantation. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 1486-1490.	0.8	9
1721	A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study. <i>Journal of Korean Medical Science</i> , 2013, 28, 1609.	1.1	6
1722	Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model. <i>Chonnam Medical Journal</i> , 2013, 49, 7.	0.5	18
1723	Long-Term Predictors of Clinical Events after Off-Label Use of Drug-Eluting Stent beyond 1 Year. <i>Korean Circulation Journal</i> , 2013, 43, 161.	0.7	2
1724	Circulating Fibroblast Growth Factor 23 Is Associated with Angiographic Severity and Extent of Coronary Artery Disease. <i>PLoS ONE</i> , 2013, 8, e72545.	1.1	27
1725	Stent Evaluation with Optical Coherence Tomography. <i>Yonsei Medical Journal</i> , 2013, 54, 1075.	0.9	28
1726	Management of Vertebral Artery Dissections and Vascular Insufficiency. , 2013, , .		0
1727	Percutaneous. Recanalization of Chronic Total Occlusion (CTO) Coronary Arteries: Looking Back and Moving Forward. , 2013, , .		3
1728	An Evolutionary Appraisal of the Efficacy of Coronary Artery Stents relevant to the Treatment of Coronary Heart Diseases. <i>International Journal of Biomedical and Advance Research</i> , 2013, 4, 764.	0.1	3
1729	Red Blood Cell Distribution Width and Long-Term Outcome in Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stenting Era: A Two-Year Cohort Study. <i>PLoS ONE</i> , 2014, 9, e94887.	1.1	29

#	ARTICLE	IF	CITATIONS
1730	Safety and Efficacy of Biodegradable Drug-Eluting vs. Bare Metal Stents: A Meta-Analysis from Randomized Trials. <i>PLoS ONE</i> , 2014, 9, e99648.	1.1	5
1731	Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients: a prospective non-randomized single-centre long-term comparison. <i>Acta Cardiologica</i> , 2014, 69, 523-531.	0.3	3
1732	Paclitaxel: new uses for an old drug. <i>Drug Design, Development and Therapy</i> , 2014, 8, 279.	2.0	74
1733	Advances in stent technologies and their effect on clinical efficacy and safety. <i>Medical Devices: Evidence and Research</i> , 2014, 7, 165.	0.4	13
1734	Second Generation DES: Better Option in Treatment ISR. <i>Journal of Vascular Medicine & Surgery</i> , 2014, 02, .	0.1	0
1735	Clinical outcomes and risk factors of coronary artery aneurysms after successful percutaneous coronary intervention and drug-eluting stent implantation for chronic total occlusions. <i>International Journal of Cardiology Heart & Vessels</i> , 2014, 4, 108-115.	0.5	5
1736	Drug-eluting stents in unprotected left main coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1349-1368.	0.6	1
1737	Surgical Versus Percutaneous Revascularization in Patients with Multivessel Coronary Artery Disease. <i>Current Atherosclerosis Reports</i> , 2014, 16, 461.	2.0	1
1738	A prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India. <i>Indian Heart Journal</i> , 2014, 66, 682-685.	0.2	0
1739	Could plasma asymmetric dimethylarginine level be a novel predictor beyond the classic predictors of stent restenosis?. <i>Anatolian Journal of Cardiology</i> , 2014, 14, 491-497.	0.4	8
1740	Incomplete Stent Apposition Causes High Shear Flow Disturbances and Delay in Neointimal Coverage as a Function of Strut to Wall Detachment Distance. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 180-189.	1.4	178
1741	Anti-CD133 Antibody Immobilized on the Surface of Stents Enhances Endothelialization. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	14
1742	Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. <i>BMJ, The</i> , 2014, 349, g6427-g6427.	3.0	82
1743	Local Delivery of Antiproliferative Agents via Stents. <i>Polymers</i> , 2014, 6, 755-775.	2.0	19
1744	Neointimal patterns obtained by optical coherence tomography correlate with specific histological components and neointimal proliferation in a swine model of restenosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 292-298.	0.5	54
1745	A clinical update on the use of resolute stents with dual anti-platelet therapy interruption. <i>Interventional Cardiology</i> , 2014, 6, 453-462.	0.0	0
1747	Heart-Targeted Nanoscale Drug Delivery Systems. <i>Journal of Biomedical Nanotechnology</i> , 2014, 10, 2038-2062.	0.5	37
1748	Resolute zotarolimus-eluting coronary stent system for the treatment of coronary artery disease. <i>Expert Review of Medical Devices</i> , 2014, 11, 247-257.	1.4	1

#	ARTICLE	IF	CITATIONS
1749	Endothelial progenitor cell (EPC)-seeded intravascular stents. , 2014, , 110-124.		2
1750	Outcomes of small coronary artery stenting with bareâ€metal stents versus drugâ€eluting stents: Results from the NHLBI dynamic registry. Catheterization and Cardiovascular Interventions, 2014, 83, 192-200.	0.7	13
1751	Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations. Circulation: Cardiovascular Interventions, 2014, 7, 768-776.	1.4	56
1752	Shifting the Focus to Recurrences. JACC: Cardiovascular Interventions, 2014, 7, 1114-1116.	1.1	2
1753	Borderline trend towards longâ€term mortality benefit from drug eluting stents implantation in STâ€elevation myocardial infarction patients in Polandâ€ data from NRDES registry. Catheterization and Cardiovascular Interventions, 2014, 83, 436-442.	0.7	13
1754	Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drugâ€coated balloon in a swine femoral artery model. Catheterization and Cardiovascular Interventions, 2014, 83, 132-140.	0.7	78
1755	Biodegradable polymer brush as nanocoupled interface for improving the durability of polymer coating on metal surface. Colloids and Surfaces B: Biointerfaces, 2014, 122, 808-817.	2.5	24
1756	Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?. Cardiology and Therapy, 2014, 3, 1-12.	1.1	5
1757	Comparative effectiveness of drugâ€eluting stents on longâ€term outcomes in elderly patients treated for inâ€stent restenosis: A report from the National Cardiovascular Data Registry. Catheterization and Cardiovascular Interventions, 2014, 83, 171-181.	0.7	6
1758	Extended followâ€up following â€fullâ€metal jacketâ€percutaneous coronary interventions with drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2014, 84, 1042-1050.	0.7	21
1759	Costâ€effectiveness of percutaneous coronary intervention with drugâ€eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery fiveâ€years after intervention. Catheterization and Cardiovascular Interventions, 2014, 84, 1029-1039.	0.7	10
1760	RAPSTROMâ„¸ Firstâ€inâ€Man Study Longâ€Term Results of a Biodegradable Polymer Sustainedâ€Release Sirolimusâ€Eluting Stent in De Novo Coronary Stenoses. Journal of Interventional Cardiology, 2014, 27, 373-380.	0.5	2
1761	Fiveâ€year clinical followâ€up of a randomized comparison of a polymerâ€free sirolimusâ€eluting stent versus a polymerâ€based paclitaxelâ€eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial). Catheterization and Cardiovascular Interventions, 2014, 83, 418-424.	0.7	22
1763	Inhibitory effects of roscovitine on proliferation and migration of vascular smooth muscle cells in vitro. Journal of Huazhong University of Science and Technology [Medical Sciences], 2014, 34, 791-795.	1.0	2
1764	Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease. Coronary Artery Disease, 2014, 25, 208-214.	0.3	12
1765	Statins and prevention of stent-related late adverse events. Coronary Artery Disease, 2014, 25, 277-278.	0.3	2
1766	Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. Coronary Artery Disease, 2014, 25, 658-664.	0.3	5
1767	Stent selection to minimize the risk of stent thrombosis. Current Opinion in Cardiology, 2014, 29, 578-585.	0.8	12

#	ARTICLE	IF	CITATIONS
1768	Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis. <i>Coronary Artery Disease</i> , 2014, 25, 638-644.	0.3	9
1769	Stenting for ST-segment elevation myocardial infarction is associated with less neointimal hyperplasia in the pooled IVUS analysis from HORIZONS-AMI and the TAXUS IV and V and ATLAS workhorse, long lesion, and direct stent studies. <i>Coronary Artery Disease</i> , 2014, 25, 575-581.	0.3	2
1770	Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. <i>BMJ Open</i> , 2014, 4, e004892-e004892.	0.8	23
1771	Anti-Angiogenesis Therapy in the Vx2 Rabbit Cancer Model with a Lipase-cleavable Sn 2 Taxane Phospholipid Prodrug using $\hat{I}\pm\hat{v}$ -Targeted Theranostic Nanoparticles. <i>Theranostics</i> , 2014, 4, 565-578.	4.6	45
1773	Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-analysis of 5834 patients. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 411-424.	0.8	21
1774	Randomized Comparison Between Polymer-Free Versus Polymer-Based Paclitaxel-Eluting Stent. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 312-321.	1.4	15
1775	A Rare and Serious Unforeseen Complication of Cutting Balloon Angioplasty. <i>Case Reports in Cardiology</i> , 2014, 2014, 1-4.	0.1	7
1776	Characterization of in-stent neointimal tissue components following drug-eluting stent implantation according to the phase of restenosis using a 40-MHz intravascular ultrasound imaging system. <i>Journal of Cardiology</i> , 2014, 64, 423-429.	0.8	10
1777	The impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: A meta-analysis of 16 randomized trials. <i>Journal of Cardiology</i> , 2014, 64, 185-193.	0.8	15
1778	Local inhibition of hypoxia-inducible factor reduces neointima formation after arterial injury in ApoE ^{-/-} mice. <i>Atherosclerosis</i> , 2014, 233, 641-647.	0.4	23
1779	Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1845-1854.	1.2	343
1780	Trend in the use of drug eluting stents in the United States. <i>International Journal of Cardiology</i> , 2014, 175, 108-119.	0.8	32
1781	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. <i>Lancet</i> , The, 2014, 383, 2047-2056.	6.3	96
1782	Clinical utility of low-pressure implantation of drug-eluting stent into very small vessels. <i>Journal of Cardiology</i> , 2014, 63, 218-222.	0.8	4
1783	Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS). <i>Heart and Vessels</i> , 2014, 29, 29-34.	0.5	8
1784	Safety and efficacy of degradable vs. permanent polymer drug-eluting stents: A meta-analysis of 18,395 patients from randomized trials. <i>International Journal of Cardiology</i> , 2014, 173, 100-109.	0.8	8
1785	Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 20-28.	1.1	124
1786	The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 10-19.	1.1	346

#	ARTICLE	IF	CITATIONS
1787	Focal Controlled Drug Delivery. <i>Advances in Delivery Science and Technology</i> , 2014, , .	0.4	25
1788	Revascularization strategies for patients with stable coronary artery disease. <i>Journal of Internal Medicine</i> , 2014, 276, 336-351.	2.7	18
1789	Current Status of Rotational Atherectomy. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 345-353.	1.1	232
1790	Zwitterionic hyperbranched polyester functionalized cardiovascular stent and its biocompatibility. <i>Journal of Colloid and Interface Science</i> , 2014, 420, 88-96.	5.0	22
1791	Impact of the Stent Length on Long-Term Clinical Outcomes Following Newer-Generation Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2014, 113, 457-464.	0.7	42
1792	Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 881-887.	0.7	36
1793	Clinical effects of routine postdilatation of drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 898-904.	0.7	18
1794	Catalytic dehydration of C ₆ carbohydrates for the production of hydroxymethylfurfural (HMF) as a versatile platform chemical. <i>Green Chemistry</i> , 2014, 16, 548-572.	4.6	523
1795	PI3K/p110 α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: potential implications for drug-eluting stent design. <i>European Heart Journal</i> , 2014, 35, 808-820.	1.0	37
1796	The Evolution of Coronary Stents: A Brief Review. <i>Canadian Journal of Cardiology</i> , 2014, 30, 35-45.	0.8	125
1797	Safety and efficacy of low-dose paclitaxel utilizing the cobra-P drug-eluting stent system with a novel biodegradable coating in de novo coronary lesions: The PLUS-ONE first-in-man study. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 18-22.	0.3	3
1798	Fabrication of nonbiofouling metal stent and in vitro studies on its hemocompatibility. <i>Journal of Biomaterials Applications</i> , 2014, 29, 14-25.	1.2	11
1799	Optimal aspirin dose in acute coronary syndromes: an emerging consensus. <i>Future Cardiology</i> , 2014, 10, 291-300.	0.5	8
1800	Are Drug-Eluting Stents Safe in the Long-Term After Saphenous Vein Graft Intervention?. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1837-1839.	1.2	1
1801	Impact on In-Hospital Outcomes With Drug-Eluting Stents Versus Bare-Metal Stents (from 665,804) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	12
1802	A journey from CABG to drug-eluting balloon. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, E21-5.	0.7	0
1803	Polymer-free drug-eluting stent in unselected patient population: A single center experience. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 350-353.	0.3	6
1804	Physical characterization of alginate-Pluronic F127 gel for endoluminal NABDs delivery. <i>Soft Matter</i> , 2014, 10, 729-737.	1.2	39

#	ARTICLE	IF	CITATIONS
1805	Current and future perspectives on drug-eluting bioresorbable coronary scaffolds. <i>Future Cardiology</i> , 2014, 10, 409-420.	0.5	6
1806	Atomic layer deposition enhanced grafting of phosphorylcholine on stainless steel for intravascular stents. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 121, 238-247.	2.5	21
1807	Effect of Solvent on Drug Release and a Spray-Coated Matrix of a Sirolimus-Eluting Stent Coated with Poly(lactic-co-glycolic acid). <i>Langmuir</i> , 2014, 30, 10098-10106.	1.6	26
1808	Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2086-2097.	1.2	388
1809	Stent Thrombosis With Second-Generation Drug-Eluting Stents Compared With Bare-Metal Stents. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 49-61.	1.4	37
1810	Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 701-707.	0.9	28
1811	Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. <i>European Heart Journal</i> , 2014, 35, 1147-1158.	1.0	152
1812	Reinforcement of Interfacial Adhesion of a Coated Polymer Layer on a Cobalt-Chromium Surface for Drug-Eluting Stents. <i>Langmuir</i> , 2014, 30, 8020-8028.	1.6	20
1813	Circulating soluble LR11, a novel marker of smooth muscle cell proliferation, is enhanced after coronary stenting in response to vascular injury. <i>Atherosclerosis</i> , 2014, 237, 374-378.	0.4	19
1814	Incidence and classification of neointimal proliferation and in-stent restenosis in post-stenting patients at 1-year interval: Findings from non-invasive coronary computed tomography angiography. <i>European Journal of Radiology</i> , 2014, 83, 1816-1821.	1.2	12
1815	Drug-eluting stents in patients with anterior STEMI undergoing primary angioplasty: a substudy of the DESERT cooperation. <i>Clinical Research in Cardiology</i> , 2014, 103, 685-699.	1.5	4
1816	Molecular Simulation of the Transport of Drugs across Model Membranes. <i>Journal of Physical Chemistry Letters</i> , 2014, 5, 1659-1665.	2.1	52
1817	Bioresorbable scaffolds: rationale, current status, challenges, and future. <i>European Heart Journal</i> , 2014, 35, 765-776.	1.0	228
1818	Choosing the Right Coronary Stent in the Modern Era. <i>Current Cardiology Reports</i> , 2014, 16, 469.	1.3	1
1819	Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 302.	0.4	1
1820	Radiation-induced biomimetic modification of dual-layered nano/microfibrous scaffolds for vascular tissue engineering. <i>Biotechnology and Bioprocess Engineering</i> , 2014, 19, 118-125.	1.4	15
1821	Coronary artery calcification as a new predictor of non-target lesion revascularization during the chronic phase after successful percutaneous coronary intervention. <i>Cardiovascular Intervention and Therapeutics</i> , 2014, 29, 315-323.	1.2	11
1822	Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: The DEMONSTRATE study. <i>International Journal of Cardiology</i> , 2014, 176, 904-909.	0.8	31

#	ARTICLE	IF	CITATIONS
1823	Drug-coated balloon angioplasty for drug-eluting stent restenosis: Insight from randomized controlled trials. <i>Annals of Medicine</i> , 2014, 46, 679-683.	1.5	10
1824	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. <i>BMJ, The</i> , 2014, 348, g3859-g3859.	3.0	291
1825	Three-Year Outcomes After Revascularization With Everolimus- and Sirolimus-Eluting Stents From the SORT OUT IV Trial. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 840-848.	1.1	28
1826	Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2111-2118.	1.2	85
1827	Impact of different tissue-simulating hydrogel compartments on in vitro release and distribution from drug-eluting stents. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 87, 570-578.	2.0	11
1828	Coronary drug-eluting stents: From design optimization to newer strategies. <i>Journal of Biomedical Materials Research - Part A</i> , 2014, 102, 1625-1640.	2.1	46
1829	Effect of Bare-Metal Nitinol Stent Implantation and Paclitaxel-Eluting Nitinol Stent Implantation on Vascular Response in the Superficial Femoral Artery Lesion Assessed on Intravascular Ultrasound. <i>Circulation Journal</i> , 2014, 78, 1451-1458.	0.7	10
1830	Drug-Coated Percutaneous Balloon Catheters. <i>Critical Reviews in Biomedical Engineering</i> , 2014, 42, 193-212.	0.5	3
1831	Bare-Metal vs. Drug-Eluting Stents in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2014, 78, 2674-2681.	0.7	21
1832	Favorable Vessel Healing After Nobori Biolimus A9-Eluting Stent Implantation. <i>Circulation Journal</i> , 2014, 78, 1882-1890.	0.7	17
1833	Prasugrel, a Third-Generation P2Y ₁₂ Receptor Antagonist, in Patients With Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2014, 78, 2926-2934.	0.7	86
1834	Optical Coherence Tomography and Histopathology Assessment After Implantation of First- and Second-Generation Drug-Eluting Stents in a Porcine Coronary Model. <i>Circulation Journal</i> , 2014, 78, 2665-2673.	0.7	14
1835	One Fits All or Which Stent for Which Lesion for Which Patient?. <i>Circulation Journal</i> , 2014, 78, 1824-1825.	0.7	0
1836	Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial. <i>Trials</i> , 2014, 15, 9.	0.7	14
1838	Drug-Eluting Balloon for the Treatment of Failing Hemodialytic Radiocephalic Arteriovenous Fistulas: Our Experience in the Treatment of Juxta-Anastomotic Stenoses. <i>Journal of Vascular Access</i> , 2014, 15, 338-343.	0.5	60
1839	Polymer-free versus permanent polymer drug eluting stents in coronary artery disease: A meta-analysis of 10 RCTs with 6575 patients. <i>Chronic Diseases and Translational Medicine</i> , 2015, 1, 221-230.	0.9	9
1840	Acetylsalicylic acid desensitization in the new era of percutaneous coronary intervention. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 253-257.	0.1	0
1841	Seguimento de 12 meses de pacientes complexos tratados com stents farmacológicos liberadores de everolimus XIENCE VÁ na prática diária – resultados do registro brasileiro BRAVO1. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2015, 23, 22-27.	0.1	0

#	ARTICLE	IF	CITATIONS
1842	Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents. <i>Scientific Reports</i> , 2015, 5, 17213.	1.6	7
1843	Message From the Editor-in-Chief. <i>Circulation Journal</i> , 2015, 79, 2285-2286.	0.7	0
1844	Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. <i>The Cochrane Library</i> , 2015, , CD004587.	1.5	2
1845	Two-Year Clinical Outcomes of Newer-Generation Drug-Eluting Stent Implantation Following Rotational Atherectomy for Heavily Calcified Lesions. <i>Circulation Journal</i> , 2015, 79, 1938-1943.	0.7	23
1848	Bioresorbable scaffolds for the treatment of complex lesions: are we there yet?. <i>Interventional Cardiology</i> , 2015, 7, 35-54.	0.0	2
1849	Twelve-month follow-up of complex patients treated with the Xience VTM everolimus drug-eluting stents in daily practice – results of the BRAVO Brazilian Registry. <i>Revista Brasileira De Cardiologia Invasiva (English Edition)</i> , 2015, 23, 22-27.	0.1	0
1850	Clinical outcomes of real-world patients treated with an amphiphilic polymer-free stent versus new generation everolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1168-1176.	0.7	13
1851	The power prior: theory and applications. <i>Statistics in Medicine</i> , 2015, 34, 3724-3749.	0.8	178
1852	Comparison of 2-year outcomes of repeated second-generation drug-eluting stent implantation for focal-type versus nonfocal-type in-stent restenosis. <i>Coronary Artery Disease</i> , 2015, 26, 587-591.	0.3	4
1854	Neoatherosclerosis: Coronary stents seal atherosclerotic lesions but result in making a new problem of atherosclerosis. <i>World Journal of Cardiology</i> , 2015, 7, 776.	0.5	32
1855	Accelerated Recovery of Endothelium Function after Stent Implantation with the Use of a Novel Systemic Nanoparticle Curcumin. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	5
1856	Polymers for Cardiovascular Stent Coatings. <i>International Journal of Polymer Science</i> , 2015, 2015, 1-11.	1.2	54
1857	Overview of Technological Development, Complications, and Crossing Techniques in Percutaneous Coronary Intervention. <i>Academic Forensic Pathology</i> , 2015, 5, 240-253.	0.3	1
1858	Randomized comparison of a sirolimus-eluting Orsiro stent with a biolimus-eluting Nobori stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome VII trial. <i>American Heart Journal</i> , 2015, 170, 210-215.	1.2	17
1859	Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	67
1860	Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2508-2510.	1.2	4
1861	Progress in interventional cardiology: challenges for the future. <i>Thrombosis and Haemostasis</i> , 2015, 113, 464-472.	1.8	17
1862	Coronary Artery Bypass Surgery and Percutaneous Coronary Revascularization: Impact on Morbidity and Mortality in Patients with Coronary Artery Disease. <i>Cardiovascular Medicine</i> , 2015, , 683-726.	0.0	2

#	ARTICLE	IF	CITATIONS
1863	Role of cAMP-Phosphodiesterase 1C Signaling in Regulating Growth Factor Receptor Stability, Vascular Smooth Muscle Cell Growth, Migration, and Neointimal Hyperplasia. <i>Circulation Research</i> , 2015, 116, 1120-1132.	2.0	80
1864	Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents?. <i>Circulation</i> , 2015, 131, 2001-2009.	1.6	2
1865	Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement. <i>Annals of Internal Medicine</i> , 2015, 163, 118-126.	2.0	51
1866	Editorial: Remaining issue after drug-eluting stent implantation: Histopathological mechanisms of early-phase in-stent restenosis. <i>Journal of Cardiology Cases</i> , 2015, 12, 150-151.	0.2	0
1867	BAYESIAN METHODS. , 2015, , 1229-1299.		0
1868	Controlling drug delivery from coronary stents: are we aiming for the right targets?. <i>Therapeutic Delivery</i> , 2015, 6, 705-720.	1.2	5
1869	Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002230.	1.4	122
1870	Relationship between stent type and quality of life after percutaneous coronary intervention for acute myocardial infarction. <i>American Heart Journal</i> , 2015, 170, 796-804.e3.	1.2	3
1871	The Food and Drug Administration and pragmatic clinical trials of marketed medical products. <i>Clinical Trials</i> , 2015, 12, 511-519.	0.7	20
1872	microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis. <i>Advances in Experimental Medicine and Biology</i> , 2015, 887, 53-77.	0.8	82
1873	Bioengineering stents with proactive biocompatibility. <i>Interventional Cardiology</i> , 2015, 7, 571-584.	0.0	2
1874	A New Hemodynamic ExVivo Model for Medical Devices Assessment. <i>Annals of Vascular Surgery</i> , 2015, 29, 1648-1655.	0.4	8
1875	Long-term clinical outcomes of drug-eluting stents in diabetic patients with small vessels compared to larger vessels—7years clinical follow-up. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 336-339.	0.3	0
1876	Serial Optical Coherence Tomography Evaluation at 6, 12, and 24 Months After Biolimus A9-Eluting Biodegradable Polymer-Coated Stent Implantation. <i>Canadian Journal of Cardiology</i> , 2015, 31, 980-988.	0.8	14
1877	Influence of proximal drug eluting stent (DES) on distal bare metal stent (BMS) in multi-stent implantation strategies in coronary arteries. <i>Medical Engineering and Physics</i> , 2015, 37, 840-844.	0.8	4
1878	An update on drug-eluting stents versus bare-metal stents in PCI treatment: are there any remaining indications for BMS use?. <i>Interventional Cardiology</i> , 2015, 7, 497-505.	0.0	1
1879	Titania nanotube arrays for local drug delivery: recent advances and perspectives. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 103-127.	2.4	146
1880	In vitro hemocompatibility and cytocompatibility of dexamethasone-eluting PLGA stent coatings. <i>Applied Surface Science</i> , 2015, 328, 154-162.	3.1	16

#	ARTICLE	IF	CITATIONS
1881	Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 183, 190-197.	0.8	4
1882	A Randomized Trial of a Dedicated Bifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation Lesions. <i>Journal of the American College of Cardiology</i> , 2015, 65, 533-543.	1.2	101
1883	Creation of a functional graded nanobiomembrane using a new electrospinning system for drug release control and an in vitro validation of drug release behavior of the coating membrane. <i>Materials Science and Engineering C</i> , 2015, 50, 133-140.	3.8	11
1884	Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF. <i>Heart</i> , 2015, 101, 50-57.	1.2	8
1885	Drug-Eluting Stents: the Past, Present, and Future. <i>Current Atherosclerosis Reports</i> , 2015, 17, 485.	2.0	39
1886	Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. <i>Pharmacological Research</i> , 2015, 93, 22-27.	3.1	45
1887	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1527-1535.	6.3	107
1888	Histopathology of vascular response to drug-eluting stents: an insight from human autopsy into daily practice. <i>Cardiovascular Intervention and Therapeutics</i> , 2015, 30, 1-11.	1.2	18
1889	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. <i>Journal of the American College of Cardiology</i> , 2015, 65, 805-815.	1.2	248
1890	Clinical outcomes of first- and second-generation drug-eluting stents in patients undergoing rotational atherectomy for heavily calcified coronary lesions. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 147-150.	0.3	16
1891	Composite outcomes in 2.25-mm drug eluting stents: a systematic review. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 237-242.	0.3	3
1892	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris) on Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	0.7	32
1893	Evaluation of Clinical Outcomes in Patients Undergoing Dual Vessel Percutaneous Coronary Intervention Using Sirolimus-Eluting Coronary Stent System in India. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2015, 9, OC05-9.	0.8	1
1894	A NEW WAY TO OPTIMIZE DRUG RELEASE RATE OF DRUG ELUTING STENT (DES). <i>Journal of Mechanics in Medicine and Biology</i> , 2015, 15, 1550064.	0.3	0
1895	Update on percutaneous intervention for left main coronary artery stenosis. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 933-943.	0.6	1
1896	Incidence, clinical presentation, and predictors of early neoatherosclerosis after drug-eluting stent implantation. <i>American Heart Journal</i> , 2015, 170, 591-597.	1.2	28
1897	Renewable Chemicals: Production or Purification by Adsorption Process. <i>Journal of Dispersion Science and Technology</i> , 2015, 36, 1297-1308.	1.3	1
1898	p53 functional mimetic peptide N24 blocks vascular proliferative disorders. <i>Journal of Molecular Medicine</i> , 2015, 93, 1107-1118.	1.7	4

#	ARTICLE	IF	CITATIONS
1899	Comparison of Strut Coverage at 6 Months by Optical Coherence Tomography With Everolimus-Eluting Stenting of Bare-Metal Stent Restenosis Versus Stenosis of Nonstented Atherosclerotic Narrowing (from the DESERT Study). <i>American Journal of Cardiology</i> , 2015, 115, 1351-1356.	0.7	6
1900	Influencia del sexo en los resultados clínicos de los stents liberadores de everolimus en comparación con los stents metálicos sin recubrimiento en el infarto agudo de miocardio con elevación del segmento ST. <i>Perspectivas del ensayo EXAMINATION. Revista Espanola De Cardiologia</i> , 2015, 68, 382-389.	0.6	11
1901	Rational use of rotational atherectomy in calcified lesions in the drug-eluting stent era: Review of the evidence and current practice. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 78-83.	0.3	20
1902	Sex-related Impact on Clinical Outcome of Everolimus-eluting Versus Bare-metal Stents in ST-segment Myocardial Infarction. <i>Insights From the EXAMINATION Trial. Revista Espanola De Cardiologia (English) Tj ETQq1 1 @.784314 8gBT /Ov</i>	0.7	11
1903	Paclitaxel-Coated Balloon Angioplasty for Symptomatic Central Vein Restenosis in Patients With Hemodialysis Fistulas. <i>Journal of Endovascular Therapy</i> , 2015, 22, 74-79.	0.8	59
1904	Efficacy and safety of limus-eluting versus paclitaxel-eluting coronary artery stents in patients with diabetes mellitus: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 184, 680-691.	0.8	11
1905	Clinical outcomes following percutaneous coronary intervention before and after introduction of drug-eluting stent. <i>Cardiovascular Intervention and Therapeutics</i> , 2015, 30, 338-346.	1.2	0
1906	Causes, assessment, and treatment of stent thrombosis—intravascular imaging insights. <i>Nature Reviews Cardiology</i> , 2015, 12, 325-336.	6.1	39
1907	Paclitaxel or 5-fluorouracil/esophageal stent combinations as a novel approach for the treatment of esophageal cancer. <i>Biomaterials</i> , 2015, 53, 592-599.	5.7	64
1908	Actualización en cardiología intervencionista 2014. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 324-330.	0.6	11
1909	Preparation of Polymeric Prodrug Paclitaxel-Poly(lactic acid)- <i>b</i> -Polyisobutylene and Its Application in Coatings of a Drug Eluting Stent. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 11263-11271.	4.0	27
1910	A finite element strategy to investigate the free expansion behaviour of a biodegradable polymeric stent. <i>Journal of Biomechanics</i> , 2015, 48, 2012-2018.	0.9	50
1911	Diffusion of di(2-ethylhexyl)phthalate in PVC quantified by ATR-IR spectroscopy. <i>Polymer</i> , 2015, 76, 70-79.	1.8	17
1912	The saga of the duration of dual antiplatelet therapy after drug-eluting stent placement. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 469-471.	0.7	2
1913	Continuation of Dual-Antiplatelet Therapy Following Percutaneous Revascularization with a Drug-Eluting Stent: What Duration Is Optimal?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 63.	2.0	3
1914	Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 1489-1496.	0.7	7
1915	Sirolimus-eluting dextran and polyglutamic acid hybrid coatings on AZ31 for stent applications. <i>Journal of Biomaterials Applications</i> , 2015, 30, 579-588.	1.2	18
1916	Comparisons of Everolimus and Paclitaxel-Eluting Stents in Patients with Acute Myocardial Infarction. <i>Journal of Interventional Cardiology</i> , 2015, 28, 147-156.	0.5	4

#	ARTICLE	IF	CITATIONS
1917	Emodin prevents intima thickness via Wnt4/Dvl-1/ β 2-catenin signaling pathway mediated by miR-126 in balloon-injured carotid artery rats. <i>Experimental and Molecular Medicine</i> , 2015, 47, e170-e170.	3.2	23
1918	Distinctive effects of CD34- and CD133-specific antibody-coated stents on re-endothelialization and in-stent restenosis at the early phase of vascular injury. <i>International Journal of Energy Production and Management</i> , 2015, 2, 87-96.	1.9	37
1919	Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 393.	0.4	24
1921	Systematic Review of Therapies for Stable Coronary Artery Disease in Diabetic Patients. <i>Annals of Thoracic Surgery</i> , 2015, 100, 2383-2397.	0.7	12
1922	Effect of Intravascular Ultrasound-Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2155.	3.8	418
1923	Coronary stent occlusion: reverse attenuation gradient sign observed at computed tomography angiography improves diagnostic performance. <i>European Radiology</i> , 2015, 25, 568-574.	2.3	8
1924	Coronary stent imaging with dual-source CT: assessment of lumen visibility using different convolution kernels and postprocessing filters. <i>Acta Radiologica</i> , 2015, 56, 42-50.	0.5	15
1925	Rationale and design: Impact of intravascular ultrasound guidance on long-term clinical outcomes of everolimus-eluting stents in long coronary lesions. <i>Contemporary Clinical Trials</i> , 2015, 40, 90-94.	0.8	7
1926	Cardiovascular OCT Imaging. , 2015, , .		5
1927	6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin. <i>Journal of the American College of Cardiology</i> , 2015, 65, 777-786.	1.2	322
1928	Business Perspective. , 2016, , 405-419.		0
1929	Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. <i>Journal of Thoracic Disease</i> , 2016, 8, E1150-E1162.	0.6	267
1930	Long-term performance of the second-generation cobalt-chromium sirolimus-eluting stents in real-world clinical practice: 3-year clinical outcomes from the prospective multicenter FOCUS registry. <i>Journal of Thoracic Disease</i> , 2016, 8, 1601-1610.	0.6	5
1931	Coronary stent thrombosis: what have we learned?. <i>Journal of Thoracic Disease</i> , 2016, 8, 1398-1405.	0.6	12
1932	The Development of Coronary Artery Stents: From Bare-Metal to Bio-Resorbable Types. <i>Metals</i> , 2016, 6, 168.	1.0	32
1933	Comparing the Clinical Outcomes between Drug Eluting Stents and Bare Metal Stents in Patients with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials. <i>PLoS ONE</i> , 2016, 11, e0154064.	1.1	14
1934	The benefits of drug-eluting stents in the treatment of coronary artery disease. <i>Research Reports in Clinical Cardiology</i> , 2016, , 9.	0.2	2
1935	Temporal Trends in Clinical Outcomes Following Percutaneous Coronary Intervention in Patients with Renal Insufficiency. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 1080-1088.	0.9	6

#	ARTICLE	IF	CITATIONS
1936	Paclitaxel-coated balloon plus bare-metal stent for de-novo coronary artery disease. <i>Coronary Artery Disease</i> , 2016, 27, 84-88.	0.3	11
1937	Comparison of clinical outcomes according to presentation of angina pectoris versus acute myocardial infarction in patients who underwent a percutaneous coronary intervention with a drug-eluting stent. <i>Coronary Artery Disease</i> , 2016, 27, 143-150.	0.3	3
1938	Same or Different Drugâ€Eluting Stent Reâ€Implantation for Drugâ€Eluting Stent Restenosis: An Assessment Including Secondâ€Generation Drugâ€Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2016, 29, 311-318.	0.5	1
1939	Comparison of longâ€Term outcomes of bareâ€metal and paclitaxelâ€eluting stents in New York. <i>Journal of Evaluation in Clinical Practice</i> , 2016, 22, 975-981.	0.9	0
1940	Longâ€Term outcomes following drugâ€eluting stents versus bare metal stents for primary percutaneous coronary intervention: A realâ€world analysis of 11,181 patients from the british columbia cardiac registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 24-35.	0.7	10
1941	Diphenylalanine peptide nanotubes selfâ€assembled on functionalized metal surfaces for potential application in drugâ€eluting stent. <i>Journal of Biomedical Materials Research - Part A</i> , 2016, 104, 2280-2290.	2.1	19
1942	Impact of coronary artery calcification in percutaneous coronary intervention with paclitaxelâ€eluting stents: Twoâ€year clinical outcomes of paclitaxelâ€eluting stents in patients from the <sc>ARRIVE</sc> program. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 891-897.	0.7	50
1943	Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multiâ€center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 881-889.	0.7	38
1944	Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network metaâ€analysis of randomized primary percutaneous coronary intervention trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 38-48.	0.7	41
1945	Resistant inâ€stent restenosis in the drug eluting stent era. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 777-785.	0.7	26
1946	Restenosis of the Coronary Arteries. <i>Interventional Cardiology Clinics</i> , 2016, 5, 281-293.	0.2	19
1947	Solely abluminal drug release from coronary stents could possibly improve reendothelialization. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E59-66.	0.7	11
1948	The influence of advancing age on implantation of drugâ€eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 516-521.	0.7	9
1949	Twoâ€year clinical outcomes of the NOBORI biolimusâ€eluting stents versus XIENCE/PROMUS everolimusâ€eluting stents in small vessel disease. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E132-E138.	0.7	11
1950	Non-acute percutaneous coronary intervention versus medical therapy in patients with ischaemic heart disease. <i>The Cochrane Library</i> , 2016, , .	1.5	2
1955	Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry. <i>BMJ Open</i> , 2016, 6, e010028.	0.8	25
1957	Direct oral anticoagulant use and stent thrombosis following an acute coronary syndrome: A potential new pharmacological option?. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 359-369.	0.7	1
1958	Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 431-443.	0.7	93

#	ARTICLE	IF	CITATIONS
1960	Polymer Biodegradation Kinetics. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2259-2262.	1.2	2
1961	A comparison of drug-eluting stent versus balloon angioplasty in patients with bare-metal stent in-stent restenosis: 5-year outcomes. <i>International Journal of the Cardiovascular Academy</i> , 2016, 2, 1-5.	0.1	1
1962	Polymeric materials for drug release system in drug eluting stents. <i>Journal of Pharmaceutical Investigation</i> , 2016, 46, 317-324.	2.7	12
1963	Impact of Baseline Angiographic Complexities Determined by Coronary Artery Bypass Grafting SYNTAX Score on the Prediction of Outcome After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016, 118, 974-979.	0.7	4
1964	Pathology of Endovascular Stents. <i>Interventional Cardiology Clinics</i> , 2016, 5, 391-403.	0.2	15
1965	Long-term outcome of patients with very small coronary artery disease: A comparison of drug-eluting and bare metal stents. <i>Journal of the Chinese Medical Association</i> , 2016, 79, 642-648.	0.6	5
1966	Review: The outcomes of different vessel diameter in patients receiving coronary artery stenting. <i>International Journal of Cardiology</i> , 2016, 224, 317-322.	0.8	7
1967	Trend to move from permanent metals to degradable, multifunctional polymer or metallic implants in the example of coronary stents. <i>Expert Review of Medical Devices</i> , 2016, 13, 1001-1003.	1.4	9
1968	Ex vivo assessment of neointimal characteristics after drug-eluting stent implantation: Optical coherence tomography and histopathology validation study. <i>International Journal of Cardiology</i> , 2016, 221, 1043-1047.	0.8	26
1969	Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2016, 8, 85-106.	3.3	26
1970	Variability in utilization of drug eluting stents in United States: Insights from nationwide inpatient sample. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 23-33.	0.7	4
1971	The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1489-1499.	2.4	11
1972	The role of angiographic follow-up after percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2016, 222, 911-920.	0.8	5
1973	Temporal Trends in Clinical Outcome After Percutaneous Coronary Intervention 1984-2010 Report From the Juntendo PCI Registry. <i>Circulation Journal</i> , 2016, 80, 93-100.	0.7	10
1974	Long term follow-up of full metal jacket of de novo coronary lesions with new generation Zotarolimus-eluting stents. <i>International Journal of Cardiology</i> , 2016, 221, 1008-1012.	0.8	5
1975	Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	104
1976	Long-term outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents: A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 223, 1066-1071.	0.8	7
1977	Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells. <i>Oncology Letters</i> , 2016, 12, 3944-3948.	0.8	46

#	ARTICLE	IF	CITATIONS
1978	Comparison of Vascular Responses Following New-Generation Biodegradable and Durable Polymer-Based Drug-Eluting Stent Implantation in an Atherosclerotic Rabbit Iliac Artery Model. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	33
1979	Very Late In-stent Restenosis due to Neoatherosclerosis in the Second-generation Everolimus-eluting Stent. <i>Shinzo Kekkan Naishikyo</i> , 2016, 2, 25-28.	0.2	1
1980	Bioresorbable Stents in PCI. <i>Current Cardiology Reports</i> , 2016, 18, 74.	1.3	9
1981	Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 38.	0.7	57
1982	Impact of stent length on clinical outcomes of first-generation and new-generation drug-eluting stents. <i>Cardiovascular Intervention and Therapeutics</i> , 2016, 31, 114-121.	1.2	11
1983	Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 34.	0.7	8
1984	Fabrication of endothelial progenitor cell capture surface via DNA aptamer modifying dopamine/polyethyleneimine copolymer film. <i>Applied Surface Science</i> , 2016, 386, 138-150.	3.1	21
1985	Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation. <i>Heart and Vessels</i> , 2016, 31, 1247-1256.	0.5	9
1986	Growth factors-loaded stents modified with hyaluronic acid and heparin for induction of rapid and tight re-endothelialization. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 141, 602-610.	2.5	38
1987	Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease. <i>Current Atherosclerosis Reports</i> , 2016, 18, 5.	2.0	4
1988	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 28-38.	1.1	31
1989	Controlled Drug Delivery Systems. <i>SpringerBriefs in Applied Sciences and Technology</i> , 2016, , .	0.2	2
1990	Nano-biomaterials for cardiovascular applications: Clinical perspective. <i>Journal of Controlled Release</i> , 2016, 229, 23-36.	4.8	34
1991	Heating drug delivery to vascular wall with Rhodamine B and fluorescence labeled Paclitaxel ranging 50 to 70°C: ex vivo study. , 2016, , .		1
1992	Nanoparticle drug delivery systems and their use in cardiac tissue therapy. <i>Nanomedicine</i> , 2016, 11, 693-714.	1.7	37
1993	Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 751-762.	1.2	116
1994	Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 51-64.	1.1	67
1995	Dual Antiplatelet Therapy in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003587.	1.4	9

#	ARTICLE	IF	CITATIONS
1996	In-stent Restenosis. <i>Interventional Cardiology Clinics</i> , 2016, 5, 211-220.	0.2	37
1997	Case Study: Drug Eluting Stent. <i>SpringerBriefs in Applied Sciences and Technology</i> , 2016, , 83-100.	0.2	0
1998	Mouse Models of Vascular Diseases. , 2016, , .		3
1999	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 426-436.	1.1	135
2000	Comparison of first- and second-generation drug-eluting stent efficacies for treating left main and/or three-vessel disease: a propensity matched study. <i>Heart and Vessels</i> , 2016, 31, 1930-1942.	0.5	7
2001	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	1.4	12
2002	Excessive stent overhang as an uncommon cause of very late stent thrombosis: Usefulness of optical coherence tomography. <i>International Journal of Cardiology</i> , 2016, 203, 123-125.	0.8	0
2003	Local Stent-Based Release of Transforming Growth Factor ^β 21 Limits Arterial In-Stent Restenosis. <i>Journal of the Association for Laboratory Automation</i> , 2016, 21, 305-311.	2.8	4
2004	Effect of exercise-based cardiac rehabilitation on non-culprit mild coronary plaques in the culprit coronary artery of patients with acute coronary syndrome. <i>Heart and Vessels</i> , 2016, 31, 846-854.	0.5	15
2005	Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries. <i>Heart and Vessels</i> , 2016, 31, 635-642.	0.5	9
2006	Reduction in incomplete stent apposition area caused by jailed struts after single stenting at left main bifurcation lesions: micro-CT analysis using a three-dimensional elastic bifurcated coronary artery model. <i>Cardiovascular Intervention and Therapeutics</i> , 2017, 32, 12-17.	1.2	14
2007	Blinded sample size recalculation in clinical trials with binary composite endpoints. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 705-715.	0.4	8
2008	Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Left Ventricular Systolic Dysfunction. <i>Angiology</i> , 2017, 68, 19-28.	0.8	11
2009	9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 160-167.	1.1	35
2010	Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 255-264.	1.1	38
2011	Bioresorbable Scaffolds for Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2017, 19, 5.	1.3	4
2012	Midterm and one-year outcome of amphilius polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (Amphilimus iTalian mUlticenter) Tj ETQq0 0 0 rgBT.8 Overload 10 Tf 50		
2013	Beyond restenosis: Patients' preference for drug eluting or bare metal stents. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 357-363.	0.7	5

#	ARTICLE	IF	CITATIONS
2014	Stents: Biomechanics, Biomaterials, and Insights from Computational Modeling. <i>Annals of Biomedical Engineering</i> , 2017, 45, 853-872.	1.3	53
2015	Single or dual antiplatelet therapy after PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 294-303.	6.1	35
2016	The effect of solvents and hydrophilic additive on stable coating and controllable sirolimus release system for drug-eluting stent. <i>Materials Science and Engineering C</i> , 2017, 78, 39-46.	3.8	11
2017	Difference in clinical presentations and related angiographic findings among early, late, and very late sirolimus-eluting stent failures requiring target lesion revascularization. <i>International Journal of Cardiology</i> , 2017, 243, 116-120.	0.8	0
2018	HIV status and type of coronary stent placed in patients presenting with ST-elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2017, 28, 239-245.	0.3	4
2019	Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. <i>International Journal of Cardiology</i> , 2017, 240, 326-331.	0.8	20
2020	Vascular response profiles following a nano polymer-free sirolimus-eluting stent implantation assessed by optical coherence tomography in a porcine model. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 829-834.	0.8	0
2021	Novel Poly(Diol Sebacate)s as Additives to Modify Paclitaxel Release From Poly(Lactic-co-Glycolic) Tj ETQq1 1 0.784314 rgBT /Overloc	1.6	7
2022	Association between plasma BMP-2 and in-stent restenosis in patients with coronary artery disease. <i>Clinica Chimica Acta</i> , 2017, 471, 150-153.	0.5	3
2023	The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2017, 235, 73-86.	0.8	6
2024	Comparison of Outcomes of Coronary Artery Bypass Grafting Using Internal Mammary Graft Versus Percutaneous Coronary Intervention for Isolated Proximal Left Anterior Descending Narrowing. <i>American Journal of Cardiology</i> , 2017, 119, 719-726.	0.7	7
2025	Polymers and coronary stents: have we come full circle?. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 471-472.	0.3	1
2026	Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. <i>Drugs</i> , 2017, 77, 1733-1754.	4.9	21
2027	Plasma treatment as an efficient tool for controlled drug release from polymeric materials: A review. <i>Journal of Controlled Release</i> , 2017, 266, 57-74.	4.8	70
2028	Contact lenses for ophthalmic drug delivery. <i>Australasian journal of optometry, The</i> , 2017, 100, 494-512.	0.6	42
2029	Should We Still Have Bare-Metal Stents Available in Our Catheterization Laboratory?. <i>Journal of the American College of Cardiology</i> , 2017, 70, 607-619.	1.2	32
2030	Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in-stent restenosis after drug-eluting or bare-metal stent implantation. The Nordic Intravascular Ultrasound Study (NIVUS). <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 577-582.	0.3	15
2031	Routine angiographic follow-up versus clinical follow-up in patients with multivessel coronary artery diseases following percutaneous coronary intervention with drug-eluting stents. <i>Coronary Artery Disease</i> , 2017, 28, 307-314.	0.3	3

#	ARTICLE	IF	CITATIONS
2032	Drug-eluting stents in clinical routine: a 1-year follow-up analysis based on German health insurance administrative data from 2008 to 2014. <i>BMJ Open</i> , 2017, 7, e017460.	0.8	3
2034	A comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 14997.	1.6	10
2035	Preparation of Vascular Endothelial Cadherin Loaded-Amphoteric Copolymer Decorated Coronary Stents for Anticoagulation and Endothelialization. <i>Langmuir</i> , 2017, 33, 13430-13437.	1.6	19
2036	Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans. <i>Coronary Artery Disease</i> , 2017, 28, 126-134.	0.3	14
2037	Vessel Size and Long-Term Outcomes After Limus-Based Drug-Eluting Stent Implantation Focusing on Medium- and Small-Diameter Vessels. <i>Angiology</i> , 2017, 68, 535-541.	0.8	9
2038	Clinical outcome of treatment with or without a final kissing balloon technique for bifurcation in-stent restenosis lesions. <i>Journal of Cardiology</i> , 2017, 69, 808-814.	0.8	0
2039	Intravascular imaging comparison of two metallic limus-eluting stents abuminally coated with biodegradable polymers: IVUS and OCT results of the DESTINY trial. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 161-168.	0.7	8
2040	Exploration of Carbon-Filled Carbon Nanotube Vascular Stents. <i>Mechanisms and Machine Science</i> , 2017, , 103-114.	0.3	0
2041	Stent-induced tracheal stenosis can be predicted by α 8 expression in rabbits. <i>European Journal of Clinical Investigation</i> , 2017, 47, 84-92.	1.7	16
2042	Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. <i>Rheumatology International</i> , 2017, 37, 59-65.	1.5	22
2043	Microactuators and Micromechanisms. <i>Mechanisms and Machine Science</i> , 2017, , .	0.3	0
2044	A rare complication of percutaneous coronary intervention: Coronary pseudoaneurysm formation. <i>Interventional Medicine & Applied Science</i> , 2017, 9, 208-211.	0.2	1
2045	Difference of Tissue Characteristics Between Early and Late Restenosis After Second-Generation Drug-Eluting Stents Implantation—An Optical Coherence Tomography Study. <i>Circulation Journal</i> , 2017, 81, 450-457.	0.7	41
2046	Drug release kinetics from a drug-eluting stent with asymmetrical coat. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 407-415.	3.0	7
2047	Clinical Implication of Optical Coherence Tomography-Based Neoatherosclerosis. <i>Journal of Korean Medical Science</i> , 2017, 32, 1056.	1.1	8
2048	7.28 Drug Eluting Stents. <i>7.28 Drug Eluting Stents</i> , 2017, , 548-590.		0
2050	Clinical Outcomes in Diabetic Patients Who Underwent Percutaneous Coronary Intervention during the Plain Old Balloon Angioplasty (POBA)-, Bare Metal Stents (BMS)- and Drug-eluting Stents (DES)-eras from 1984 to 2010. <i>Internal Medicine</i> , 2017, 56, 1-9.	0.3	5
2051	Drug-eluting balloon versus bare-metal stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials. <i>PLoS ONE</i> , 2017, 12, e0176365.	1.1	10

#	ARTICLE	IF	CITATIONS
2052	A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. PLoS ONE, 2017, 12, e0182632.	1.1	6
2053	Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents. PLoS ONE, 2017, 12, e0183079.	1.1	4
2054	Coronary Artery Disease and Type 2 Diabetes Mellitus. International Heart Journal, 2017, 58, 475-480.	0.5	123
2055	Drug-Eluting vs. Bare-Metal Stents: Is it a Matter of Vessel Size?. Journal of Clinical Trials, 2017, 07, .	0.1	0
2056	Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching. Yonsei Medical Journal, 2017, 58, 290.	0.9	3
2057	Routine Angiographic Follow-Up versus Clinical Follow-Up after Percutaneous Coronary Intervention in Acute Myocardial Infarction. Yonsei Medical Journal, 2017, 58, 720.	0.9	9
2058	Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer. Korean Circulation Journal, 2017, 47, 898.	0.7	5
2059	Diagnosis and management challenges of in-stent restenosis in coronary arteries. World Journal of Cardiology, 2017, 9, 640.	0.5	56
2060	A Brief History of Coronary Artery Stents. Revista Espanola De Cardiologia (English Ed), 2018, 71, 312-319.	0.4	17
2061	Hypersensitivity to Cardiovascular Implants: Stents. , 2018, , 263-271.		2
2062	Vascular smooth muscle cell proliferation as a therapeutic target. Part 2: Natural products inhibiting proliferation. Biotechnology Advances, 2018, 36, 1608-1621.	6.0	38
2063	Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. Clinical Research in Cardiology, 2018, 107, 816-823.	1.5	21
2064	Breve historia de los stents coronarios. Revista Espanola De Cardiologia, 2018, 71, 312-319.	0.6	23
2065	Coronary plaque characteristics on baseline CT predict the need for late revascularization in symptomatic patients after percutaneous intervention. European Radiology, 2018, 28, 3441-3453.	2.3	10
2066	Third generation dual-source CT enables accurate diagnosis of coronary restenosis in all size stents with low radiation dose and preserved image quality. European Radiology, 2018, 28, 2647-2654.	2.3	26
2067	Nine-month results of the BIOHELIX clinical trial study: Evaluation of the PROKinetic Energy cobalt chromium bare-metal stent system. Catheterization and Cardiovascular Interventions, 2018, 92, 1030-1039.	0.7	2
2068	Initial pathological responses of second-generation everolimus-eluting stents implantation in Japanese coronary arteries: Comparison with first-generation sirolimus-eluting stents. Journal of Cardiology, 2018, 71, 452-457.	0.8	9
2069	Recent alternative approaches of vascular drug-eluting stents. Journal of Pharmaceutical Investigation, 2018, 48, 153-165.	2.7	5

#	ARTICLE	IF	CITATIONS
2071	In-Stent Restenosis: Definition, Entity of the Problem, Etiopathogenesis and Treatment Options. , 2018, , 975-994.		0
2072	Local delivery of thalidomide to inhibit neointima formation in rat model with artery injury. Pathology Research and Practice, 2018, 214, 1303-1308.	1.0	2
2073	Routine angiographic follow-up versus clinical follow-up in patients with diabetes following percutaneous coronary intervention with drug-eluting stents in Korean population. Diabetes Research and Clinical Practice, 2018, 138, 138-148.	1.1	4
2074	Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries. Cardiovascular Intervention and Therapeutics, 2018, 33, 55-61.	1.2	11
2075	Hydroxyapatite-polymer biocomposites for bone regeneration: A review of current trends. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2018, 106, 2046-2057.	1.6	232
2076	Very long-term serial luminal changes after sirolimus-eluting stent implantation and progression process of very late stent failure. Cardiovascular Revascularization Medicine, 2018, 19, 88-94.	0.3	0
2077	Long-term results of a sirolimus-eluting stent with biodegradable polymer (RAPSTROM [®]) in de novo coronary stenoses. Cardiovascular Revascularization Medicine, 2018, 19, 429-432.	0.3	1
2078	Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases. Drug Delivery and Translational Research, 2018, 8, 868-882.	3.0	22
2079	Late Stent Evaluation (Neoatherosclerosis). , 2018, , 165-175.		0
2081	Inhibition of neddylation by MLN4924 improves neointimal hyperplasia and promotes apoptosis of vascular smooth muscle cells through p53 and p62. Cell Death and Differentiation, 2018, 25, 319-329.	5.0	29
2082	Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries. Circulation, 2018, 137, 166-183.	1.6	77
2083	Stents, Restenosis, and Stent Thrombosis. , 2018, , 179-199.		2
2084	Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial. American Heart Journal, 2018, 197, 35-42.	1.2	30
2085	Impact of everolimus-eluting stent length on long-term clinical outcomes of percutaneous coronary intervention. Journal of Cardiology, 2018, 71, 444-451.	0.8	12
2086	Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. American Heart Journal, 2018, 197, 103-112.	1.2	9
2087	Impact of previous drug-eluting stent restenosis in non-left main coronary artery lesions on long-term outcomes after left main coronary artery stenting: an observation from the AOI-LMCA registry. Cardiovascular Intervention and Therapeutics, 2018, 33, 350-359.	1.2	0
2088	Visit-to-visit variability of systolic blood pressure predicts all-cause mortality in patients received percutaneous coronary intervention with drug-eluting stents. Heart and Vessels, 2018, 33, 489-497.	0.5	8
2089	Revascularization Approaches. , 2018, , 337-354.		4

#	ARTICLE	IF	CITATIONS
2090	Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007045.	1.4	17
2091	Long-term clinical outcomes after treatment of stent restenosis with two drug-coated balloons. <i>Coronary Artery Disease</i> , 2018, 29, 632-637.	0.3	2
2092	Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering. <i>Frontiers in Pharmacology</i> , 2018, 9, 1329.	1.6	19
2093	Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study. <i>International Journal of Angiology</i> , 2018, 27, 213-222.	0.2	4
2094	Antiplatelet agents in uncertain clinical scenariosâ€”a bleeding nightmare. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 647-662.	0.7	7
2095	Polymer-free drug-eluting stents. , 2018, , 57-74.		0
2096	Impact of body fat distribution on long-term clinical outcomes after drug-eluting stent implantation. <i>PLoS ONE</i> , 2018, 13, e0197991.	1.1	2
2097	40 Years of Percutaneous Coronary Intervention: History and Future Directions. <i>Journal of Personalized Medicine</i> , 2018, 8, 33.	1.1	72
2098	Open-labeled randomized controlled trial to evaluate the 1-year clinical outcomes of polymer-free sirolimus-eluting coronary stents as compared with biodegradable polymer-based sirolimus-eluting coronary stents. <i>Indian Heart Journal</i> , 2018, 70, S323-S328.	0.2	3
2099	Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 735-748.	0.6	8
2101	Historical Account Cardiology. , 2018, , 1837-1849.		0
2102	Cochrane Corner: drug-eluting stents versus bare-metal stents for acute coronary syndrome. <i>Heart</i> , 2018, 104, 1895-1897.	1.2	4
2103	Cardiovascular Outcomes in Patients on Hemodialysis following Drug-Eluting versus Bare-Metal Coronary Stents. <i>Cardiology Research and Practice</i> , 2018, 2018, 1-7.	0.5	1
2105	Non-Inferiority of Resolute Integrity Drug-Eluting Stent to Benchmark Xience Drug-Eluting Stent. <i>Circulation Journal</i> , 2018, 82, 2284-2291.	0.7	2
2106	Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. <i>Journal of Clinical Medicine</i> , 2018, 7, 74.	1.0	5
2107	Rhombic-Shaped Channel Stent with Enhanced Drug Capacity and Fatigue Life. <i>Micromachines</i> , 2018, 9, 3.	1.4	8
2108	Nanosecond pulsed electric fields promoting the proliferation of porcine iliac endothelial cells: An in vitro study. <i>PLoS ONE</i> , 2018, 13, e0196688.	1.1	17
2109	In vitro and in vivo Assessment of Keratose as a Novel Excipient of Paclitaxel Coated Balloons. <i>Frontiers in Pharmacology</i> , 2018, 9, 808.	1.6	18

#	ARTICLE	IF	CITATIONS
2110	Overview of cardiovascular stent designs. , 2018, , 3-26.		9
2111	9-year clinical follow-up of patients with ST-segment elevation myocardial infarction with Genous or TAXUS Libert� stents. PLoS ONE, 2018, 13, e0201416.	1.1	6
2112	Drug delivery from polymeric matrices. Computer Aided Chemical Engineering, 2018, 42, 325-356.	0.3	4
2113	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. European Heart Journal Supplements, 2018, 20, F1-F74.	0.0	25
2114	Five-Year Clinical Outcomes After Drug-Eluting Stent Implantation Following Rotational Atherectomy for Heavily Calcified Lesions. Circulation Journal, 2018, 82, 983-991.	0.7	16
2115	Long-term clinical outcomes of permanent-polymer everolimus-eluting stent implantation following rotational atherectomy for severely calcified de novo coronary lesions: Results of a 22-center study (Tokyo-MD PCI Study). Cardiovascular Revascularization Medicine, 2019, 20, 120-125.	0.3	8
2116	A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation. Journal of Translational Medicine, 2019, 17, 274.	1.8	17
2117	The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era. Journal of Interventional Cardiology, 2019, 2019, 1-13.	0.5	12
2119	<p>Real-World Use Of Ultrathin-Strut Biodegradable Polymer��Coated Sirolimus-Eluting Stents In Patients With Coronary Artery Disease: 6-Month Clinical Outcomes</p>. Vascular Health and Risk Management, 2019, Volume 15, 439-447.	1.0	4
2120	The Smoker��s Paradox Revisited. JACC: Cardiovascular Interventions, 2019, 12, 1941-1950.	1.1	20
2121	Progress in Drug-Eluting Stent Technology. JACC: Cardiovascular Interventions, 2019, 12, 1661-1664.	1.1	4
2122	A Review based on Biodegradable and Bioabsorbable Stents for Coronary Artery Disease. Procedia Computer Science, 2019, 152, 354-359.	1.2	13
2123	Leveraging Cumulative Network Meta-analysis and Value of Information Analysis to Understand the Evolving Value of Medical Research. Medical Decision Making, 2019, 39, 119-129.	1.2	5
2124	Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet, The, 2019, 394, 230-239.	6.3	111
2125	Efficacy and safety of drug-eluting stenting compared with bypass grafting in diabetic patients with multivessel and/or left main coronary artery disease. Scientific Reports, 2019, 9, 7268.	1.6	9
2126	Comparative Effectiveness and Safety of Polymer-Free Biolimus-Eluting Stent and Durable Polymer Everolimus-Eluting Stent in All-Corner Patients Who Underwent Percutaneous Coronary Interventions. American Journal of Cardiology, 2019, 124, 195-204.	0.7	8
2127	Delivery of Cell-Specific Aptamers to the Arterial Wall with an Occlusion Perfusion Catheter. Molecular Therapy - Nucleic Acids, 2019, 16, 360-366.	2.3	10
2128	Evaluation of the suitability of a fluidized bed process for the coating of drug-eluting stents. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 139, 85-92.	2.0	4

#	ARTICLE	IF	CITATIONS
2129	Prevalence of Decreased Myocardial Blood Flow in Symptomatic Patients with Patent Coronary Stents: Insights from Low-Dose Dynamic CT Myocardial Perfusion Imaging. Korean Journal of Radiology, 2019, 20, 621.	1.5	8
2130	Complex robotic compared to manual coronary interventions: 6â€and 12â€month outcomes. Catheterization and Cardiovascular Interventions, 2019, 93, 613-617.	0.7	26
2131	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0
2132	12-Month clinical results of drug-coated balloons for de novo coronary lesion in vessels exceeding 3.0Âmm. International Journal of Cardiovascular Imaging, 2019, 35, 579-586.	0.7	13
2133	Perioperative major adverse cardiac events in urgent femoral artery repair after coronary stenting are less common than previously reported. Journal of Vascular Surgery, 2019, 70, 216-223.	0.6	0
2134	Five-year outcomes after first- and second-generation drug-eluting stent implantation in all patients undergoing percutaneous coronary intervention. Journal of Cardiology, 2019, 74, 169-174.	0.8	7
2135	<p>Improving the anti-keloid outcomes through liposomes loading paclitaxel–cholesterol complexes</p>. International Journal of Nanomedicine, 2019, Volume 14, 1385-1400.	3.3	21
2136	Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007311.	1.4	30
2137	Developing and Testing a Personalized, Evidence-Based, Shared Decision-Making Tool for Stent Selection in Percutaneous Coronary Intervention Using a Pre-Post Study Design. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005139.	0.9	12
2138	Intravascular ultrasound guidance reduces cardiac death and coronary revascularization in patients undergoing drug-eluting stent implantation: results from a meta-analysis of 9 randomized trials and 4724 patients. International Journal of Cardiovascular Imaging, 2019, 35, 239-247.	0.7	43
2139	BioCoStent: A Holistic Approach for Development of a Drug-Eluting Stent with Retinoic Acid. , 2019, , .		2
2140	Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial. BMJ Open, 2019, 9, e033774.	0.8	1
2141	The Current Literature on Bioabsorbable Stents: a Review. Current Atherosclerosis Reports, 2019, 21, 54.	2.0	35
2142	An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial. Scientific Reports, 2019, 9, 18549.	1.6	0
2143	Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis. Coronary Artery Disease, 2019, 30, 473-480.	0.3	10
2144	Treatment of juxta-anastomotic stenoses for failing distal radiocephalic arteriovenous fistulas: Drug-coated balloons versus angioplasty. Journal of Vascular Access, 2019, 20, 209-216.	0.5	12
2145	Fractureâ€Resistant and Bioresorbable Drugâ€Eluting Poly(glycerol Sebacate) Coils. Advanced Therapeutics, 2019, 2, 1800109.	1.6	7
2146	Influence of Dissolution Vessel Geometry and Dissolution Medium on In Vitro Dissolution Behaviour of Triamterene-Coated Model Stents in Different Test Setups. AAPS PharmSciTech, 2019, 20, 27.	1.5	3

#	ARTICLE	IF	CITATIONS
2147	Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 201-211.	2.4	20
2148	In vitro thrombogenicity of drug-eluting and bare metal stents. <i>Thrombosis Research</i> , 2020, 185, 43-48.	0.8	5
2149	Low ankle brachial index predicts poor outcomes including target lesion revascularization during the long-term follow up after drug-eluting stent implantation for coronary artery disease. <i>Journal of Cardiology</i> , 2020, 75, 250-254.	0.8	9
2150	A retrospective comparison analysis of results of drug-coated balloon versus plain balloon angioplasty in treatment of juxta-anastomotic de novo stenosis of radiocephalic arteriovenous fistulas. <i>Journal of Vascular Access</i> , 2020, 21, 596-601.	0.5	6
2151	SWEDHEART-1-year data show no benefit of newer generation drug-eluting stents over bare-metal stents in patients with severe kidney dysfunction following percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2020, 31, 49-58.	0.3	2
2152	Drug-Eluting Stents and Balloons—Materials, Structure Designs, and Coating Techniques: A Review. <i>Molecules</i> , 2020, 25, 4624.	1.7	40
2153	The role of extracellular vesicles in neointima formation post vascular injury. <i>Cellular Signalling</i> , 2020, 76, 109783.	1.7	10
2154	Coronary Artery Aneurysm After Drug-Eluting Stent Implantation Causing Coronary-Bronchial Fistula. <i>JACC: Case Reports</i> , 2020, 2, 1692-1697.	0.3	5
2155	Assessment of Mortality and Factors Affecting Outcome of Use of Paclitaxel-Coated Stents and Bare Metal Stents in Femoropopliteal PAD. <i>Journal of Clinical Medicine</i> , 2020, 9, 2221.	1.0	8
2156	Health Care Monitoring and Treatment for Coronary Artery Diseases: Challenges and Issues. <i>Sensors</i> , 2020, 20, 4303.	2.1	8
2157	Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 119.	1.1	65
2158	Clinical characteristics and in hospital outcomes of heart transplant recipients undergoing percutaneous coronary intervention: Insights from the National Inpatient Sample. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E585-E592.	0.7	2
2159	Clinical and procedure characteristics in patients treated with polytetrafluoroethylene-covered stents after coronary perforation: a CIRC-8U multicenter registry and literature review. <i>Cardiovascular Intervention and Therapeutics</i> , 2021, 36, 418-428.	1.2	5
2160	Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1087-1099.	0.7	23
2161	Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1521-1531.	1.2	106
2162	The state-of-the-art coronary stent with crystallized sirolimus: the MiStent technology and its clinical program. <i>Future Cardiology</i> , 2020, 17, 593-607.	0.5	1
2163	Myostatin Inhibits Vascular Smooth Muscle Cell Proliferation and Local 14q32 microRNA Expression, But Not Systemic Inflammation or Restenosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3508.	1.8	11
2164	Durable polymer everolimus-eluting stents: history, current status and future prospects. <i>Expert Review of Medical Devices</i> , 2020, 17, 671-682.	1.4	3

#	ARTICLE	IF	CITATIONS
2165	Additional postdilatation using noncompliant balloons after everolimus-eluting stent implantation: Results of the PRESS trial. <i>Clinical Cardiology</i> , 2020, 43, 606-613.	0.7	1
2166	First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha registry. <i>IJC Heart and Vasculature</i> , 2020, 26, 100472.	0.6	12
2167	The Effect of Drug-Eluting Stents on Target Lesion Revascularization in Native Coronary Arteries: Results from the NORSTENT Randomized Study. <i>Cardiology</i> , 2020, 145, 333-341.	0.6	2
2168	Conditional power analysis of the DEBUT trial – Authors' reply. <i>Lancet, The</i> , 2020, 395, 561.	6.3	0
2169	Mechanistic insights into the superior clinical efficacy of prasugrel over ticagrelor. <i>European Heart Journal</i> , 2020, 41, 3153-3155.	1.0	1
2170	Tailoring of cardiovascular stent material surface by immobilizing exosomes for better pro-endothelialization function. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 189, 110831.	2.5	37
2171	Recent Advances in Manufacturing Innovative Stents. <i>Pharmaceutics</i> , 2020, 12, 349.	2.0	72
2172	Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons. <i>Molecules</i> , 2020, 25, 1596.	1.7	9
2173	Drug-eluting stents versus bare-metal stents for acute coronary syndrome. <i>The Cochrane Library</i> , 2021, 2021, CD012481.	1.5	20
2174	Multivariable prediction model to estimate the probability of restenosis at proximal edge after 2nd-generation drug-eluting-stent implantation: development and internal validation using a quantitative coronary angiography from the post-marketing surveillance studies of everolimus-eluting stent in Japan. <i>Cardiovascular Intervention and Therapeutics</i> , 2021, 36, 190-197.	1.2	2
2175	Italian Multicenter Registry of Bare Metal Stent Use in Modern Percutaneous Coronary Intervention Era (AMARCORD): A multicenter observational study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 411-420.	0.7	6
2176	The birth, decline, and contemporary re-emergence of endovascular brachytherapy for prevention of in-stent restenosis. <i>Brachytherapy</i> , 2021, 20, 485-493.	0.2	7
2177	Designing Better Cardiovascular Stent Materials: A Learning Curve. <i>Advanced Functional Materials</i> , 2021, 31, .	7.8	50
2178	Drug-Eluting Stents Versus Bare-Metal Stents in Large Coronary Artery Revascularization: Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 23, 42-49.	0.3	15
2179	Lumen Loss at 1 Year After Bare Nitinol Stent Implantation in the Superficial Femoral Artery. <i>Journal of Endovascular Therapy</i> , 2021, 28, 132-138.	0.8	1
2180	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 17-24.	0.3	9
2181	Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 801-816.	0.6	8
2182	Evaluation of in Vitro Corrosion Behavior of Titanium Oxynitride Coated Stainless Steel Stents. <i>IEEE Access</i> , 2021, 9, 59766-59782.	2.6	3

#	ARTICLE	IF	CITATIONS
2183	Influence of Drug Incorporation on the Physico-Chemical Properties of Poly(l-Lactide) Implant Coating Matrices—A Systematic Study. <i>Polymers</i> , 2021, 13, 292.	2.0	14
2184	<i>Device Trials</i> , 2021, , 1-18.		0
2185	Preclinical Evaluation of a Novel Polymer-free Everolimus-eluting Stent in a Mid-term Porcine Coronary Restenosis Model. <i>Journal of Korean Medical Science</i> , 2021, 36, e259.	1.1	3
2186	Second generation drug-eluting stents: a focus on safety and efficacy of current devices. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 107-127.	0.6	4
2187	Multivessel Disease Patients™ Outcome and Second Generation Stent: Is Syntax Still a Valid Score? A RealWorld Study from a Tertiary Center. <i>Acta Medica Academica</i> , 2021, 49, 265.	0.3	0
2188	Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients. <i>Scientific Reports</i> , 2021, 11, 9364.	1.6	13
2189	Critical evaluation of stents in coronary angioplasty: a systematic review. <i>BioMedical Engineering OnLine</i> , 2021, 20, 46.	1.3	9
2190	Rituximab in the treatment of primary glomerulopathies - our experience. <i>Vnitri Lekarstvi</i> , 2021, 67, e03-e07.	0.1	0
2191	The Development of an ex vivo Flow System to Assess Acute Arterial Drug Retention of Cardiovascular Intravascular Devices. <i>Frontiers in Medical Technology</i> , 2021, 3, 675188.	1.3	4
2192	Clinical Outcomes of Drug-Coated Balloon in Coronary Patients with and without Diabetes Mellitus: A Multicenter, Propensity Score Study. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-11.	1.0	7
2193	Mechanical programming of arterial smooth muscle cells in health and ageing. <i>Biophysical Reviews</i> , 2021, 13, 757-768.	1.5	6
2194	Coronary Stenting: Reflections on a 35-Year Journey. <i>Canadian Journal of Cardiology</i> , 2022, 38, S17-S29.	0.8	7
2195	New antithrombotic strategies and coronary stent technologies for patients at high bleeding risk undergoing percutaneous coronary intervention. <i>Current Vascular Pharmacology</i> , 2021, 19, .	0.8	1
2196	Development of In Vitro Endothelialised Stents - Review -. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 179-197.	1.7	5
2197	Salt-Inducible Kinase 3 Promotes Vascular Smooth Muscle Cell Proliferation and Arterial Restenosis by Regulating AKT and PKA-CREB Signaling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2431-2451.	1.1	8
2198	The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy. <i>Polymers</i> , 2021, 13, 446.	2.0	9
2199	Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1213-1221.	0.7	2
2200	Nonviral Gene Delivery for Applications in Regenerative Medicine. , 2012, , 285-319.		1

#	ARTICLE	IF	CITATIONS
2201	Vascular Remodeling in Health and Disease. , 2007, , 1541-1565.		3
2202	Coronary Stents. , 2019, , 1-13.		1
2203	Bare Metal and Drug-Eluting Coronary Stents. , 2012, , 171-196.		4
2204	Restenosis. , 2012, , 421-431.		1
2206	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. <i>European Heart Journal</i> , 2021, 42, 339-351.	1.0	57
2207	Safety and Efficacy of the Drug-Eluting Stent: A Double-Edged Sword?. <i>Southern Medical Journal</i> , 2008, 101, 174-178.	0.3	8
2208	Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk. <i>Current Opinion in Cardiology</i> , 2015, 30, 325-332.	0.8	8
2209	Local paclitaxel delivery after coronary stenting in an experimental animal model. <i>Thrombosis and Haemostasis</i> , 2007, 98, 674-680.	1.8	23
2210	In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario. <i>Egyptian Heart Journal</i> , 2019, 71, 28.	0.4	13
2211	Two Years Efficacy of Paclitaxel-Coated Balloon Dilation for In-Stent Renal Artery Restenosis Due to Takayasu Arteritis. <i>American Journal of Case Reports</i> , 2019, 20, 1089-1093.	0.3	7
2212	Clinical Outcomes from Unselected Real-World Patients with Acute Myocardial Infarction Receiving Biodegradable Polymer Coated Sirolimus-Eluting Stents. <i>Journal of Cardiology and Therapeutics</i> , 0, , .	0.1	1
2213	Precise ultrasonic coating and controlled release of sirolimus with biodegradable polymers for drug-eluting stent. <i>Biomaterials and Biomechanics in Bioengineering</i> , 2014, 1, 13-25.	0.1	3
2214	Non Thermal Irreversible Electroporation: Novel Technology for Vascular Smooth Muscle Cells Ablation. <i>PLoS ONE</i> , 2009, 4, e4757.	1.1	127
2215	The Association of Diabetes Mellitus with Clinical Outcomes after Coronary Stenting: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e72710.	1.1	27
2216	Targeted Inhibitory Effect of Lenti-SM22alpha-p27-EGFP Recombinant Lentiviral Vectors on Proliferation of Vascular Smooth Muscle Cells without Compromising Re-Endothelialization in a Rat Carotid Artery Balloon Injury Model. <i>PLoS ONE</i> , 2015, 10, e0118826.	1.1	3
2217	Dialysis Patients with Implanted Drug-Eluting Stents Have Lower Major Cardiac Events and Mortality than Those with Implanted Bare-Metal Stents: A Taiwanese Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0146343.	1.1	10
2218	Mid-to-long term mortality following surgical versus percutaneous coronary revascularization stratified according to stent subtype: An analysis of 6,682 patients with multivessel disease. <i>PLoS ONE</i> , 2018, 13, e0191554.	1.1	2
2219	Biorelevant Dissolution Testing of Drug-Eluting Stents: Experiences with a Modified Flow-Through Cell Setup. <i>Dissolution Technologies</i> , 2011, 18, 26-35.	0.2	13

#	ARTICLE	IF	CITATIONS
2220	A Methodology for Quantifying Deformations in Stented Coronary Arteries Based on Three-Dimensional Angiography. <i>Journal of ASTM International</i> , 2010, 7, 1-15.	0.2	1
2221	Late Angiographic Stent Thrombosis in a Drug-Eluting Stent That Occurred 20 Months After Premature Discontinuation of Clopidogrel Administration. <i>International Heart Journal</i> , 2006, 47, 707-713.	0.5	9
2222	Direct Stenting Versus Predilatation and Stenting Technique When Using Paclitaxel-Eluting Stents. <i>International Heart Journal</i> , 2008, 49, 545-552.	0.5	3
2223	Occurrence of Late Acquired Peri-Stent Contrast Staining. <i>International Heart Journal</i> , 2012, 53, 165-169.	0.5	11
2224	LEONARDO "Clinical Evaluation of a Last Generation Coronary Stent in a Real World Typical Non-DES Population" A Prospective, Single-centre Registry. <i>Interventional Cardiology Review</i> , 2007, , 38.	0.7	1
2225	Stent Passivation with Silicon Carbide as a Possible Alternative to Drug-eluting Stents " A Comprehensive Review of Pre-clinical and Clinical Results. <i>Interventional Cardiology Review</i> , 2009, 4, 60.	0.7	16
2226	Pre-clinical and Clinical Study Results for the Coracto, Rapamycin-eluting Stent " A New-generation Drug-eluting Stent. <i>Interventional Cardiology Review</i> , 2010, 5, 39.	0.7	2
2227	Drug-coated Balloons for Small Coronary Vessel Interventions: A Literature Review. <i>Interventional Cardiology Review</i> , 2019, 14, 131-136.	0.7	14
2228	Rotational Atherectomy: A Contemporary Appraisal. <i>Interventional Cardiology Review</i> , 2019, 14, 182-189.	0.7	42
2230	An Update on Endovascular Therapy of the Lower Extremities. <i>Journal of Endovascular Therapy</i> , 2004, 11, II-107-II-127.	0.8	18
2231	Intravascular Stents in the Last and the Next 10 Years. <i>Journal of Endovascular Therapy</i> , 2004, 11, II-200-II-206.	0.8	20
2233	Economic impact of chronic ischemic cardiopathy treatment in Brazil: the challenge of new cardiovascular technology inclusion. <i>Arquivos Brasileiros De Cardiologia</i> , 2005, 85, .	0.3	7
2235	Drug-eluting stent in diabetes. <i>Sao Paulo Medical Journal</i> , 2007, 125, 259-260.	0.4	2
2236	Trombose de stent farmacológico no "mundo-real": análise crítica do Registro DESIRE (Drug-Eluting) Tj ETQq1 1 0,784314,rgBT /Over	0.1	0
2237	Incidência e preditores de revascularização da lesão-alvo no seguimento clínico de longo prazo: análise crítica do Registro DESIRE. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2010, 18, 157-164.	0.1	3
2238	Resultados da intervenção coronária percutânea com o stent BiomatrixTM em pacientes não-selecionados. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2011, 19, 40-46.	0.1	1
2239	Tratamento de enxertos de veia safena com stents farmacológicos: resultados talvez não tão satisfatórios como em vasos nativos. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2011, 19, 113-117.	0.1	3
2240	Seguimento angiográfico e clínico tardio do novo stent farmacológico não-polimérico liberador de paclitaxel para o tratamento de lesões coronárias de novo: resultados do estudo PAX-B. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2012, 20, 146-154.	0.1	1

#	ARTICLE	IF	CITATIONS
2241	Comparison of Contemporary Drug-eluting Coronary Stents – Is Any Stent Better than the Others?. Heart International, 2020, 14, 34.	0.4	3
2242	Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). Vascular Health and Risk Management, 2006, 2, 379-387.	1.0	3
2243	Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®). Vascular Health and Risk Management, 2008, 4, 31-38.	1.0	95
2244	Clopidogrel. American Journal of Cardiovascular Drugs, 2012, 12, 361-374.	1.0	7
2245	The Adverse Events Rate of Endothelial Progenitor Cell Capturing Stent in the Treatment of CAD Patients. Combinatorial Chemistry and High Throughput Screening, 2019, 21, 725-733.	0.6	2
2246	Increased incidence of serious late adverse events with drug-eluting stents when compared with coronary artery bypass surgery: a cause of concern. Future Cardiology, 2020, 16, 711-723.	0.5	4
2247	Advances in vein graft intervention. Interventional Cardiology, 2010, 2, 735-754.	0.0	3
2249	Stent thrombosis after Cypher and Taxus stent implantation. , 2005, , 187-198.		1
2252	Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberté stents. Korean Journal of Internal Medicine, 2013, 28, 72.	0.7	1
2253	Long-term outcomes of intravascular ultrasound-guided implantation of bare metal stents versus drug-eluting stents in primary percutaneous coronary intervention. Korean Journal of Internal Medicine, 2014, 29, 66.	0.7	3
2254	Clinicopathologic Correlations of Poly-(styrene-b-isobutylene-b-styrene) Glaucoma Drainage Devices of Different Internal Diameters in Rabbits. Ophthalmic Surgery Lasers and Imaging Retina, 2011, 42, 338-345.	0.4	35
2255	QCA, IVUS and OCT in interventional cardiology in 2011. Cardiovascular Diagnosis and Therapy, 2011, 1, 57-70.	0.7	19
2256	Coronary artery aneurysms following drug eluting stents implantation: A retrospective analysis from series of cases at tertiary care cardiac centre over three years. Heart India, 2019, 7, 110.	0.2	2
2257	A Discussion of the Role of Complex Evolved Systems in the Development of Invasive Cardiovascular Interventions as Illustrated by the Blalock- Taussig Shunt and Intra-Arterial Stents. Biological Systems, Open Access, 2014, 03, .	0.1	3
2258	Clinical Performance of the Cobalt-Chromium Biodegradable Polymer Coated Sirolimus-Eluting Stent in an Unselected Real-World Population. International Journal of Clinical Medicine, 2014, 05, 206-215.	0.1	4
2259	Self-Assembled Monolayers (SAMs): Which Perspectives in Implant Dentistry?. Journal of Biomaterials and Nanobiotechnology, 2011, 02, 533-543.	1.0	22
2260	Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis. EuroIntervention, 2017, 13, 1202-1209.	1.4	11
2261	Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials. EuroIntervention, 2018, 13, 1904-1913.	1.4	18

#	ARTICLE	IF	CITATIONS
2262	A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial. <i>EuroIntervention</i> , 2018, 14, 86-93.	1.4	11
2263	First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial. <i>EuroIntervention</i> , 2019, 15, e1081-e1089.	1.4	5
2264	Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. <i>EuroIntervention</i> , 2010, 6, 437-446.	1.4	6
2265	Drug-eluting stents and bare metal stents in patients with NSTEMI-ACS: 2-year outcome from the randomised BASKET-PROVE trial. <i>EuroIntervention</i> , 2014, 10, 58-64.	1.4	10
2266	Coronary stents seeded with human trophoblastic endovascular progenitor cells show accelerated strut coverage without excessive neointimal proliferation in a porcine model. <i>EuroIntervention</i> , 2014, 10, 709-716.	1.4	8
2267	Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). <i>EuroIntervention</i> , 2007, 3, 206-212.	1.4	26
2268	Safety and efficacy of multiple, overlapping polymer-based paclitaxel-eluting stents. <i>EuroIntervention</i> , 2007, 3, 213-221.	1.4	11
2269	A novel ultra-thin bare metal stent (BMS): results from a worldwide registry. <i>EuroIntervention</i> , 2007, 3, 249-255.	1.4	5
2270	Efficiency and safety of the sirolimus eluting stent in complex coronary artery lesions after cessation of dual antiplatelet therapy: fifteen months clinical outcome of the randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. <i>EuroIntervention</i> , 2007, 3, 309-314.	1.4	3
2271	Effectiveness and safety of paclitaxel-eluting stents in patients with ST-segment elevation acute myocardial infarction. <i>EuroIntervention</i> , 2007, 3, 386-391.	1.4	9
2272	A pooled safety analysis of data comparing paclitaxel-eluting stents with bare-metal stents. <i>EuroIntervention</i> , 2007, 3, 392-399.	1.4	10
2273	Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial. <i>EuroIntervention</i> , 2008, 3, 566-573.	1.4	14
2274	First clinical comparison of Nobori Biolimus A9 eluting stents with Cypher Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. <i>EuroIntervention</i> , 2008, 3, 574-579.	1.4	59
2275	EXCELLA, First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. <i>EuroIntervention</i> , 2008, 4, 53-58.	1.4	32
2276	Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study. <i>EuroIntervention</i> , 2008, 4, 64-70.	1.4	43
2277	Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results. <i>EuroIntervention</i> , 2008, 4, 71-76.	1.4	6
2278	Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. <i>EuroIntervention</i> , 2008, 4, 108-114.	1.4	32
2279	The role of thrombectomy and distal protection devices during percutaneous coronary interventions. <i>EuroIntervention</i> , 2008, 4, 115-123.	1.4	20

#	ARTICLE	IF	CITATIONS
2280	Lower levels of in-stent late loss are not associated with the risk of stent thrombosis in patients receiving drug-eluting stents. <i>EuroIntervention</i> , 2008, 4, 124-132.	1.4	17
2281	Very late thrombosis in acute myocardial infarction: drug-eluting versus uncoated stents. <i>EuroIntervention</i> , 2008, 4, 324-330.	1.4	5
2282	Meeting report ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007. <i>EuroIntervention</i> , 2009, 4, 427-436.	1.4	4
2283	Long-term follow-up of percutaneous coronary intervention of unprotected left main lesions with drug eluting stents: predictors of clinical outcome. <i>EuroIntervention</i> , 2009, 4, 457-463.	1.4	18
2284	Clinical investigation into the observation that silicon carbide coating on cobalt chromium stents leads to early differentiating functional endothelial layer, increased safety and DES-like recurrent stenosis rates: results of the PRO-Heal Registry (PRO-Kinetic enhancing rapid in-stent) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 572 Td (end	1.4	32
2285	TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. <i>EuroIntervention</i> , 2009, 4, 572-577.	1.4	61
2286	Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry. <i>EuroIntervention</i> , 2009, 5, 57-66.	1.4	11
2287	Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. <i>EuroIntervention</i> , 2009, 5, 67-77.	1.4	28
2288	Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. <i>EuroIntervention</i> , 2009, 5, 255-264.	1.4	24
2289	Cost effectiveness of coronary revascularisation. <i>EuroIntervention</i> , 2010, 5, 763-767.	1.4	6
2290	A pooled gender based analysis comparing the XIENCE VÂ® everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. <i>EuroIntervention</i> , 2010, 5, 788-794.	1.4	28
2291	Assimilating the current clinical data of fully bioabsorbable stents. <i>EuroIntervention</i> , 2009, 5, F103-F108.	1.4	12
2292	The bioabsorption process: tissue and cellular mechanisms and outcomes. <i>EuroIntervention</i> , 2009, 5, F28-F35.	1.4	49
2293	Late loss in a disappearing frame of reference: is it still applicable to fully absorbable scaffolds?. <i>EuroIntervention</i> , 2009, 5, F43-F48.	1.4	5
2294	Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial. <i>EuroIntervention</i> , 2010, 6, 63-68.	1.4	17
2295	A quantitative coronary angiography-matched comparison between a prospective randomised multicentre cutting balloon angioplasty and bare metal stent trial (REDUCE III) and the Rapamycin-Eluting Stent Evaluation At Rotterdam Cardiology Hospital (RESEARCH) study. <i>EuroIntervention</i> , 2010, 6, 400-406.	1.4	11
2296	Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating. <i>EuroIntervention</i> , 2010, 6, 630-637.	1.4	40
2297	Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. <i>EuroIntervention</i> , 2010, 6, 562-567.	1.4	44

#	ARTICLE	IF	CITATIONS
2298	Sirolimus-eluting stent implantation versus beta-irradiation for the treatment of in-stent restenotic lesions: clinical and ultrasound results from a randomised trial. <i>EuroIntervention</i> , 2011, 6, 687-694.	1.4	14
2299	Late outcomes of drug eluting and bare metal stents in saphenous vein graft percutaneous coronary intervention. <i>EuroIntervention</i> , 2011, 6, 985-991.	1.4	9
2300	Hybrid strategy of a bare metal stent combined with a drug-eluting stent versus exclusive drug-eluting stent implantation for multivessel percutaneous coronary intervention. <i>EuroIntervention</i> , 2011, 6, 1085-1090.	1.4	5
2301	Atheroma and coronary bifurcations: before and after stenting. <i>EuroIntervention</i> , 2010, 6, J24-J30.	1.4	13
2302	Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial. <i>EuroIntervention</i> , 2012, 7, 1376-1385.	1.4	34
2303	Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial. <i>EuroIntervention</i> , 2011, 7, 64-73.	1.4	8
2304	PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. <i>EuroIntervention</i> , 2011, 7, 84-90.	1.4	37
2305	In vivo assessment of optimal viewing angles from X-ray coronary angiography. <i>EuroIntervention</i> , 2011, 7, 112-120.	1.4	17
2306	Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme. <i>EuroIntervention</i> , 2011, 7, 314-322.	1.4	1
2307	Optical coherence tomography at follow-up after percutaneous coronary intervention: relationship between procedural dissections, stent strut malapposition and stent healing. <i>EuroIntervention</i> , 2011, 7, 353-361.	1.4	24
2308	Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. <i>EuroIntervention</i> , 2011, 7, 505-516.	1.4	32
2309	Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. <i>EuroIntervention</i> , 2011, 7, 730-737.	1.4	77
2310	In vitro and in vivo characterisation of biodegradable polymer-based drug-eluting stent. <i>EuroIntervention</i> , 2011, 7, 835-843.	1.4	19
2311	Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents. <i>EuroIntervention</i> , 2012, 7, 1030-1042.	1.4	4
2312	Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry. <i>EuroIntervention</i> , 2012, 7, 1062-1068.	1.4	9
2313	A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods. <i>EuroIntervention</i> , 2011, 7, K93-K99.	1.4	11
2314	Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. <i>EuroIntervention</i> , 2012, 8, 109-116.	1.4	47
2315	Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials. <i>EuroIntervention</i> , 2012, 8, 187-195.	1.4	35

#	ARTICLE	IF	CITATIONS
2316	Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. <i>EuroIntervention</i> , 2012, 8, 599-606.	1.4	51
2317	A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study. <i>EuroIntervention</i> , 2012, 8, 815-822.	1.4	30
2318	Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry. <i>EuroIntervention</i> , 2012, 8, 896-903.	1.4	9
2319	An intravascular ultrasound comparison of left anterior descending artery/first diagonal branch versus distal left main coronary artery bifurcation lesions. <i>EuroIntervention</i> , 2013, 8, 1040-1046.	1.4	13
2320	Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts. <i>EuroIntervention</i> , 2014, 9, 1432-1440.	1.4	21
2321	First-in-human evaluation of a sirolimus-eluting coronary stent on an integrated delivery system: the DIRECT study. <i>EuroIntervention</i> , 2013, 9, 46-53.	1.4	17
2322	First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the meriT-1 trial. <i>EuroIntervention</i> , 2013, 9, 493-500.	1.4	29
2323	Current treatment and outcome of coronary in-stent restenosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). <i>EuroIntervention</i> , 2013, 9, 564-572.	1.4	15
2324	Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions. <i>EuroIntervention</i> , 2013, 9, 788-796.	1.4	21
2325	Preserved endothelial vasomotor function after everolimus-eluting stent implantation. <i>EuroIntervention</i> , 2015, 11, 643-649.	1.4	14
2326	A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study. <i>EuroIntervention</i> , 2015, 11, 541-548.	1.4	32
2327	Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index. <i>EuroIntervention</i> , 2015, 11, 634-642.	1.4	30
2328	One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE). <i>EuroIntervention</i> , 2015, 10, 1261-1266.	1.4	5
2329	DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial. <i>EuroIntervention</i> , 2016, 12, e1336-e1342.	1.4	15
2330	Angiographic and intravascular ultrasound findings following implantation of the Endeavor [®] zotarolimus-eluting stents in patients from the real-world clinical practice. <i>EuroIntervention</i> , 2009, 5, 355-362.	1.4	8
2331	Rotational atherectomy followed by drug-eluting stent implantation in calcified coronary lesions. <i>EuroIntervention</i> , 2009, 5, 370-374.	1.4	78
2332	Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. <i>EuroIntervention</i> , 2009, 5, 384-393.	1.4	69
2333	Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. <i>World Journal of Cardiology</i> , 2015, 7, 119.	0.5	42

#	ARTICLE	IF	CITATIONS
2334	Modern Stents: Where Are We Going?. Rambam Maimonides Medical Journal, 2020, 11, e0017.	0.4	12
2335	Comparison of bypass surgery and drug-eluting stenting in diabetic patients with left main and/or multivessel disease: A systematic review and meta-analysis of randomized and nonrandomized studies. Cardiology Journal, 2015, 22, 123-134.	0.5	15
2336	IVUS Guided PCI. , 0, , .		1
2337	Coronary Arterial Drug-Eluting Stent: From Structure to Clinical. , 0, , .		2
2338	Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions. Cardiovascular Journal of Africa, 2010, 21, 311-315.	0.2	1
2340	Late Restenosis in Patients Receiving a Polymer-Coated Sirolimus-Eluting Stent. Annals of Internal Medicine, 2005, 143, 392.	2.0	70
2341	Ten Years of Advancements in Interventional Cardiology. Journal of Endovascular Therapy, 2004, 11, II-10-II-18.	0.8	1
2346	Optimal deployment strategies for drug-eluting stents Georges A Feghali and Bahji N Khuri. , 2005, , 136-145.		0
2347	Drug-eluting stent platforms: antiproliferative drugs and polymer coatings. , 2005, , 30-41.		0
2348	Optimal antiplatelet and anticoagulation therapy for drug-eluting stents. , 2005, , 126-135.		0
2349	Clinical trials: bare metal stents versus drug-eluting stents. , 2005, , 80-91.		1
2350	Broader indications (off-label use) for coronary drug-eluting stents. , 2005, , 92-105.		0
2351	Patient selection criteria for drug-eluting stents. , 2005, , 118-125.		0
2352	æŠ—ç,Žç—†ā«ā,ā,«â†ç«çª,,äºé~2â~3/4ç— : éªâ1/4âæªªâ†ªâ,1âftâf3âf^â«ā,â,«æ¬jâ,—â»£èj€ç®jâ†...âCE»ç™,â,â,1âftâfââé—ç™ª¶7. Drug el		
2353	Attending to Links in the Safety Chain for Drug-eluting Stents. European Cardiology Review, 2006, 2, 1.	0.7	0
2354	Angioplastica coronarica. , 2006, , 92-103.		0
2355	Heart Attacks. , 2006, , 397-431.		0
2356	Computational Modeling of Stented Arteries: Considerations for Evolving Stent Designs. , 2006, , 241-253.		0

#	ARTICLE	IF	CITATIONS
2357	Percutaneous coronary intervention in the drug-eluting stent era. Journal of the Japanese Society of Intensive Care Medicine, 2006, 13, 221-227.	0.0	0
2358	Interventional cardiology in Switzerland 2004. Cardiovascular Medicine, 2006, 9, .	0.2	2
2361	The Process of Regulatory Review for New Cardiovascular Devices * *This chapter represents the professional opinions of the authors and is not an official document, agency guidance, or policy of the U.S. Government, the Department of Health and Human Services, or the Food and Drug Administration, nor should any official endorsement be inferred.. , 2007, , 67-75.		4
2362	Percutaneous Coronary Intervention for Unstable Coronary Artery Disease. , 2007, , 1005-1020.		0
2364	Thrombotic Events after Implantation of Drug-eluting Stents. European Cardiology Review, 2007, 3, 81.	0.7	0
2365	Mechanical Approaches to Percutaneous Coronary Intervention. , 2007, , 121-134.		0
2366	Incidência de aposição incompleta persistente e tardia após implante de stents com sirolimus e zotarolimus. Revista Brasileira De Cardiologia Invasiva, 2007, 15, 363-369.	0.1	0
2367	The Frequency, Treatment and Clinical Outcomes of Stent Thrombosis after Use of TAXUSâ,ç Stent. Korean Circulation Journal, 2007, 37, 641.	0.7	3
2368	Angiographic and Clinical Outcome Following Sirolimus-Eluting Stent (Cypher) Implantation A Single Center Experience. International Heart Journal, 2007, 48, 11-23.	0.5	3
2369	Coronary Artery Bypass Surgery and Percutaneous Coronary Revascularization: Impact on Morbidity and Mortality in Patients with Coronary Artery Disease. , 2007, , 1073-1111.		1
2370	Drug-Eluting Coronary Stents. , 2007, , 1031-1050.		0
2371	Drug-eluting stent restenosis John Cosgrave and George Dangas. , 2007, , 167-178.		0
2372	Genetics of Ischemic Heart Disease. , 2007, , 261-262.		0
2373	Nano-Carriers of Drugs and Genes for the Treatment of Restenosis. Drugs and the Pharmaceutical Sciences, 2007, , 235-269.	0.1	0
2374	Cardiovascular interventional pharmacology in the diabetic patient. , 2007, , 473-482.		0
2375	Role of systemic antineoplastic drugs in the treatment of restenosis after percutaneous stent implantation. , 2007, , 195-209.		0
2378	Journal of JCS Cardiologists, 2007, 15, 32		0
2380	Fratura de stent como causa de reestenose em stent farmacológico. Revista Brasileira De Cardiologia Invasiva, 2008, 16, 106-109.	0.1	0

#	ARTICLE	IF	CITATIONS
2381	Perfil de segurança dos stents farmacológicos nas síndromes coronárias agudas: dados do Registro INCOR. Revista Brasileira De Cardiologia Invasiva, 2008, 16, 289-294.	0.1	1
2382	23 Percutane coronaire interventies. , 2008, , 197-202.		0
2384	Implante de stent farmacológico para o tratamento da reestenose de outro stent farmacológico: análise tardia do Registro DESIRE. Revista Brasileira De Cardiologia Invasiva, 2008, 16, 273-278.	0.1	0
2385	Characterization of Hammerhead Ribozymes Potentially Suitable for the Treatment of Hyper-Proliferative Vascular Diseases. , 2008, , 185-207.		0
2386	Interventional cardiology in Switzerland 2006. Cardiovascular Medicine, 2008, 11, 187-195.	0.2	2
2387	éžä;è·â· â†â·è,,^ä>â¹éƒç—...â%â«â³/4âªMâ,«sirolimusæª†ªâ,1â†ªfªâfªªpaclitaxelæª†ªâ,1â†ªfªâfªªâªçÿæœÿßâ,ªªéoæœÿèª		
2388	â†ç-¾æ,£ç”ç©ªªé€²æ©(â¾ªçªªª™ª-â- 2008ªªªªé€²æ©). Journal of JCS Cardiologists, 2008, 16, 319-325.	0.1	0
2389	The Role of Percutaneous Coronary Revascularization in Advanced Ischemic Heart Disease. , 2009, , 69-83.		0
2390	Predictors for very late stent thrombosis after drug-eluting stent implantation in diabetic patients. EuroIntervention, 2009, 4, 485-491.	1.4	5
2392	Experiência inicial com o uso de stents eluidores de everolimus em pacientes do mundo real: seguimento clínico de um ano. Revista Brasileira De Cardiologia Invasiva, 2009, 17, 484-490.	0.1	0
2393	Comparison of Sirolimus and Paclitaxel-Eluting Stents for Complex Coronary Lesions: An Intravascular Ultrasound Study. Korean Journal of Internal Medicine, 2009, 24, 323.	0.7	2
2394	Transcatheter Intervention on the Central Pulmonary Arteriesâ€”Current Techniques and Outcomes. , 2009, , 73-84.		0
2395	What Would Be the Ideal Drug-eluting Stent for Managing Patients with Long Lesions?. Interventional Cardiology Review, 2009, 4, 44.	0.7	0
2396	Stent selection in patients on oral anticoagulants: can we prevent restenosis and avoid bleeding?. EuroIntervention, 2009, 5, 405-407.	1.4	0
2397	Intravascular ultrasound guidance of stent deployment. , 2009, , 80-95.		0
2399	Surgery Against Cancer of Gastrointestinal Tract and Perioperative Management in Patients Receiving Drug-Eluting Coronary Stent Implantation. Japanese Journal of Gastroenterological Surgery, 2010, 43, 882-892.	0.0	1
2400	Interventional Cardiology in Switzerland during the Year 2007. Cardiovascular Medicine, 2010, 13, 18-24.	0.2	4
2405	Aplicação intracoronária de nanopartículas de paclitaxel durante intervenção percutânea para supressão da hiperplasia intimal após implante de stents não-farmacológicos. Revista Brasileira De Cardiologia Invasiva, 2010, 18, 140-150.	0.1	1

#	ARTICLE	IF	CITATIONS
2406	Stent selection in patients with acute coronary syndromes and unstable coronary lesions. <i>Interventional Cardiology</i> , 2010, 2, 545-557.	0.0	1
2407	Percutaneous coronary intervention. , 2011, , 434-443.		0
2409	Are Drug-Eluting Stents Safer and More Effective Than Bare-Metal Stents in Patients With Acute Myocardial Infarction? 3-Year Follow-Up. <i>International Heart Journal</i> , 2011, 52, 78-83.	0.5	1
2415	Moxy® drug-coated balloon: a novel device for the treatment of coronary and peripheral vascular disease. <i>EuroIntervention</i> , 2011, 7, 274-277.	1.4	0
2416	Evolução tardia de pacientes com infarto agudo do miocárdio tratados com stents farmacológicos na prática diária do mundo real: subanálise do Registro DESIRE (Drug-Eluting Stent In the REal World). <i>Revista Brasileira De Cardiologia Invasiva</i> , 2011, 19, 244-254.	0.1	0
2417	Therapeutic Goals in Patients with Refractory Angina. , 2012, , 29-37.		0
2418	Principles of Endovascular Therapy. , 2012, , 828-851.		0
2420	Real World Application of Stenting of Unprotected Left Main Coronary Stenosis: A Single-Center Experience. <i>Cardiology Research</i> , 2012, 3, 100-108.	0.5	1
2421	Femoropoplitealer Gefäßabschnitt. , 2012, , 633-661.		0
2424	Statins and stent thrombosis. <i>Swiss Medical Weekly</i> , 2012, 142, w13525.	0.8	4
2425	Questão simples, resposta multivariada. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2012, 20, 11-12.	0.1	0
2426	Stenting and angioplasty for intracranial atherosclerotic occlusive disease. , 2012, , 434-449.		1
2427	Paclitaxel Coating on ePTFE Artificial Graft and the Release Behavior. <i>Porrime</i> , 2012, 36, 326-331.	0.0	0
2428	Historical Account: Interventional Cardiology. , 2013, , 3-14.		1
2429	Principles of Clinical and Engineering Integration in Hemocompatibility. , 2012, , 17-40.		0
2430	Principles of Clinical and Engineering Integration in Hemocompatibility. , 2012, , 5-28.		0
2431	Occurrence and Prognosis for the Thrombosis in the Drug-Eluting Stents and Bare-Metal Stents. <i>The Journal of the Korea Contents Association</i> , 2012, 12, 273-283.	0.0	0
2432	Interventional perspectives on the management of advanced stable coronary artery disease. , 2012, , 385-393.		0

#	ARTICLE	IF	CITATIONS
2433	Interventional perspectives on the management of advanced stable coronary artery disease. , 2012, , 385-393.		0
2437	Angioplasty Guided by Intravascular Ultrasound: Meta-Analysis of Randomized Clinical Trials. Arquivos Brasileiros De Cardiologia, 2013, 101, 106-16.	0.3	6
2438	Restenosis and Drug-Eluting Stents. , 2013, , 168-183.		0
2439	CT Angiography of Coronary Stents. , 2013, , 115-130.		0
2440	Assessment of Restenosis Cases with Drug-eluting Stents by Various Intravascular Imaging Modalities. Cardiovascular Intervention and Therapeutics Japanese Edition, 2013, 5, 108-111.	0.0	0
2441	Fatigue Fracture of Coronary Stents: Visualization of Fracture Resistance. Journal of the Visualization Society of Japan, 2013, 33, 19-24.	0.0	0
2442	Coronary drug-eluting stents: progress and remaining issues. Journal of the Japanese Coronary Association, 2013, 19, 248-256.	0.0	0
2443	Clinical follow up of patients with premature coronary artery disease (PCAD) implanted with drug-eluting stents. World Journal of Cardiovascular Diseases, 2013, 03, 329-335.	0.0	0
2444	Major clinical and angiographic outcome of drug eluting stents in native ostial coronary artery disease. World Journal of Cardiovascular Diseases, 2013, 03, 320-327.	0.0	0
2445	Designing Biomedical Stents for Vascular Therapy. Advances in Medical Technologies and Clinical Practice Book Series, 2013, , 216-239.	0.3	0
2446	Diamond-Like Carbon Coated on Polymers for Biomedical Applications. Biological and Medical Physics Series, 2013, , 171-228.	0.3	3
2447	Drug-Eluting Stent (DES) Induced Coronary Artery Aneurysm - A Case Report. Cardiovascular Journal, 2013, 6, 63-67.	0.0	0
2448	Drug-Eluting Stents. Advances in Delivery Science and Technology, 2014, , 387-403.	0.4	0
2449	Seven Years Follow-Up of Biodegradable Polymer Coated Paclitaxel-Eluting Infimum Coronary Stent in Saudi Arabia. International Journal of Clinical Medicine, 2014, 05, 216-224.	0.1	0
2450	Coronary Imaging and Percutaneous Coronary Intervention. , 2014, , .		0
2451	Comparison of Two Biodegradable Polymer Coated, Drug-Eluting Coronary Stents Paclitaxel vs. Sirolimus, with 6-Years Clinical Follow-Up: BIOPRESS (BIODEgradable Polymer REGistry Smt Stents) Infimum vs. Supralimus. Journal of Cardiology and Therapeutics, 2014, 2, 12-20.	0.1	0
2452	Testing Drug Eluting Paclitaxel Balloon Valvuloplasty in an Experimental Model of Aortic Stenosis. , 2014, , 41-47.		1
2453	Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents. World Journal of Cardiology, 2014, 6, 148.	0.5	2

#	ARTICLE	IF	CITATIONS
2457	Unexpected Discontinuation of Dual Antiplatelet Therapy within 14 Days after Percutaneous Coronary Intervention: A Single-center Case Series. <i>British Journal of Medicine and Medical Research</i> , 2015, 5, 642-650.	0.2	0
2458	<i>Vascular Pathology and Interventional Treatments.</i> , 2015, , 303-325.		0
2459	Study of Novel Coating Strategy: Simutaneous Coating of VEGF and anti-CD34 Antibody. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2015, 30, 159-63.	0.2	3
2461	Rotational Atherectomy through Inner Guiding Catheter System for 1.25 mm Rotational Burr Non-Crossable Heavily Calcified Coronary Stenosis. <i>Soonchunhyang Medical Science</i> , 2015, 21, 15-19.	0.0	0
2462	Bioresorbable Scaffolds: Current Evidences in the Treatment of Coronary Artery Disease. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, OE01-OE07.	0.8	2
2464	<i>Percutaneous Coronary Intervention of Saphenous Vein Graft Failure.</i> , 2016, , 595-602.		0
2465	<i>Cuff-Induced Neointimal Formation in Mouse Models.</i> , 2016, , 21-41.		0
2466	Clinical Characteristics of In-stent Neoatherosclerosis Causing Late Stent Failure. <i>Journal of the Japanese Coronary Association</i> , 2016, 22, 245-250.	0.0	0
2468	DAPT: a historical accident in the pharmacological treatment of post-percutaneous coronary intervention. <i>EuroIntervention</i> , 2016, 11, 1449-1450.	1.4	1
2470	Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 678-684.	0.7	0
2471	Interventional in-stent restenosis treatment with usage of dedicated drug coated balloons SeQuent ^Å ® Please. <i>Intervencni A Akutni Kardiologie</i> , 2016, 15, 114-118.	0.0	0
2472	Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial. <i>Advanced Biomedical Research</i> , 2017, 6, 154.	0.2	0
2474	Temporal Trends in Patients's Characteristics and Clinical Outcomes in the Elderly Following Percutaneous Coronary Intervention. <i>Juntendo Medical Journal</i> , 2018, 64, 379-385.	0.1	0
2476	Dependence of perpendicular pressure to luminal surface on heating drug delivery performance using a laser-mediated thermal balloon with porcine carotid artery walls ex vivo. , 2018, , .		0
2477	Influence of Elevated Temperature During Crimping on Results of Numerical Simulation of a Bioresorbable Stent Deployment Process. <i>Advances in Intelligent Systems and Computing</i> , 2019, , 81-89.	0.5	0
2478	Collagen reversible denaturation by a weak near-infrared laser light irradiation for vascular softening. , 2018, , .		0
2479	Intravascular ultrasound versus angiography-guided drug eluting stent implantation in patients with complex coronary lesions: an updated meta-analysis of 9 randomized clinical trials. <i>Anatolian Journal of Cardiology</i> , 2019, 22, 160-167.	0.5	1
2480	<i>Diabetes and Cardiovascular Disease.</i> , 2019, , 709-730.		1

#	ARTICLE	IF	CITATIONS
2481	Long-term results of stenting of long coronary artery stenosis with consecutive implantation of stents of different types with overlapping edges in patients with acute coronary syndrome without ST-segment elevation and multivessel coronary artery disease. <i>Journal of Clinical Practice</i> , 2019, 10, 53-59.	0.2	0
2482	Capturing Endothelial Cells by Coronary Stents - From Histology to Clinical Outcomes. <i>Serbian Journal of Experimental and Clinical Research</i> , 2019, .	0.2	1
2483	Emerging therapies in coronary balloon angioplasty, stenting, and bioabsorbable scaffolds. , 2020, , 527-557.		0
2484	Predictors of procedural and clinical outcome in rotational atherectomy: analysis of a single center registry. <i>Minerva Cardioangiologica</i> , 2020, 68, 126-133.	1.2	1
2485	In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial). <i>American Journal of Cardiology</i> , 2022, 162, 24-30.	0.7	4
2486	Coronary Stents and Metal Allergy. , 2020, , 1-13.		0
2487	Everolimus-Eluting Second-Generation Stents for Treatment of De Novo Lesions in Patients with Cardiac Allograft Vasculopathy. <i>Annals of Transplantation</i> , 2020, 25, e921266.	0.5	7
2488	Designing Biomedical Stents for Vascular Therapy. , 0, , 972-996.		0
2491	Local Gene and Cell Delivery Devices. , 2007, , 419-442.		0
2492	Clinical Presentation of Restenosis. , 2007, , 29-46.		0
2493	Endovascular Treatment of Carotid Stenosis. , 2007, , 181-199.		0
2494	Assessment of Coronary Artery Stents by Coronary CT Angiography. <i>Medical Radiology</i> , 2009, , 225-232.	0.0	0
2495	Myocardial Perfusion Scintigraphy in the Assessment of Post-Revascularization â€œ Current Status and Limitations. , 2009, , 275-285.		0
2496	Coronary Stents and Metal Allergy. , 2021, , 1171-1183.		1
2497	Stents or surgery: the case for stents. <i>Texas Heart Institute Journal</i> , 2005, 32, 331-8.	0.1	0
2498	Update on stents: recent studies on the TAXUS stent system in small vessels. <i>Vascular Health and Risk Management</i> , 2007, 3, 481-90.	1.0	4
2499	Drug-eluting stents not for all patients. <i>Netherlands Heart Journal</i> , 2006, 14, 174-176.	0.3	0
2500	Antiplatelet therapy in patients undergoing coronary stenting: The risk of late stent thrombosis. <i>Netherlands Heart Journal</i> , 2006, 14, 297-300.	0.3	1

#	ARTICLE	IF	CITATIONS
2501	Attending to links in the safety chain for drug-eluting stents. Netherlands Heart Journal, 2006, 14, 285-286.	0.3	0
2502	Nanoparticulate carriers for the treatment of coronary restenosis. International Journal of Nanomedicine, 2007, 2, 143-61.	3.3	23
2504	Drug-eluting stents. International Journal of Clinical and Experimental Medicine, 2010, 3, 192-201.	1.3	10
2505	Translational research: current status, challenges and future strategies. American Journal of Translational Research (discontinued), 2011, 3, 422-33.	0.0	12
2506	Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman. Oman Medical Journal, 2008, 23, 247-52.	0.3	5
2507	On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomes. Texas Heart Institute Journal, 2012, 39, 24-9.	0.1	3
2508	One-year clinical outcomes of ultra long apollo polymer-based Paclitaxel-eluting stents in patients with complex, long coronary artery lesions. Journal of Tehran University Heart Center, 2011, 6, 138-42.	0.2	3
2509	Perioperative management of antiplatelet therapy in patients with drug-eluting stents. HSR Proceedings in Intensive Care & Cardiovascular Anesthesia, 2012, 4, 153-67.	0.6	9
2510	Controversies in the use & implementation of drug-eluting stent technology. Indian Journal of Medical Research, 2012, 136, 926-41.	0.4	0
2511	Application of rotational atherectomy in the drug-eluting stent era. Journal of Geriatric Cardiology, 2013, 10, 213-6.	0.2	6
2512	Early clinical outcomes of primary percutaneous coronary intervention in bharatpur, Nepal. MÃ dica, 2013, 8, 103-7.	0.4	0
2513	Outcome and Predictors of Stent Thrombosis in the First Romanian Registry of Drug Eluting Stent (RODESINO EXTENSION). MÃ dica, 2013, 8, 153-63.	0.4	3
2514	Long-term clinical outcomes of drug-eluting stents vs. bare-metal stents in Chinese geriatric patients. Journal of Geriatric Cardiology, 2013, 10, 330-5.	0.2	3
2515	Comparison of coronary DES and BMS in octogenarians: A systematic review and meta-analysis. Journal of Geriatric Cardiology, 2013, 10, 336-43.	0.2	5
2516	In-hospital and mid-term adverse clinical outcomes of a direct stenting strategy versus stenting after pre-dilatation for the treatment of coronary artery lesions. Cardiovascular Journal of Africa, 2008, 19, 297-302.	0.2	0
2517	Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction. Cardiovascular Journal of Africa, 2008, 19, 17-21.	0.2	8
2518	Interventional Revascularization of Coronary Artery Lesions in Diabetic Patients; In-hospital and One Year Follow up. , 2012, 6, 113-7.		2
2519	Stent underexpansion in angiographic guided percutaneous coronary intervention, despite adjunctive balloon post-dilatation, in drug eluting stent era. ARYA Atherosclerosis, 2014, 10, 13-7.	0.4	3

#	ARTICLE	IF	CITATIONS
2520	Wnt4/ β -catenin signaling pathway modulates balloon-injured carotid artery restenosis via disheveled-1. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8421-31.	0.5	9
2521	Histological validation of frequency domain optical coherence tomography for the evaluation of neointimal formation after a novel polymer-free sirolimus-eluting stent implantation. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 11068-75.	0.5	4
2522	Comparison of Bare-Metal Stent and Drug-Eluting Stent for the Treatment of Patients Undergoing Percutaneous Coronary Intervention for Unprotected Left Main Coronary Artery Disease - Long-Term Result from a Single Center Experience. <i>Acta Cardiologica Sinica</i> , 2015, 31, 381-9.	0.1	6
2523	One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. <i>The Journal of Tehran Heart Center</i> , 2016, 11, 62-67.	0.3	1
2524	Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. <i>Acta Cardiologica Sinica</i> , 2017, 33, 10-19.	0.1	30
2525	XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: â€œThe New Normalâ€™?. <i>Heart International</i> , 2021, 15, 65.	0.4	1
2526	Association between coronary artery calcium score and in-stent restenosis after drug-eluting stent implantation. <i>Coronary Artery Disease</i> , 2022, Publish Ahead of Print, .	0.3	2
2527	Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis. <i>JAMA Neurology</i> , 2022, 79, 176.	4.5	37
2528	Current status and future direction of metallic and polymeric materials for advanced vascular stents. <i>Progress in Materials Science</i> , 2022, 126, 100922.	16.0	19
2529	Differential Expression of miRNA-223 in Coronary In-Stent Restenosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 849.	1.0	1
2530	Advances in the treatment of ST Elevation Myocardial Infarction in the UK. <i>JRSM Cardiovascular Disease</i> , 2022, 11, 204800402210755.	0.4	2
2531	IMP3 promotes reâ€œndothelialization after arterial injury via increasing stability of VEGF mRNAhv. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2023-2037.	1.6	2
2532	Sirolimus Versus Paclitaxel. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 780-782.	1.1	2
2533	Angiogenic factor AGGF1 blocks neointimal formation after vascular injury via interaction with integrin β 7 on vascular smooth muscle cells. <i>Journal of Biological Chemistry</i> , 2022, 298, 101759.	1.6	9
2534	β -Blockers Reduced the Target Lesion Revascularization After Percutaneous Coronary Intervention Using an Everolimus-eluting Stent. <i>In Vivo</i> , 2022, 36, 416-423.	0.6	2
2536	An Interventionalist's Perspective. , 0, , 343-349.		0
2540	Synopsis of Adult Cardiac Surgical Disease. , 0, , 1-58.		1
2547	Hemocompatibility of All-trans Retinoic Acidâ€œLoaded Citrate Polymer Coatings for Vascular Stents. <i>Regenerative Engineering and Translational Medicine</i> , 0, , .	1.6	0

#	ARTICLE	IF	CITATIONS
2550	Outcomes and prognostic factors of patients treated for in-stent restenosis: a retrospective single-center experience. <i>Egyptian Heart Journal</i> , 2022, 74, .	0.4	0
2553	3D Printing of Biodegradable Polymer Vascular Stents: A Review. , 2022, 1, 100020.		3
2554	Association between Oxidative Burden and Restenosis: A Case-Control Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-10.	1.9	3
2555	Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?. <i>Current Atherosclerosis Reports</i> , 2022, 24, 731-744.	2.0	7
2557	Local intraluminal delivery of a smooth muscle-targeted RNA ligand inhibits neointima growth in a porcine model of peripheral vascular disease. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 577-583.	2.3	2
2558	Device Trials. , 2022, , 1399-1416.		0
2559	Historical overview and future perspective of the percutaneous coronary intervention with special emphasis on the development of coronary stent. <i>Journal of Biorheology</i> , 2022, 36, 23-30.	0.2	1
2560	Important Parameters for Design and Evolution of Coronary Stents: A Review. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2561	3D Printing of Triamcinolone Acetonide in Triblock Copolymers of Styrene- <i>l</i> -Isobutylene- <i>l</i> -Styrene as a Slow-Release System. <i>Polymers</i> , 2022, 14, 3742.	2.0	1
2562	Long-term outcomes of drug-coated balloons in patients with diffuse coronary lesions. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
2563	MiR-146a gene variant rs2910164 might be associated with coronary in-stent restenosis risk: Results from a pilot study and meta-analysis. <i>Genetika</i> , 2022, 54, 933-946.	0.1	0
2564	Structural and temporal dynamics analysis on drug-eluting stents: History, research hotspots and emerging trends. <i>Bioactive Materials</i> , 2023, 23, 170-186.	8.6	14
2566	Three-Year Clinical Outcomes of a Thin-Strut Biodegradable-Polymer Everolimus-Eluting Stent in Patients With Acute Coronary Syndrome. , 0, 2, .		0
2567	Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention. <i>Molecules</i> , 2022, 27, 8144.	1.7	4
2568	Microporous surface as a new solution for stent surface modification: A review. <i>Consilium Medicum</i> , 2022, 24, 718-725.	0.1	0
2569	Therapeutics in Metabolic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 255-273.	0.8	0
2570	â€˜Leave Nothing Behindâ€™™ Strategy in Coronary and Peripheral Artery Disease: An Insight into Sirolimus-Coated Balloons. <i>European Medical Journal Interventional Cardiology</i> , 0, , 60-71.	0.0	2
2571	Importance of Plaque Modification Before Coronary Artery Stenting. <i>European Medical Journal Interventional Cardiology</i> , 0, , 64-69.	0.0	1

#	ARTICLE	IF	CITATIONS
2572	Evolution of Drug-Eluting Stent Drug Elution Profile: Is a Crystalline Drug Form the Ideal Solution?. European Medical Journal Interventional Cardiology, 0, , 55-67.	0.0	0
2573	How Bioresorbable Vascular Can Be Beneficial for Patients in the Long-Term. European Medical Journal Interventional Cardiology, 0, , 2-14.	0.0	0
2574	“Spongy skin” as a robust strategy to deliver 4-octyl itaconate for conducting dual-regulation against in-stent restenosis. Biomaterials, 2023, 296, 122069.	5.7	2
2575	Current Status And Future Perspectives On Drug-Eluting Bioresorbable Coronary Scaffolds: Will The Paradigm Of PCI Shift?. European Medical Journal Interventional Cardiology, 0, , 81-90.	0.0	0
2576	Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence. Journal of Clinical Medicine, 2023, 12, 1238.	1.0	15
2577	Evaluation of coronary stents: A review of types, materials, processing techniques, design, and problems. Heliyon, 2023, 9, e13575.	1.4	10
2578	Perturbed post-translational modification (PTM) network atlas of collagen I during stent-induced neointima formation. Journal of Proteomics, 2023, 276, 104842.	1.2	3
2579	Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovascular Intervention and Therapeutics, 2023, 38, 166-176.	1.2	18
2580	Nanostructured electrode materials in bioelectrocommunication systems. , 2023, , 187-204.		0
2581	Diabetes and Cardiovascular Disease. , 2023, , 813-835.		0
2582	Les dispositifs médicaux dans la prise en charge des coronaropathies en cardiologie interventionnelle. , 2023, , 259-268.		0